<!DOCTYPE html><html lang="en" prefix="og: https://ogp.me/ns#"><head><meta charset="utf-8"><title data-static-tag-from="prerender">ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript | Seeking Alpha</title><script>!function(e,t,o){e&&e.documentElement&&"object"==typeof e.documentElement.dataset&&t&&"function"==typeof t.getItem&&t.getItem(o)&&(e.documentElement.dataset.colorScheme=t.getItem(o))}(document,localStorage,"COLOR_SCHEME")</script><link rel="preconnect" href="https://static.seekingalpha.com"><link rel="preconnect" href="https://static1.seekingalpha.com"><link rel="preconnect" href="https://static2.seekingalpha.com"><link rel="preconnect" href="https://static3.seekingalpha.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="anonymous"><meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover,maximum-scale=1"><meta content="ie=edge" http-equiv="X-UA-Compatible"><meta name="application-name" content="Seeking Alpha"><meta name="HandheldFriendly" content="True"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-title" content="SeekingAlpha"><meta name="apple-mobile-web-app-status-bar-style" content="black"><meta name="apple-itunes-app" content="app-id=552799694"><meta name="format-detection" content="telephone=yes"><meta name="theme-color" content="#333333"><meta property="fb:app_id" content="159723149420031"><meta property="fb:pages" content="224867310939090"><meta content="SeekingAlpha" property="al:ios:app_name"><meta content="552799694" property="al:ios:app_store_id"><meta content="SeekingAlpha" property="al:android:app_name"><meta content="com.seekingalpha.webwrapper" property="al:android:package"><meta name="google-site-verification" content="8arRaWMkVniCnxJWf9hbm-0PYkb_LhjaXAk7rGd97iw"><meta name="msvalidate.01" content="0FEA0055AC330065CFA87CA3045E9860"><meta property="og:locale" content="en_US"><meta property="og:site_name" content="Seeking Alpha"><link rel="mask-icon" href="/samw/static/images/favicon.svg" color="#ff7200"><link rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon.png"><link sizes="57x57" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-57x57.png"><link sizes="60x60" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-60x60.png"><link sizes="72x72" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-72x72.png"><link sizes="76x76" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-76x76.png"><link sizes="114x114" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-114x114.png"><link sizes="120x120" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-120x120.png"><link sizes="144x144" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-144x144.png"><link sizes="152x152" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-152x152.png"><link sizes="180x180" rel="apple-touch-icon" href="/samw/static/images/apple-touch-icon-180x180.png"><link sizes="16x16" rel="icon" type="image/png" href="/samw/static/images/favicon-16x16.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-32x32.png"><link sizes="32x32" rel="icon" type="image/png" href="/samw/static/images/favicon-96x96.png"><link sizes="192x192" rel="icon" type="image/png" href="/samw/static/images/favicon-192x192.png"><link href="https://seekingalpha.com/javascripts/seeking.xml" title="Seeking Alpha&#x27;s Symbol search" type="application/opensearchdescription+xml"><script>performance&&"function"==typeof performance.mark&&performance.mark("SA_booted")</script><script id="sa_build_number">window.SA_PR_NUMBER = "null";
    window.SA_RUN_NUMBER = "12356";
    window.SA_BUILD_DATE = 1696602425426;</script><link href="/samw/favicon.ico" rel="icon"><style data-href="/samw/static/styles/app.217b4ccc.css">@keyframes au_eN{to{transform:rotate(1turn)}}.au_gs{animation:au_eN 1s linear infinite;color:var(--sa-spinner-color,currentColor);height:1em;width:1em}@media screen and (prefers-reduced-motion:reduce){.au_gs{animation:none}}.s_as{padding:0}.s_at{margin:0}.s_au{padding-top:0}.s_av{padding-top:2px}.s_aw{padding-top:4px}.s_ax{padding-top:6px}.s_ay{padding-top:8px}.s_az{padding-top:10px}.s_aA{padding-top:12px}.s_aB{padding-top:14px}.s_aC{padding-top:16px}.s_aE{padding-top:18px}.s_aF{padding-top:20px}.s_aG{padding-top:24px}.s_aH{padding-top:28px}.s_aI{padding-top:30px}.s_aJ{padding-top:32px}.s_aK{padding-top:36px}.s_aL{padding-top:40px}.s_aM{padding-top:42px}.s_aN{padding-top:48px}.s_aO{padding-top:64px}.s_aP{padding-top:72px}.s_aQ{padding-left:0}.s_aR{padding-left:2px}.s_aS{padding-left:4px}.s_aT{padding-left:6px}.s_aU{padding-left:8px}.s_aV{padding-left:10px}.s_aW{padding-left:12px}.s_aX{padding-left:14px}.s_aY{padding-left:16px}.s_aZ{padding-left:18px}.s_a0{padding-left:20px}.s_a1{padding-left:24px}.s_a2{padding-left:28px}.s_a3{padding-left:30px}.s_a4{padding-left:32px}.s_a5{padding-left:36px}.s_a6{padding-left:40px}.s_a7{padding-left:44px}.s_a8{padding-left:48px}.s_a9{padding-left:50px}.s_ba{padding-left:54px}.s_bb{padding-left:64px}.s_bc{padding-left:72px}.s_bd{padding-right:0}.s_be{padding-right:2px}.s_bf{padding-right:4px}.s_bg{padding-right:6px}.s_bh{padding-right:8px}.s_bi{padding-right:10px}.s_bj{padding-right:12px}.s_bk{padding-right:14px}.s_bl{padding-right:16px}.s_bm{padding-right:18px}.s_bn{padding-right:20px}.s_bo{padding-right:24px}.s_bp{padding-right:26px}.s_bq{padding-right:28px}.s_br{padding-right:30px}.s_bs{padding-right:32px}.s_bt{padding-right:36px}.s_bu{padding-right:40px}.s_bv{padding-right:48px}.s_bw{padding-right:64px}.s_bx{padding-right:72px}.s_by{padding-bottom:0}.s_bz{padding-bottom:2px}.s_bA{padding-bottom:4px}.s_bB{padding-bottom:6px}.s_bC{padding-bottom:8px}.s_bD{padding-bottom:10px}.s_bE{padding-bottom:12px}.s_bF{padding-bottom:14px}.s_bG{padding-bottom:16px}.s_bH{padding-bottom:18px}.s_bI{padding-bottom:20px}.s_bJ{padding-bottom:24px}.s_bK{padding-bottom:28px}.s_bL{padding-bottom:30px}.s_bM{padding-bottom:32px}.s_bN{padding-bottom:36px}.s_bO{padding-bottom:40px}.s_bP{padding-bottom:42px}.s_bQ{padding-bottom:44px}.s_bR{padding-bottom:48px}.s_bS{padding-bottom:64px}.s_bT{padding-bottom:72px}.s_bU,.s_bV{margin-top:0}.s_bW{margin-top:2px}.s_bX{margin-top:-2px}.s_bY{margin-top:4px}.s_bZ{margin-top:-4px}.s_b0{margin-top:6px}.s_b1{margin-top:-6px}.s_b2{margin-top:8px}.s_b3{margin-top:-8px}.s_b4{margin-top:10px}.s_b5{margin-top:-10px}.s_b6{margin-top:12px}.s_b7{margin-top:-12px}.s_b8{margin-top:14px}.s_b9{margin-top:-14px}.s_ca{margin-top:16px}.s_cb{margin-top:-16px}.s_cc{margin-top:18px}.s_cd{margin-top:-18px}.s_ce{margin-top:20px}.s_cf{margin-top:-20px}.s_cg{margin-top:24px}.s_ch{margin-top:-24px}.s_ci{margin-top:28px}.s_cj{margin-top:-28px}.s_ck{margin-top:30px}.s_cl{margin-top:-30px}.s_cm{margin-top:32px}.s_cn{margin-top:-32px}.s_co{margin-top:36px}.s_cp{margin-top:-36px}.s_cq{margin-top:40px}.s_cr{margin-top:-40px}.s_cs{margin-top:48px}.s_ct{margin-top:-48px}.s_cu{margin-top:64px}.s_cv{margin-top:-64px}.s_cw{margin-top:72px}.s_cx{margin-top:-72px}.s_cy{margin-left:auto}.s_cA,.s_cz{margin-left:0}.s_cB{margin-left:2px}.s_cC{margin-left:-2px}.s_cD{margin-left:4px}.s_cE{margin-left:-4px}.s_cF{margin-left:6px}.s_cG{margin-left:-6px}.s_cH{margin-left:8px}.s_cI{margin-left:-8px}.s_cJ{margin-left:10px}.s_cK{margin-left:-10px}.s_cL{margin-left:12px}.s_cM{margin-left:-12px}.s_cN{margin-left:14px}.s_cO{margin-left:-14px}.s_cP{margin-left:16px}.s_cQ{margin-left:-16px}.s_cR{margin-left:18px}.s_cS{margin-left:-18px}.s_cT{margin-left:20px}.s_cU{margin-left:-20px}.s_cV{margin-left:24px}.s_cW{margin-left:-24px}.s_cX{margin-left:28px}.s_cY{margin-left:-28px}.s_cZ{margin-left:30px}.s_c0{margin-left:-30px}.s_c1{margin-left:32px}.s_c2{margin-left:-32px}.s_c3{margin-left:36px}.s_c4{margin-left:-36px}.s_c5{margin-left:40px}.s_c6{margin-left:-40px}.s_c7{margin-left:48px}.s_c8{margin-left:-48px}.s_c9{margin-left:64px}.s_da{margin-left:-64px}.s_db{margin-left:72px}.s_dc{margin-left:-72px}.s_dd{margin-right:auto}.s_de,.s_df{margin-right:0}.s_dg{margin-right:2px}.s_dh{margin-right:-2px}.s_di{margin-right:4px}.s_dj{margin-right:-4px}.s_dk{margin-right:6px}.s_dl{margin-right:-6px}.s_dm{margin-right:8px}.s_dn{margin-right:-8px}.s_do{margin-right:10px}.s_dp{margin-right:-10px}.s_dq{margin-right:12px}.s_dr{margin-right:-12px}.s_ds{margin-right:14px}.s_dt{margin-right:-14px}.s_du{margin-right:16px}.s_dv{margin-right:-16px}.s_dw{margin-right:18px}.s_dx{margin-right:-18px}.s_dy{margin-right:20px}.s_dz{margin-right:-20px}.s_dA{margin-right:24px}.s_dB{margin-right:-24px}.s_dC{margin-right:28px}.s_dD{margin-right:-28px}.s_dE{margin-right:30px}.s_dF{margin-right:-30px}.s_dG{margin-right:32px}.s_dH{margin-right:-32px}.s_dI{margin-right:36px}.s_dJ{margin-right:-36px}.s_dK{margin-right:40px}.s_dL{margin-right:-40px}.s_dM{margin-right:48px}.s_dN{margin-right:-48px}.s_dO{margin-right:64px}.s_dP{margin-right:-64px}.s_dQ{margin-right:72px}.s_dR{margin-right:-72px}.s_dS{margin-bottom:auto}.s_dT,.s_dU{margin-bottom:0}.s_dV{margin-bottom:2px}.s_dW{margin-bottom:-2px}.s_dX{margin-bottom:4px}.s_dY{margin-bottom:-4px}.s_dZ{margin-bottom:6px}.s_d0{margin-bottom:-6px}.s_d1{margin-bottom:8px}.s_d2{margin-bottom:-8px}.s_d3{margin-bottom:10px}.s_d4{margin-bottom:-10px}.s_d5{margin-bottom:12px}.s_d6{margin-bottom:-12px}.s_d7{margin-bottom:14px}.s_d8{margin-bottom:-14px}.s_d9{margin-bottom:16px}.s_ea{margin-bottom:-16px}.s_eb{margin-bottom:18px}.s_ec{margin-bottom:-18px}.s_ed{margin-bottom:20px}.s_ee{margin-bottom:-20px}.s_ef{margin-bottom:22px}.s_eg{margin-bottom:24px}.s_eh{margin-bottom:26px}.s_ei{margin-bottom:-24px}.s_ej{margin-bottom:28px}.s_ek{margin-bottom:-28px}.s_el{margin-bottom:30px}.s_em{margin-bottom:-30px}.s_en{margin-bottom:32px}.s_eo{margin-bottom:-32px}.s_ep{margin-bottom:36px}.s_eq{margin-bottom:-36px}.s_er{margin-bottom:40px}.s_es{margin-bottom:42px}.s_et{margin-bottom:-40px}.s_eu{margin-bottom:48px}.s_ev{margin-bottom:-48px}.s_ew{margin-bottom:64px}.s_ex{margin-bottom:-64px}.s_ey{margin-bottom:72px}.s_ez{margin-bottom:-72px}.s_eA{margin-top:auto}.r_4{display:flex}.r_5{display:inline-flex}.r_6{align-items:center}.r_7{align-items:flex-start}.r_8{align-items:flex-end}.r_9{align-items:baseline}.r_aa{align-items:stretch}.r_ab{justify-content:center}.r_ac{justify-content:flex-end}.r_ae{justify-content:flex-start}.r_af{justify-content:space-between}.r_ag{justify-content:space-around}.r_ah{flex-flow:row wrap}.r_ai{flex-flow:column wrap}.r_aj{flex-flow:row}.r_ak{flex-flow:row-reverse}.r_al{flex-flow:row nowrap}.r_am{flex-flow:column}.r_an{flex-flow:column-reverse}.r_ao{flex-flow:column nowrap}.r_ap{flex-grow:1}.r_aq{flex-grow:9999}.r_ar{flex-shrink:0}.U_gW{--modal-padding:36px;max-width:420px;width:calc(100vw - var(--modal-padding))}@media(min-width:768px){.U_gW{flex-grow:0;max-width:none;min-height:566px;width:408px}}.U_gs{font-size:2.5rem}.ax_g{position:relative;text-align:center}@media(min-width:768px){.ax_g{padding:0 54px 28px}}.ax_H{justify-content:center}.ax_iE{background-color:var(--black-5)}@media(min-width:768px){.ax_iE{padding:36px}}[data-color-scheme=dark] .ax_iE:not([data-skip-color-scheme]){background-color:var(--black-95)}.ax_G{border:0;color:var(--sa-link-color);font-weight:500;vertical-align:initial}@media(min-width:768px){.ax_I{left:54px;margin-bottom:0;position:absolute;right:54px}}p+.aR_jh{margin-top:12px}p+.aR_ji{margin-top:18px}p+.aR_jj{margin-top:20px}p+.aR_jk{margin-top:24px}.aS_jl{font-size:.625rem}.aS_jm{font-size:.6875rem}.aS_jn{font-size:.75rem}.aS_jo{font-size:.875rem}.aS_jp{font-size:1rem}.aS_jq{font-size:1.125rem}.aS_jr{font-size:1.25rem}.aS_js{font-size:1.375rem}.aS_jt{font-size:1.5rem}.aS_ju{font-size:1.75rem}.aS_jv{font-size:2rem}.aS_jw{font-size:2.25rem}.aS_jx{font-size:2.375rem}.aS_jy{font-size:3.125rem}.aS_jz{font-size:4.25rem}.aS_jA{line-height:.75rem}.aS_jB{line-height:.8125rem}.aS_jC{line-height:.875rem}.aS_jD{line-height:1.25rem}.aS_jE{line-height:1rem}.aS_jF{line-height:1.75rem}.aS_jG{line-height:1.5rem}.aS_jH{line-height:1.375rem}.aS_jI{line-height:1.625rem}.aS_jJ{line-height:1.875rem}.aS_jK{line-height:2rem}.aS_jL{line-height:2.25rem}.aS_jM{line-height:2.125rem}.aS_jN{line-height:2.375rem}.aS_jO{line-height:2.75rem}.aS_jP{line-height:2.875rem}.aS_jQ{line-height:3.75rem}.aS_jR{line-height:5.125rem}.aS_jS{font-weight:400}.aS_jT{font-weight:700}.aS_jU{font-style:italic}@media(min-width:768px){.aS_jV{font-size:.625rem}.aS_jW{font-size:.6875rem}.aS_jX{font-size:.75rem}.aS_jY{font-size:.875rem}.aS_jZ{font-size:1rem}.aS_j0{font-size:1.125rem}.aS_j1{font-size:1.25rem}.aS_j2{font-size:1.375rem}.aS_j3{font-size:1.5rem}.aS_j4{font-size:1.75rem}.aS_j5{font-size:2rem}.aS_j6{font-size:2.25rem}.aS_j7{font-size:2.375rem}.aS_j8{font-size:3.125rem}.aS_j9{font-size:4.25rem}.aS_ka{line-height:.75rem}.aS_kb{line-height:.8125rem}.aS_kc{line-height:.875rem}.aS_kd{line-height:1.25rem}.aS_ke{line-height:1rem}.aS_kf{line-height:1.75rem}.aS_kg{line-height:1.5rem}.aS_kh{line-height:1.375rem}.aS_ki{line-height:1.625rem}.aS_kj{line-height:1.875rem}.aS_kk{line-height:2rem}.aS_kl{line-height:2.25rem}.aS_km{line-height:2.125rem}.aS_kn{line-height:2.375rem}.aS_ko{line-height:2.75rem}.aS_kp{line-height:2.875rem}.aS_kq{line-height:3.75rem}.aS_kr{line-height:5.125rem}.aS_ks{font-weight:400}.aS_kt{font-weight:700}.aS_ku{font-style:italic}}@media(min-width:1024px){.aS_kv{font-size:.625rem}.aS_kw{font-size:.6875rem}.aS_kx{font-size:.75rem}.aS_ky{font-size:.875rem}.aS_kz{font-size:1rem}.aS_kA{font-size:1.125rem}.aS_kB{font-size:1.25rem}.aS_kC{font-size:1.375rem}.aS_kD{font-size:1.5rem}.aS_kE{font-size:1.75rem}.aS_kF{font-size:2rem}.aS_kG{font-size:2.25rem}.aS_kH{font-size:2.375rem}.aS_kI{font-size:3.125rem}.aS_kJ{font-size:4.25rem}.aS_kK{line-height:.75rem}.aS_kL{line-height:.8125rem}.aS_kM{line-height:.875rem}.aS_kN{line-height:1.25rem}.aS_kO{line-height:1rem}.aS_kP{line-height:1.75rem}.aS_kQ{line-height:1.5rem}.aS_kR{line-height:1.375rem}.aS_kS{line-height:1.625rem}.aS_kT{line-height:1.875rem}.aS_kU{line-height:2rem}.aS_kV{line-height:2.25rem}.aS_kW{line-height:2.125rem}.aS_kX{line-height:2.375rem}.aS_kY{line-height:2.75rem}.aS_kZ{line-height:2.875rem}.aS_k0{line-height:3.75rem}.aS_k1{line-height:5.125rem}.aS_k2{font-weight:400}.aS_k3{font-weight:700}.aS_k4{font-style:italic}}@media(min-width:1200px){.aS_k5{font-size:.625rem}.aS_k6{font-size:.6875rem}.aS_k7{font-size:.75rem}.aS_k8{font-size:.875rem}.aS_k9{font-size:1rem}.aS_la{font-size:1.125rem}.aS_lb{font-size:1.25rem}.aS_lc{font-size:1.375rem}.aS_ld{font-size:1.5rem}.aS_le{font-size:1.75rem}.aS_lf{font-size:2rem}.aS_lg{font-size:2.25rem}.aS_lh{font-size:2.375rem}.aS_li{font-size:3.125rem}.aS_lj{font-size:4.25rem}.aS_lk{line-height:.75rem}.aS_ll{line-height:.8125rem}.aS_lm{line-height:.875rem}.aS_ln{line-height:1.25rem}.aS_lo{line-height:1rem}.aS_lp{line-height:1.75rem}.aS_lq{line-height:1.5rem}.aS_lr{line-height:1.375rem}.aS_ls{line-height:1.625rem}.aS_lt{line-height:1.875rem}.aS_lu{line-height:2rem}.aS_lv{line-height:2.25rem}.aS_lw{line-height:2.125rem}.aS_lx{line-height:2.375rem}.aS_ly{line-height:2.75rem}.aS_lz{line-height:2.875rem}.aS_lA{line-height:3.75rem}.aS_lB{line-height:5.125rem}.aS_lC{font-weight:400}.aS_lD{font-weight:700}.aS_lE{font-style:italic}}.k_g{color:var(--sa-text-color-1);text-align:center}@media(min-width:768px){.k_g{width:590px}}.k_D{max-width:420px}.k_E{word-break:break-all}.k_H{text-align:center}@media(min-width:768px){.k_I{margin-top:36px}}.E_fc{padding:0!important}[data-color-scheme=dark] .E_fc:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--white-100)}.E_fc>header{pointer-events:none;position:absolute;width:100%}.E_fd{fill:var(--black-35)}.E_fd:hover{fill:var(--black-50)}.d_m{background-color:var(--red-100);border-radius:50%;bottom:20px;flex-shrink:0;height:30px;position:fixed;right:20px;width:30px;z-index:1070}.t_eB{display:none}.t_eC{display:inline}.t_eD{display:block}.t_eE{display:inline-block}.g_p{align-items:center;background:var(--black-100-alpha-80);justify-content:center;left:0;overflow:hidden;position:fixed;top:0;z-index:1060}.g_g,.g_p{height:100%;width:100%}.g_g{--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background:var(--white-100);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px}@supports(padding:max(0px)){.g_g{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.g_g:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.g_g:before{height:var(--env-safe-area-inset-top,0)}}@media(min-width:768px){.g_g{height:500px;width:400px}}.g_f{min-height:424px}.px-captcha-visible{display:flex}.c_g{bottom:-56px;height:56px;left:0;opacity:0;position:fixed;right:0;z-index:1070}.c_h{background-color:var(--black-100);border:1px solid var(--black-10);border-radius:28px;color:var(--white-100);font-size:.875rem;font-weight:700;min-width:252px;text-align:center}@media(min-width:1024px){.c_h{min-width:172px}}[data-color-scheme=dark] .c_h:not([data-skip-color-scheme]){background-color:var(--black-10);border-color:var(--black-10);color:var(--black-100)}.c_i{background:var(--red-100-alpha-75)}.c_j{background:var(--teal-100-alpha-75)}@keyframes c_l{0%{bottom:-56px;opacity:0}10%{bottom:26px;opacity:1}90%{bottom:26px;opacity:1}to{bottom:-56px;opacity:0}}.c_k{animation-name:c_l;animation-timing-function:linear}@media screen and (prefers-reduced-motion:reduce){.c_k{animation:none}}.bh_l4{overflow:hidden;text-overflow:ellipsis}.p_g{background-color:var(--orange-60)}.p_a{height:44px}@media(min-width:1024px){.p_a{height:30px}}.p_G{font-size:.875rem;font-weight:700;white-space:nowrap}.p_G,.p_G:focus,.p_G:hover,.p_G:visited{color:var(--white-100);text-decoration:none}.p_G:focus,.p_G:hover{text-decoration:underline}.p_U{height:25px;opacity:.7;position:relative;width:25px}.p_U:focus,.p_U:hover{cursor:pointer;opacity:1}.p_U:after,.p_U:before{background-color:var(--white-100);content:" ";height:25px;left:12.5px;position:absolute;top:0;width:1px}.p_U:before{transform:rotate(45deg)}.p_U:after{transform:rotate(-45deg)}.m_h{min-height:30px;position:relative}.m_N{height:100%;position:absolute;right:0;top:0}.m_O{height:-webkit-fit-content;height:-moz-fit-content;height:fit-content}.m_O:active,.m_O:focus,.m_O:hover{background-color:var(--black-100-alpha-10)}.m_O:active,.m_O:focus{background-color:#0000}.I_fw{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fw.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}.I_fy{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fy.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}.I_fz{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fz.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}.I_fA{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fA.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}.I_fB{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fB.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}@media(min-width:768px){.I_fC{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fC.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:768px){.I_fD{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fD.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:768px){.I_fE{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fE.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:768px){.I_fF{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fF.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:768px){.I_fG{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fG.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1024px){.I_fH{--sa-button-size:1.5rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fH.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:4px;--sa-button-x-padding:4px}}@media(min-width:1024px){.I_fI{--sa-button-size:1.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:0.875rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fI.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:6px;--sa-button-x-padding:6px}}@media(min-width:1024px){.I_fJ{--sa-button-size:2.25rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:0.75rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fJ.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px}}@media(min-width:1024px){.I_fK{--sa-button-size:2.75rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fK.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:5px;--sa-button-x-padding:5px;min-width:var(--sa-button-size)}}@media(min-width:1024px){.I_fL{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fL.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}@media(min-width:1200px){.I_fM{--sa-button-size:3.375rem;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.0625rem;--sa-button-x-padding:1.125rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.5rem;border:1px solid var(--sa-button-border-color,#0000)}.I_fM.I_fx{--sa-btn-icon-margin:0rem;--sa-button-y-padding:10px;--sa-button-x-padding:10px}}.I_fN{--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000)}.I_fN.I_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.I_fN:active{--sa-button-border-color:#0000}.I_fO{--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color)}.I_fO.I_fx{--sa-btn-icon-margin:0rem}.I_fO:active{--sa-button-border-color:#0000}.I_fP{--sa-button-background-color:var(--black-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fP:active,.I_fP:hover{--sa-button-background-color:var(--black-70)}.I_fP.I_fQ,.I_fP:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-70)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):active{--sa-button-background-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]).I_fQ,[data-color-scheme=dark] .I_fP:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fR{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);--sa-button-border-color:var(--black-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fR:active,.I_fR:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-100)}.I_fR.I_fQ,.I_fR:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-100);opacity:.6}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]){--sa-button-color:var(--black-10);--sa-button-border-color:var(--black-10)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):hover{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-30)}[data-color-scheme=dark] .I_fR:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-30);--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}.I_fS{--sa-button-background-color:var(--teal-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fS:active,.I_fS:hover{--sa-button-background-color:var(--green-90)}.I_fS .I_fQ,.I_fS:disabled{--sa-button-background-color:var(--teal-100);opacity:.6}.I_fT{--sa-button-background-color:var(--red-100);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fT:active,.I_fT:hover{--sa-button-background-color:var(--orange-100)}.I_fT .I_fQ,.I_fT:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]){--sa-button-background-color:var(--red-80);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-100)}[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fT:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fU{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);--sa-button-border-color:var(--red-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fU:active,.I_fU:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--red-100)}.I_fU .I_fQ,.I_fU:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--red-100);opacity:.6}.I_fV{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fV:active,.I_fV:hover{--sa-button-background-color:var(--orange-70)}.I_fV .I_fQ,.I_fV:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]){--sa-button-background-color:var(--orange-60);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--orange-70)}[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fV:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fW{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fW:active,.I_fW:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--orange-70);--sa-button-border-color:var(--orange-70)}.I_fW .I_fQ,.I_fW:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--orange-60);--sa-button-border-color:var(--orange-60);opacity:.6}.I_fX{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-70);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fX:active,.I_fX:hover{--sa-button-background-color:var(--black-10)}.I_fX .I_fQ,.I_fX:disabled{--sa-button-background-color:var(--black-20)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-border-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fX:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_fY{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_fY:active,.I_fY:hover{--sa-button-background-color:var(--black-5)}.I_fY .I_fQ,.I_fY:disabled{--sa-button-background-color:#0000;opacity:.6}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-95);--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-80)}[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fY:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-95);opacity:.6}.I_fZ{--sa-button-background-color:var(--black-5);--sa-button-color:var(--sa-link-color);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_fZ:active,.I_fZ:hover{--sa-button-background-color:var(--black-10)}.I_fZ .I_fQ,.I_fZ:disabled{--sa-button-background-color:var(--black-5);opacity:.6}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30-alpha-20);--sa-button-color:var(--blue-70)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30-alpha-30)}[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_fZ:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f0{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f0:active,.I_f0:hover{--sa-button-color:var(--white-100);--sa-button-background-color:var(--black-70)}.I_f0 .I_fQ,.I_f0:disabled{--sa-button-color:var(--black-20);--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30-alpha-20)}.I_f1{--sa-button-background-color:#0000;--sa-button-color:var(--black-50);--sa-button-border-color:var(--black-10);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f1:active,.I_f1:hover{--sa-button-background-color:var(--black-70);--sa-button-border-color:var(--black-70);--sa-button-color:var(--white-100)}.I_f1 .I_fQ,.I_f1:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-95);--sa-button-border-color:var(--black-10);opacity:.6}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]){--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-30);--sa-button-border-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f1:not([data-skip-color-scheme]):disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-30);--sa-button-border-color:var(--black-80);opacity:.6}.I_f2{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f2:active,.I_f2:hover{--sa-button-background-color:var(--blue-80)}.I_f2 .I_fQ,.I_f2:disabled{--sa-button-background-color:var(--blue-75);opacity:.6}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]){--sa-button-background-color:var(--blue-75);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--blue-80)}[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f2:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f3{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);--sa-button-border-color:var(--blue-75);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f3:active,.I_f3:hover{--sa-button-background-color:var(--blue-75);--sa-button-color:var(--white-100)}.I_f3 .I_fQ,.I_f3:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-75);opacity:.6}.I_f4{--sa-button-background-color:var(--yellow-85);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f4:active,.I_f4:hover{--sa-button-background-color:var(--yellow-100)}.I_f4 .I_fQ,.I_f4:disabled{--sa-button-background-color:var(--yellow-85);opacity:.6}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]){--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f4:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f5{--sa-button-background-color:var(--blue-80);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f5:active,.I_f5:hover{--sa-button-background-color:var(--blue-100);--sa-button-border-color:var(--blue-80)}.I_f5 .I_fQ,.I_f5:disabled{--sa-button-background-color:var(--blue-80);opacity:.6}.I_f6{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);--sa-button-border-color:var(--blue-80);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f6:active,.I_f6:hover{--sa-button-background-color:var(--blue-100);--sa-button-color:var(--white-100)}.I_f6 .I_fQ,.I_f6:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--blue-80);opacity:.6}.I_f7{--sa-button-background-color:var(--black-35);--sa-button-color:var(--white-100);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f7:active,.I_f7:hover{--sa-button-background-color:var(--black-50)}.I_f7 .I_fQ,.I_f7:disabled{--sa-button-background-color:var(--black-35);opacity:.6}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-100)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-10)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):active{--sa-button-border-color:var(--black-50)}[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f7:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30)}.I_f8{--sa-button-background-color:#0000;--sa-button-color:var(--black-35);--sa-button-border-color:var(--black-35);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_f8:active,.I_f8:hover{--sa-button-background-color:var(--black-50);--sa-button-border-color:var(--black-50);--sa-button-color:var(--white-100)}.I_f8 .I_fQ,.I_f8:disabled{--sa-button-background-color:#0000;--sa-button-border-color:var(--black-35);--sa-button-color:var(--black-35);opacity:.6}.I_f9{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor;--sa-button-border-color:var(--sa-button-background-color)}.I_f9:active,.I_f9:hover{--sa-button-background-color:var(--black-10);--sa-button-color:var(--black-70)}.I_f9 .I_fQ,.I_f9:disabled{--sa-button-background-color:var(--black-5);--sa-button-color:var(--black-50);opacity:.6}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-80);--sa-button-color:var(--black-30)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-90);--sa-button-color:var(--black-10)}[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_f9:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-30);--sa-button-color:var(--black-30)}.I_ga{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);--sa-button-border-color:var(--black-50);--sa-button-border-radius:4px;--sa-btn-icon-color:currentColor}.I_ga:active,.I_ga:hover{--sa-button-background-color:var(--black-50);--sa-button-color:var(--white-100)}.I_ga .I_fQ,.I_ga:disabled{--sa-button-background-color:#0000;--sa-button-color:var(--black-70);opacity:.6}.I_G{--sa-button-color:var(--sa-link-color);display:inline}.I_G:active,.I_G:focus,.I_G:hover{text-decoration:underline}.I_gb{--sa-button-background-color:var(--orange-60);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gb:active,.I_gb:hover{--sa-button-background-color:var(--orange-70)}.I_gb:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gb .I_fQ,.I_gb:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gc{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gc:active,.I_gc:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gc:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gc .I_fQ,.I_gc:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gc:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gd:active,.I_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.I_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gd .I_fQ,.I_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_ge{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--navy-80-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_ge:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_ge:active,.I_ge:hover{--sa-button-background-color:var(--black-15-v2);--sa-button-color:var(--navy-80-v2)}.I_ge .I_fQ,.I_ge:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_ge:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gf{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gf:active,.I_gf:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gf:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gf .I_fQ,.I_gf:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gf:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gg{--sa-button-background-color:var(--black-60-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gg:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gg:active,.I_gg:hover{--sa-button-background-color:var(--black-55-v2)}.I_gg .I_fQ,.I_gg:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-25-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gg:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}.I_gh{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gh:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gh:active,.I_gh:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gh .I_fQ,.I_gh:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gh:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gi:active,.I_gi:hover{--sa-button-background-color:var(--black-5-v2)}.I_gi .I_fQ,.I_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.I_gj:active,.I_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.I_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.I_gj .I_fQ,.I_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]) .I_fQ,[data-color-scheme=dark] .I_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.I_0{background-clip:padding-box;background-color:var(--sa-button-background-color);border-radius:var(--sa-button-border-radius);color:var(--sa-button-color);cursor:pointer;min-height:var(--sa-button-height);padding:var(--sa-button-y-padding) var(--sa-button-x-padding);position:relative;transition:color .15s ease-in-out,background-color .15s ease-in-out,border-color .15s ease-in-out,box-shadow .15s ease-in-out;-webkit-user-select:none;user-select:none;white-space:nowrap;word-break:break-word}@media screen and (prefers-reduced-motion:reduce){.I_0{transition:none}}.I_0 svg{transition:fill .15s ease-in-out}@media screen and (prefers-reduced-motion:reduce){.I_0 svg{transition:none}}.I_gk{height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.I_gk svg{fill:var(--sa-btn-icon-color,currentColor);color:var(--sa-btn-icon-color,inherit);display:block;height:100%;width:100%}.I_gl{margin-right:var(--sa-btn-icon-margin)}.I_gm{margin-left:var(--sa-btn-icon-margin)}.I_fx{--sa-btn-icon-margin:0}.I_gn{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.I_go{width:100%}.I_gp{white-space:normal}.I_gq{pointer-events:none;position:relative}.I_gr{opacity:0}.I_gs{left:50%;position:absolute;top:50%;transform:translate(-50%,-50%)}.I_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}@keyframes I_eN{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.L_G,.L_G:hover{text-decoration:none}.L_gv,.L_gv:visited{--sa-button-color:var(--sa-link-color)}[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-98)}@media(min-width:768px){[data-color-scheme=dark] .n_f:not([data-skip-color-scheme]){--sa-modal-container-bg-color:var(--black-80)}}.H_ft{width:130px}.H_e9{max-height:30px;max-width:130px}.H_e9,[data-color-scheme=dark] .H_e9:not([data-skip-color-scheme]){background:0 0}.u_h{padding-top:0}@media(min-width:1024px){.u_h{height:30px;padding-bottom:0;padding-top:0}}.u_eG{width:768px}@media(min-width:1024px){.u_eG .u_h{height:auto}}.u_eH{max-width:576px;width:100%}@media(min-width:1024px){.u_eH .u_h{height:auto}}.u_eI{background:var(--background)}@media(min-width:576px){.u_eI{text-align:center}}.u_O{color:var(--closeColor);position:relative}.u_O:after{background-color:var(--closeColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.u_O:focus,.u_O:hover{background-color:#0000}.u_O:focus:after,.u_O:hover:after{opacity:.4}[data-color-scheme=dark] .u_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .u_O:hover:not([data-skip-color-scheme]){background-color:#0000}.u_eJ{height:100%;opacity:0;position:absolute;width:100%}@media(min-width:768px){.u_eK{margin-left:18px;margin-right:18px}}.u_eK p{color:var(--black-100);margin-bottom:0}@media(min-width:768px){.u_eK p{text-overflow:ellipsis;white-space:nowrap}}.u_eK a,.u_eK a:focus,.u_eK a:hover,.u_eK a:visited{color:currentColor;text-decoration:inherit}.u_eK a:before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.i_r{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);padding-bottom:0}@supports(padding:max(0px)){.i_r{padding-bottom:var(--env-safe-area-inset-bottom,0)}}.bE_a{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);margin-left:auto;margin-right:auto;padding-left:18px;padding-right:18px;width:100%}@supports(padding:max(0px)){.bE_a{padding-left:max(18px,var(--env-safe-area-inset-left,0));padding-right:max(18px,var(--env-safe-area-inset-right,0))}}.O_gA{color:var(--sa-text-color-2);font-size:.875rem;line-height:1.75}.bP_mY{list-style:none;margin:0;padding-left:0}.bP_G,.bP_G:focus,.bP_G:hover,.bP_G:visited{color:var(--white-100);text-decoration:none}.bP_G:focus,.bP_G:hover{text-decoration:underline}.T_gQ{background-image:url(/samw/static/images/stock-exchange.6df9b8a9.jpg);background-size:cover;height:100%}.T_gR{background-image:linear-gradient(180deg,#0000,#0000001a 0,#0000001c 0,#000 55%)}.T_f{color:var(--white-100);padding-top:170px}.T_gS{font-size:3rem;line-height:1}.T_gT{font-size:.875rem}.T_gU{color:var(--sa-text-color-3);font-weight:400}.T_gV{height:0;visibility:hidden;width:0}@keyframes a_c{0%{transform:translateY(100%)}to{transform:translateY(0)}}.a_a{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1030}.a_b{animation:a_c .4s ease-out;height:100%}@media screen and (prefers-reduced-motion:reduce){.a_b{animation:none}}.o_P{background-color:var(--sa-modal-container-bg-color);position:relative;text-align:center;width:320px}@media(min-width:576px){.o_P{padding:32px 36px;width:544px}}@media(min-width:768px){.o_P{width:736px}}@media(min-width:1024px){.o_P{width:800px}}.o_f{white-space:break-spaces}@media(min-width:576px){.o_S{padding:32px 0}}.o_T{border-radius:.25rem;height:44px;width:100%}@media(min-width:576px){.o_T{height:35px;width:160px}}.v_g{color:var(--white-100);text-align:center;width:320px}.v_eM{fill:currentColor;animation:v_eN 1.4s linear infinite;height:62px;width:62px}@media screen and (prefers-reduced-motion:reduce){.v_eM{animation:none}}@keyframes v_eN{to{transform:rotate(1turn)}}.f_g{height:100vh;left:0;min-width:100%;position:fixed;top:0;z-index:1040}.f_f{position:relative;z-index:1050}.f_f,.f_n{height:100%;width:100%}.f_n{background:var(--black-100);left:0;opacity:.6;position:fixed;top:0;z-index:1040}.f_o{overflow:hidden}.hf_fd{flex-shrink:0;height:1.125rem;width:1.125rem}.cT_P{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);background-color:var(--white-100);box-shadow:0 4px 8px 0 #00000040;color:var(--black-100);pointer-events:auto;position:relative;width:100%}.cT_P:before{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.cT_P:before{height:var(--env-safe-area-inset-top,0)}}.cT_o8{height:100%;max-height:none;max-width:none;width:100%}@media(min-width:768px){.cT_o9{border-radius:10px;height:608px;max-width:360px;padding-bottom:44px}}.av_n{opacity:0!important}.ex_eM{fill:var(--black-10);animation:ex_eN 1.4s linear infinite;height:54px;width:55px}@media screen and (prefers-reduced-motion:reduce){.ex_eM{animation:none}}@keyframes ex_eN{to{transform:rotate(1turn)}}.scrollLocked .aB_iS{padding-right:var(--scrollbar-width)}@media print{.aQ_jg{display:none!important}}.bodyNavOpened .j_n{background:var(--black-100);height:100%;left:0;opacity:.6;position:fixed;top:0;width:100%;z-index:1040}.scrollLocked{overflow:hidden!important}.j_a{min-width:0}.j_s a:focus,.j_s a:hover{text-decoration:none}.j_t{padding-top:var(--headerFullHeight)}@media print{.j_t{padding-top:0!important}}.j_u{padding-bottom:var(--sa-mobile-bottom-navigation-height)}@media(min-width:768px){.j_v .j_a{display:flex}}.j_v .tp-backdrop,.j_v .tp-modal{display:none!important}.j_v.tp-modal-open{height:auto}.j_w{--env-safe-area-inset-top:env(safe-area-inset-top);--sa-header-bar-height:calc(50px + var(--env-safe-area-inset-top));--sa-drawer-top-offset:0;min-height:100vh;position:relative}@media(min-width:1024px){.j_w{--sa-header-bar-height:calc(90px + var(--env-safe-area-inset-top));z-index:0}}.j_x{--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);min-height:calc(100vh - var(--sa-header-bar-height));padding-top:var(--headerHeight);position:relative}.j_x:after{content:" ";display:block;flex-shrink:0;height:0;width:100%}@supports(height:max(0px)){.j_x:after{height:var(--env-safe-area-inset-bottom,0)}}@media print{.j_x *{font-family:sans-serif!important}}@media(min-width:1024px){.j_y{padding-top:0}}@media(min-width:768px){.j_z{min-height:18px}}@media(min-width:1024px){.j_z{min-height:40px}}.j_A+.j_z{display:none}.J_gu{min-height:1.875rem}.h_f{box-shadow:0 4px 8px 0 #00000040}@media(min-width:768px){.h_f{max-width:500px;width:100%}}.bi_fu{text-align:left}.bi_l5{text-align:center}.bi_fv{text-align:right}.q_g{background:var(--black-100-alpha-50);height:100%;min-height:100vh;position:fixed;top:0;width:100%;z-index:1050}[data-color-scheme=dark] .q_g:not([data-skip-color-scheme]){background:var(--white-100-alpha-50)}.q_V{border-top:1px solid var(--sa-section-separator-thin-color);font-size:.875rem}.q_W{background:var(--sa-card-bg-color);border-radius:10px;box-sizing:border-box;position:relative;width:330px}.q_Y,.q_Z{text-align:center}.q_Z{word-wrap:break-word;font-size:.875rem}.q_0{border-top:1px solid var(--sa-section-separator-thin-color);bottom:0;color:var(--sa-link-color);font-weight:400}.q_1{width:100%}.q_2{left:0;width:50%}.q_3{border-left:1px solid var(--sa-section-separator-thin-color);right:0;width:50%}.aj_e2,.aj_e2:focus,.aj_e2:hover,.aj_e2:visited{color:inherit;text-decoration:none}.aj_gy{height:26px;width:142px}@media(min-width:375px){.aj_gy{height:30px;width:150px}}.aj_hl{color:var(--orange-60)}.aj_hL{fill:var(--orange-60);color:var(--white-100)}.aj_hM{fill:var(--teal-50)}.aj_hN{fill:var(--yellow-85)}.aj_hO{display:none;width:35px}@media(min-width:768px){.aj_hO{display:block}}.aj_hP{height:26px}@media(min-width:1024px){.aj_hP{height:32px;margin-bottom:2px}}.aj_gi{color:var(--white-100)}.aj_fP{color:var(--sa-text-color-1)}.aj_hQ{clip:rect(0,0,0,0);border:0!important;height:1px!important;left:0!important;overflow:hidden;padding:0!important;position:absolute!important;top:0!important;white-space:nowrap;width:1px!important}.aa_g0{display:none}@media(min-width:375px){.aa_g0{display:block}.aa_g1{display:none}}.aa_g2{display:none}@media(min-width:576px){.aa_g2{display:block}.aa_g3{display:none}}.aa_g4{display:none}@media(min-width:768px){.aa_g4{display:block}.aa_g5{display:none}}.aa_g6{display:none}@media(min-width:1024px){.aa_g6{display:block}.aa_g7{display:none}}.aa_g8{display:none}@media(min-width:1200px){.aa_g8{display:block}.aa_g9{display:none}}.aa_ha{display:none}@media(min-width:1540px){.aa_ha{display:block}.aa_hb{display:none}}.R_gL{height:20px;position:relative;width:18px}.R_gM{background-color:var(--white-100);height:2px;position:absolute;top:calc(50% - 1px);transition:background-color .05s ease-in-out .05s;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM{transition:none}}.R_gM:before{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(-5px);transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:before{transition:none}}.R_gM:after{background-color:var(--white-100);content:"";display:block;height:2px;position:absolute;transform:translateY(calc(100% + 3px));transition:transform .1s ease-in-out;width:18px}@media screen and (prefers-reduced-motion:reduce){.R_gM:after{transition:none}}.R_gN{background-color:var(--white-100-alpha-0);transition:background-color .05s ease-in-out}.R_gN:before{transform:rotate(45deg) translateY(0)}.R_gN:after{transform:rotate(-45deg) translateY(0)}.ah_hI{transform:rotate(90deg)}.dz_nE{background-color:var(--orange-60);border:2px solid var(--sa-notification-badge-border-color,var(--black-70));border-radius:4px;color:var(--sa-notification-badge-color,var(--black-100));font-weight:700;min-width:1.25rem;padding:var(--sa-notification-badge-padding,2px);position:absolute;right:0;top:0;transform:translateX(var(--sa-notification-badge-translateX,50%)) translateY(var(--sa-notification-badge-translateY,-25%))}.dG_fd{height:25px;width:31px}.br_mj{--sa-header-sub-menu-bg:var(--white-100);background-color:var(--sa-header-sub-menu-bg);box-shadow:0 0 5px 2px #00000021;z-index:1060}[data-color-scheme=dark] .br_mj:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--black-80)}.br_mk:hover .br_mj{display:block}.br_ml{background-color:var(--sa-header-sub-menu-bg)}.br_ml,.br_ml:focus,.br_ml:hover,.br_ml:visited{color:var(--sa-header-sub-menu-color);text-decoration:none}.br_ml:focus,.br_ml:hover{--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--white-100);text-decoration:underline;text-decoration:none}[data-color-scheme=dark] .br_ml:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .br_ml:hover:not([data-skip-color-scheme]){--sa-header-sub-menu-bg:var(--blue-80);--sa-header-sub-menu-color:var(--black-100)}.ce_nE{background-color:var(--orange-100-v2);border:1px solid var(--sa-notification-badge-border-color,var(--white-100));color:var(--sa-notification-badge-color,var(--white-100));font-size:8px;font-weight:600;left:50%;line-height:8px;min-height:.375rem;min-width:.375rem;padding:var(--sa-notification-badge-padding,1px);position:absolute;top:0}.al_a{height:var(--sa-btn-icon-size,24px);line-height:0;width:var(--sa-btn-icon-size,24px)}.ak_a,.al_a{--sa-notification-badge-color:var(--white-100);--sa-notification-badge-border-color:var(--sa-button-background-color,var(--black-90-v2));position:relative}.bz_gd{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gd:active,.bz_gd:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_gd:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gd .bz_fQ,.bz_gd:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gd:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gi{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gi:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gi:active,.bz_gi:hover{--sa-button-background-color:var(--black-5-v2)}.bz_gi .bz_fQ,.bz_gi:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gi:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_gj{--sa-button-background-color:var(--navy-80-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;text-transform:uppercase}.bz_gj:active,.bz_gj:hover{--sa-button-background-color:var(--navy-75-v2)}.bz_gj:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_gj .bz_fQ,.bz_gj:disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]){--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--navy-95-v2)}[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_gj:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0{--sa-button-size:2.25rem;--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;min-height:var(--sa-button-size);min-width:var(--sa-button-size)}@media(min-width:768px){.bz_0{--sa-button-background-color:var(--navy-100-v2);--sa-button-color:var(--white-100);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:2.25rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.25rem;--sa-button-x-padding:0.25rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color);text-transform:uppercase}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--navy-95-v2)}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem}.bz_0:active{--sa-button-border-color:#0000}}@media(min-width:1024px){.bz_0{--sa-button-background-color:var(--white-100);--sa-button-color:var(--black-90-v2);--sa-button-border-radius:0;--sa-btn-icon-color:currentColor;--sa-button-size:3rem;--sa-button-border-width:2px;--sa-button-height:var(--sa-button-size);--sa-button-y-padding:0.625rem;--sa-button-x-padding:1.375rem;--sa-btn-icon-size:1.5rem;--sa-btn-icon-margin:0.375rem;border:var(--sa-button-border-width) solid var(--sa-button-border-color,#0000);text-transform:uppercase}.bz_0:not(:active){--sa-button-border-color:var(--sa-button-background-color)}.bz_0:active,.bz_0:hover{--sa-button-background-color:var(--black-5-v2)}.bz_0 .bz_fQ,.bz_0:disabled{--sa-button-background-color:var(--black-20-v2);--sa-button-color:var(--black-60-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]){--sa-button-background-color:var(--black-70-v2);--sa-button-color:var(--black-20-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):active,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):hover{--sa-button-background-color:var(--black-65-v2)}[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]) .bz_fQ,[data-color-scheme=dark] .bz_0:not([data-skip-color-scheme]):disabled{--sa-button-background-color:var(--black-25-v2);--sa-button-color:var(--black-70-v2)}.bz_0.bz_fx{--sa-btn-icon-margin:0rem;--sa-button-x-padding:0.625rem}.bz_0:active{--sa-button-border-color:#0000}}.bz_f{display:none}@media(min-width:768px){.bz_f{display:flex}}.bz_fd{display:inline-flex}@media(min-width:768px){.bz_fd{display:none}}.Q_gE{margin-left:auto;margin-right:-12px}.Q_0{color:var(--white-100);min-width:36px}.Q_0:empty{display:none}@media(min-width:1024px){.Q_gF{margin-right:20px}}.Q_gG{--sa-notification-badge-padding:1px 2px;--sa-notification-badge-translateX:20%;--sa-notification-badge-translateY:-33%}.Q_gH{--sa-notification-badge-border-color:var(--black-100);--sa-notification-badge-color:var(--black-100)}.Q_gI{--sa-notification-badge-border-color:var(--black-5);--sa-notification-badge-color:var(--white-100)}[data-color-scheme=dark] .Q_gI:not([data-skip-color-scheme]){--sa-notification-badge-border-color:var(--black-98);--sa-notification-badge-color:var(--black-98)}.Q_gJ{width:24px}.Q_gK{fill:var(--sa-text-color-2);color:var(--sa-text-color-2)}.B_B{z-index:1030}.B_eY{min-height:var(--sa-header-bar-height)}.B_eZ{max-width:362px}@media(min-width:1200px){.B_eZ{max-width:430px}}@media(min-width:1540px){.B_eZ{max-width:604px}}.B_eZ .B_e0{--sa-searchbox-results-border-color:var(--navy-40-v2)}[data-color-scheme=dark] .B_eZ .B_e0:not([data-skip-color-scheme]){--sa-searchbox-results-border-color:var(--black-70-v2);--sa-search-category-bg:var(--black-80)}.B_e1{height:36px;width:36px}.B_e2{height:24px;width:120px}@media(min-width:1024px){.B_e2{height:32px;width:140px}}.B_0{--sa-btn-icon-size:18px;min-width:36px}.scrollLocked .B_e3{right:calc(var(--scrollbar-width,0)*-1)}.N_0:active,.N_0:focus,.N_0:hover{text-decoration:underline}.ag_hG{overflow:visible}@media(min-width:768px){.ag_hG{overflow:hidden}}.ag_hG :before{height:0}@media(min-width:768px){.ag_hH{align-items:center;background-color:#0000;box-shadow:none;display:flex;height:100%;max-width:100%}}.A_a{background:var(--white-100);border-bottom:1px solid var(--black-50);color:var(--sa-text-color-3);font-size:.875rem;line-height:1.125rem;padding:15px 0;width:100%;z-index:1}.A_eV{height:10px;width:10px}.A_eW{align-self:center;height:20px;width:20px}[data-color-scheme=dark] .A_eW:not([data-skip-color-scheme]){fill:var(--black-50)}.A_f{max-width:960px}.z_eU{background-color:var(--sa-aside-background-color);left:0;opacity:0;padding:12px;pointer-events:none;position:absolute;right:0;top:0;transform:translateY(-100%);transition:transform .1s ease .1s;z-index:1060}@media screen and (prefers-reduced-motion:reduce){.z_eU{transition:none}}.z_eU,.z_eU:focus,.z_eU:hover,.z_eU:visited{color:var(--white-100);text-decoration:none}.z_eU:focus,.z_eU:hover{text-decoration:underline}.z_eU:focus{opacity:1;pointer-events:auto;transform:translateY(0)}.S_gO{bottom:0;left:var(--sa-aside-width,0);position:fixed;right:0;z-index:1020}.S_gP{visibility:hidden}.S_u{bottom:var(--sa-mobile-bottom-navigation-height)}.aw_fd svg{fill:currentColor;display:block;height:100%;width:100%}.V_gX{height:var(--sa-mobile-bottom-navigation-height)}.V_gY{min-width:60px}@media(min-width:576px){.V_gY{min-width:78px}}.V_gY:last-child{min-width:60px}.l_K{left:0;position:fixed;z-index:1030}.l_K,.l_L{bottom:0;width:100%}.l_L{position:-webkit-sticky;position:sticky;z-index:1029}.P_g{--scrollbar-width:4px}.P_g:after,.P_g:before{content:"";height:24px;left:0;position:absolute;right:0}.P_gB{scrollbar-color:var(--black-50) var(--black-70);scrollbar-width:thin}.P_gB::-webkit-scrollbar-thumb{background-color:var(--black-50);border-radius:0}.P_gB::-webkit-scrollbar-track{background-color:var(--black-70);border-radius:0}.P_gB::-webkit-scrollbar{width:var(--scrollbar-width)}.P_gC:after,.P_gC:before,.P_gD:after,.P_gD:before{pointer-events:none}.P_gC:before{background:linear-gradient(180deg,var(--black-100),var(--black-100-alpha-0) 100%);content:"";top:0;z-index:1}@supports(scrollbar-width:thin){.P_gC:before{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gC:before{margin-right:var(--scrollbar-width)}}.P_gD:after{background:linear-gradient(180deg,var(--black-100-alpha-0) 0,var(--black-100) 100%);bottom:0;content:""}@supports(scrollbar-width:thin){.P_gD:after{margin-right:14px}}@supports not (scrollbar-width:thin){.P_gD:after{margin-right:var(--scrollbar-width)}}.x_eQ{width:var(--sa-aside-width,0)}.x_h,.x_n{top:var(--sa-header-bar-height)}.x_h{transition:transform .3s;width:20rem}@media screen and (prefers-reduced-motion:reduce){.x_h{transition:none}}@media(min-width:768px){.x_h{width:21.875rem}}.x_eR .x_h{transform:translateX(-100%)}@media(min-width:1024px){.x_eS{width:var(--sa-aside-width)}.x_eR .x_eS,.x_eS{transform:translateX(0)}}.hydratingAsideCollapsed .x_eT{display:none}.cX_g{list-style:none;margin:0;padding-left:0}.cX_pf{background-color:var(--sa-accordion-caption-bg);width:100%}.cX_pg{align-items:baseline}@media(min-width:1024px){.cX_pg{align-items:center;padding:20px 0}}.cX_ph{align-items:center}.cX_pg,.cX_ph{text-align:left}@media(min-width:1024px){.cX_pg,.cX_ph{align-items:center}}.cX_pg:focus,.cX_pg:hover,.cX_ph:focus,.cX_ph:hover{text-decoration:underline}.cX_pi,.cX_pj{font-size:1.125rem;font-weight:700;line-height:1.375rem}@media(min-width:1024px){.cX_pi,.cX_pj{font-size:1rem;font-weight:700;line-height:1.25rem}}.cX_pk{--sa-accordion-caption-bg:var(--sa-card-bg-color-2);color:var(--sa-text-color-4);font-weight:500;justify-content:space-between;min-height:55px;position:relative}.cX_pl,.cX_pm{background-color:var(--black-10);border-radius:5px;flex-shrink:0;height:24px;transition:transform .1s linear;width:24px}@media screen and (prefers-reduced-motion:reduce){.cX_pl,.cX_pm{transition:none}}@media(min-width:1024px){.cX_pl,.cX_pm{height:20px;width:20px}}[data-color-scheme=dark] .cX_pl:not([data-skip-color-scheme]),[data-color-scheme=dark] .cX_pm:not([data-skip-color-scheme]){background-color:var(--black-95)}.cX_pm{background-color:var(--black-50);border-radius:0;transition:none}.cX_po{transform:rotate(-90deg)}.cX_pp{transform:rotate(0)}.cX_hI{flex-shrink:0}.cX_pq{fill:currentColor;transition:fill .1s linear;width:.75rem}@media screen and (prefers-reduced-motion:reduce){.cX_pq{transition:none}}.cX_pr,.cX_ps{fill:var(--sa-text-color-3);height:8px;width:14px}@media(min-width:1024px){.cX_pr,.cX_ps{height:6px;width:12px}}.cX_ps{fill:var(--white-100);transition:transform .1s linear}@media screen and (prefers-reduced-motion:reduce){.cX_ps{transition:none}}.cX_pt{order:-1}@media(min-width:1024px){.cX_pv,.cX_pw{margin-left:30px}}.cX_px,.cX_py{order:-1}@media(min-width:1024px){.cX_px,.cX_py{margin-right:30px}}.cX_pz{margin-left:18px;transform:rotate(-90deg);transition:transform .25s}@media screen and (prefers-reduced-motion:reduce){.cX_pz{transition:none}}.cX_pA{background-color:var(--sa-section-separator-color)}.cX_pB .cX_pl{background-color:var(--sa-text-color-3)}.cX_pB .cX_pr{fill:var(--sa-invert-default-color)}.cX_pB .cX_po{transform:rotate(0)}.cX_pB .cX_pp{transform:rotate(-180deg)}.cX_pB .cX_pz{transform:rotate(0)}.cX_pB .cX_pm{background-color:var(--black-50);transform:none}.cX_pB .cX_ps{fill:var(--white-100);transform:rotate(-180deg)}.cX_pB .cX_pA{background-color:var(--black-10)}.cX_pC,.cX_pD{font-size:1rem;font-weight:400;line-height:1.5rem}@media(min-width:1024px){.cX_pC,.cX_pD{font-size:.875rem;font-weight:400;line-height:1.25rem}.cX_pC,.cX_pE{padding-left:54px}}.cX_pF{color:var(--sa-text-color-4)}.cX_pG{border-bottom:1px solid var(--sa-section-separator-color)}.cX_pG:last-child,.cX_pG:only-child{border-bottom:0}.cX_pH:last-child{margin-bottom:0}.cV_eI{--sa-menu-active-color:var(--orange-60)}.cV_pa:after,.cV_pa:before{content:"";height:12px;left:0;pointer-events:none;position:absolute;right:0;width:100%}.cV_pa:before{top:-12px}.cV_pa:after{bottom:-12px}.cV_pa:hover:after,.cV_pa:hover:before{pointer-events:auto}.cV_nr{--sa-link-content-color:var(--black-20)}.cV_pb{pointer-events:none}.cV_pb:before{display:none}.cV_pb.cV_o{--sa-link-bg-color:var(--sa-aside-background-color);--sa-link-active-color:var(--orange-60)}.cV_pc{-ms-overflow-style:none;max-height:var(--sa-hovered-height);scrollbar-width:none}.cV_pc::-webkit-scrollbar{display:none}.dh_o{color:var(--sa-link-active-color)}.cv_oi{width:100%}.cv_oj{width:auto}.jQ_f{text-decoration:none;white-space:nowrap;width:0}.jQ_o4{color:var(--black-20)}.eY_gY{--sa-link-bg-color:var(--sa-aside-background-color);background-color:var(--sa-link-bg-color);min-height:2.75rem}@media(hover:hover)and (pointer:fine){.eY_gY:hover{--sa-link-bg-color:var(--black-30-alpha-20)}}.eY_gY:before{background-color:var(--sa-link-active-color);bottom:10px;content:"";left:0;position:absolute;top:10px;width:4px}@media(min-width:1024px){.eY_tu{min-height:1.875rem}.eY_tu .eY_G,.eY_tu.eY_G{padding-bottom:.25rem;padding-top:.25rem}.eY_tu:before{bottom:0;top:0}}.eY_o{--sa-link-active-color:var(--sa-menu-active-color,var(--orange-60));--sa-link-content-color:var(--orange-60)}.eY_f{color:var(--sa-link-content-color,var(--sa-link-active-color))}.eA_mY{--sa-hovered-menu-width:0;width:var(--sa-hovered-menu-width)}.eA_sB{--sa-hovered-menu-width:288px}.eL_rv{min-width:20px}.bX_m4 .bX_m5,.bX_m4:focus-within .bX_m6,.bX_m4:hover .bX_m6{display:none}.bX_m4:focus-within .bX_m5,.bX_m4:hover .bX_m5{display:flex}.do_a,.do_a:focus,.do_a:hover,.do_a:visited{color:inherit;text-decoration:none}.lV_a{border-width:.0625rem;width:100%}@media(min-width:576px){.lV_a{width:168px}}[data-color-scheme=dark] .lV_a:not([data-skip-color-scheme]){border-color:var(--black-30-alpha-20)}@media(min-width:576px){.lV_La{min-height:2.5rem}.lV_Lb{min-height:1.75rem}}.lV_fi{border-top:1px solid var(--black-10)}[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:1px solid var(--black-30-alpha-20)}@media(min-width:576px){[data-color-scheme=dark] .lV_fi:not([data-skip-color-scheme]){border-top:none}}.lV_gt{color:var(--sa-btn-spinner-color,var(--sa-btn-color));height:var(--sa-btn-icon-size);width:var(--sa-btn-icon-size)}.hj_Bo{margin-left:-18px;margin-right:-18px}@media(min-width:576px){.hj_Bo{margin-left:2px;margin-right:2px}}[data-color-scheme=dark] .hj_Bp:not([data-skip-color-scheme]){background-color:var(--black-30-alpha-20)}@media(min-width:768px){.cB_eP{max-width:37.5rem;min-width:37.5rem}}.cU_fd{height:16px;width:16px}.bb_o{--sa-link-content-color:var(--blue-75);--sa-menu-active-color:var(--blue-75)}.C_e4{background:var(--largeTopBannerBackground);position:relative}@media(min-width:768px){.C_e4{margin-bottom:24px}}.C_e4.C_eH{max-width:375px}.C_e4.C_eG{max-width:768px}.C_e4.C_eF{max-width:100%}.C_e5.C_eH{height:60px;margin-bottom:18px}.C_e5.C_eG{margin-bottom:26px}.C_e5.C_eF{margin-bottom:36px;width:260px}.C_e5 img{max-height:100%;max-width:100%}.C_e6 p:last-of-type{margin:0}.C_e6.C_eH{text-align:center}.C_e6.C_eG,.C_e6.C_eH{margin-bottom:24px}.C_e6.C_eF{margin-bottom:36px}.C_e7.C_eH{align-items:center}.C_e8{height:100%;width:100%}.C_e8.C_eH{justify-content:center;max-width:339px}.C_e8.C_eG{max-width:331px}.C_e8.C_eF{max-width:535px}.C_e8 img{max-height:100%;max-width:100%}.C_0{background-color:var(--largeTopBannerButtonColor);max-width:235px;width:100%}.C_0,.C_0:visited{color:var(--largeTopBannerButtonCopyColor)}.C_0.C_eH{margin-bottom:12px;max-width:339px}.C_0.C_eG{max-width:272px}.C_0.C_eF{max-width:300px}.C_g{background-position:bottom;background-repeat:no-repeat}.C_g[data-is-asset-exist=false][data-template-type=top_bottom]{padding-bottom:36px}.C_g[data-template-type=left_right]{align-items:flex-end;gap:26px;justify-content:center}.C_g[data-template-type=left_right].C_eF{gap:48px}.C_g[data-template-type=left_right] .C_e7{align-self:center;padding-bottom:18px;padding-top:18px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eH{max-width:339px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eG{max-width:347px}.C_g[data-template-type=left_right][data-is-asset-exist=true] .C_e6.C_eF{max-width:609px}.C_g[data-fixed-height=true].C_eG{min-height:349px}.C_g[data-fixed-height=true].C_eF{min-height:580px}.C_g[data-template-type=top_bottom]{align-items:center;flex-direction:column}.C_g[data-template-type=top_bottom].C_eH{padding-top:36px}.C_g[data-template-type=top_bottom].C_eF,.C_g[data-template-type=top_bottom].C_eG{padding-top:80px}.C_g[data-template-type=top_bottom] .C_e5{align-content:center;display:flex;flex-flow:column wrap}.C_g[data-template-type=top_bottom] .C_e7{align-items:center;text-align:center}.C_g[data-template-type=top_bottom] .C_e8{justify-content:center}.C_g[data-template-type=top_bottom] .C_0{margin-bottom:12px}.C_e9,[data-color-scheme=dark] .C_e9:not([data-skip-color-scheme]){background-color:#0000}.C_e9.C_eG{margin:0}.C_N{position:absolute;right:18px;top:18px}.C_O{color:var(--largeTopBannerCloseButtonColor);position:relative}.C_O:after{background-color:var(--largeTopBannerCloseButtonColor);content:"";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s ease-in-out;width:100%}.C_O:focus,.C_O:hover{background-color:#0000}.C_O:focus:after,.C_O:hover:after{opacity:.4}[data-color-scheme=dark] .C_O:focus:not([data-skip-color-scheme]),[data-color-scheme=dark] .C_O:hover:not([data-skip-color-scheme]){background-color:#0000}.bO_mW{color:var(--black-35);line-height:1.75}.b_d{max-height:100%}@media(orientation:landscape){.b_d{max-height:668px}}@media(min-width:768px){.b_d{max-height:unset}}.b_e.b_f{padding:0;width:100%}@media(min-width:768px){.b_e.b_f{height:668px;max-width:375px}}@media(min-width:1024px){.b_e.b_f{height:656px;max-width:700px}}@media(min-width:768px){.w_eO{display:flex;flex-flow:row}}@media(min-width:768px){.w_eP{flex-grow:0}}.e_a{left:0;position:fixed;right:0;top:90px;width:100%;z-index:1050}@media(min-width:1540px){.e_a{padding-left:26px;padding-right:26px}}</style><style data-href="/samw/static/styles/prerender.680caa56.css">:root{--sa-mobile-bottom-navigation-height:5rem;--env-safe-area-inset-top:env(safe-area-inset-top);--env-safe-area-inset-bottom:env(safe-area-inset-bottom);--env-safe-area-inset-left:env(safe-area-inset-left);--env-safe-area-inset-right:env(safe-area-inset-right);--twitter-color:#38a1f3;--reddit-color:#ff5700;--facebook-color:#3b5998;--linkedIn-color:#0077b5;--email-color:#999;--sa-sticky-top:calc(var(--headerHeight, 0px) + var(--stripBarHeight, 0px) + var(--headerBottomNav, 0px));--black-98-grad:linear-gradient(90deg,var(--black-98-alpha-0) 0%,var(--black-98) 100%);--black-95-grad:linear-gradient(90deg,var(--black-95-alpha-0) 0%,var(--black-95) 100%);--black-90-grad:linear-gradient(90deg,var(--black-90) 0%,var(--black-100-95) 100%);--black-80-grad:linear-gradient(90deg,var(--black-80) 0%,var(--black-95) 100%);--black-70-grad:linear-gradient(90deg,var(--black-70-alpha-0) 0%,var(--black-70) 100%);--black-60-grad:linear-gradient(180deg,var(--black-60-alpha-50) 0%,var(--black-60) 100%);--black-40-grad:linear-gradient(180deg,var(--black-40-alpha-50) 0%,var(--black-40) 100%);--black-10-grad:linear-gradient(90deg,var(--black-10) 0%,var(--white-100) 100%);--black-5-grad:linear-gradient(90deg,var(--black-5-alpha-0) 0%,var(--black-5) 100%);--white-100-grad:linear-gradient(90deg,var(--white-100-alpha-0) 0%,var(--white-100) 100%);--red-90-grad:linear-gradient(90deg,var(--red-90-alpha-50) 0%,var(--red-90) 100%);--orange-60-grad:linear-gradient(90deg,var(--orange-60-alpha-50) 0%,var(--orange-60) 100%);--teal-80-grad:linear-gradient(90deg,var(--teal-80-alpha-50) 0%,var(--teal-80) 100%);--box-shadow:0 8px 8px var(--black-100-alpha-15);--shadow-elevation-1:0 0 10px #0003;--shadow-elevation-2:0 4px 8px #00000040;--shadow-elevation-3:0 0 10px #000000bf;--shadow-elevation-4:0 4px 8px #000000bf;--black-100:#000;--black-100-alpha-80:#000c;--black-100-alpha-75:#000000bf;--black-100-alpha-50:#00000080;--black-100-alpha-25:#00000040;--black-100-alpha-15:#00000026;--black-100-alpha-10:#0000001a;--black-100-alpha-0:#0000;--black-98:#04080b;--black-98-alpha-0:#04080b00;--black-95:#111517;--black-95-alpha-0:#11151700;--black-90:#232a32;--black-90-alpha-0:#232a3200;--black-80:#2c3032;--black-80-alpha-0:#2c303200;--black-70:#333;--black-70-alpha-0:#3330;--black-70-alpha-50:#33333380;--black-60:#434348;--black-60-alpha-50:#43434880;--black-50:#555;--black-50-alpha-10:#55555580;--black-40:#697173;--black-40-alpha-50:#69717380;--black-35:#757575;--black-35-alpha-50:#75757580;--black-35-alpha-0:#75757500;--black-30:#838d8f;--black-30-alpha-30:#838d8f4d;--black-30-alpha-20:#838d8f33;--black-30-alpha-40:#838d8f66;--black-20:#acacac;--black-20-alpha-20:#acacac33;--black-10:#dbdbdb;--black-5:#f2f4f7;--black-5-alpha-0:#f2f4f700;--black-4:#f9f9f9;--black-90-v2:#101114;--black-85-v2:#1c1d20;--black-80-v2:#212224;--black-70-v2:#3f4248;--black-70-v2-alpha-60:#3f424899;--black-65-v2:#464b54;--black-60-v2:#5e6167;--black-55-v2:#72757b;--black-25-v2:#adb1ba;--black-20-v2:#e0e1e4;--black-15-v2:#e8e8e8;--black-10-v2:#f5f2f1;--black-5-v2:#fcfcfc;--white-96:#f3f4f7;--white-100:#fff;--white-100-alpha-75:#ffffffbf;--white-100-alpha-50:#ffffff80;--white-100-alpha-0:#fff0;--red-100:#c9392c;--red-100-alpha-80:#c9392ccc;--red-100-alpha-75:#c9392cbf;--red-100-alpha-20:#c9392c33;--red-95:#e32b30;--red-95-alpha-50:#e32b3080;--red-90:#d23f31;--red-90-alpha-50:#d23f3180;--red-80:#d94d41;--red-80-alpha-20:#d94d4133;--red-100-v2:#7c1f1f;--red-90-v2:#b94848;--red-80-v2:#bf1d1d;--red-70-v2:#ce3434;--red-60-v2:#d66363;--red-50-v2:#de4e4e;--red-40-v2:#e07575;--red-30-v2:#eb8888;--orange-100:#ff1a00;--orange-100-alpha-50:#ff1a0080;--orange-90:#ea4215;--orange-80:#ff3c00;--orange-70:#d15e00;--orange-60:#ff7200;--orange-60-alpha-50:#ff720080;--orange-60-alpha-0:#ff720000;--orange-100-v2:#ef6d0a;--orange-100-v2-alpha-50:#ef6d0a80;--orange-100-v2-alpha-12:#ef6d0a1f;--orange-95-v2:#f47819;--yellow-100:#e59310;--yellow-100-alpha-50:#e5931080;--yellow-90:#efa818;--yellow-90-alpha-50:#efa81880;--yellow-85:#fec20f;--yellow-80:#fcc131;--yellow-70:#dfbf18;--yellow-100-v2:#d6c100;--yellow-90-v2:#e8da58;--yellow-80-v2:#ebd517;--yellow-70-v2:#ffeb33;--yellow-60-v2:#f3e56a;--yellow-50-v2:#fcef7e;--green-100:#3d5f12;--green-90:#5d921c;--green-90-alpha-50:#5d921c80;--green-80:#70c30e;--green-80-alpha-50:#70c30e80;--green-75:#85c90e;--green-60:#9ace49;--green-60-alpha-50:#9ace4980;--green-50:#a9b667;--green-100-v2:#184515;--green-95-v2:#265523;--green-90-v2:#366332;--green-85-v2:#2c7a26;--green-80-v2:#408e3a;--green-75-v2:#489c43;--green-70-v2:#55a550;--green-65-v2:#59a353;--green-60-v2:#62b05d;--green-55-v2:#74bd6f;--green-50-v2:#87c782;--green-45-v2:#99d194;--teal-100:#0a7b44;--teal-100-alpha-75:#0a7b44bf;--teal-100-alpha-50:#0a7b4480;--teal-80:#0f9d58;--teal-80-alpha-50:#0f9d5880;--teal-75:#32a667;--teal-50:#00d885;--teal-45:#67d9a2;--blue-100:#410cda;--blue-80:#2867db;--blue-75:#1a98ff;--blue-75-alpha-20:#1a98ff33;--blue-75-alpha-50:#1a98ff80;--blue-75-alpha-66:#1a98ffa8;--blue-75-alpha-0:#1a98ff00;--blue-70:#5994ff;--blue-50:#7cb5ec;--blue-50-alpha-20:#7cb5ec33;--blue-10:#e8f5ff;--blue-100-v2:#11718f;--blue-30-v2:#b8c8e5;--navy-100-v2:#242832;--navy-95-v2:#373c49;--navy-80-v2:#414a5f;--navy-75-v2:#46526f;--navy-40-v2:#8d929f;--purple-100:#d423c3;--sa-pro-color:#cce55c;--sa-premium-color:#11718f;--seeking-alpha-color:#ff7200;--sa-body-bg-color:var(--white-96);--sa-body-bg-color-2:var(--white-100);--sa-body-bg-color-3:var(--black-5);--sa-body-bg-color-4:var(--black-10-v2);--sa-link-color:var(--blue-80);--sa-card-bg-color:var(--white-100);--sa-card-bg-color-2:var(--black-5);--sa-card-bg-color-3:var(--white-100);--sa-invert-default-color:var(--white-100);--sa-text-color-1:var(--black-100);--sa-text-color-2:var(--black-35);--sa-text-color-3:var(--black-50);--sa-text-color-4:var(--black-70);--sa-text-color-5:var(--black-100);--sa-text-color-6:var(--black-90-v2);--sa-negative-color:var(--red-100);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-100);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-10);--sa-section-separator-thin-color:var(--black-10);--sa-very-bearish-color:var(--red-95);--sa-bearish-color:var(--orange-100);--sa-neutral-color:var(--yellow-90);--sa-bullish-color:var(--green-60);--sa-very-bullish-color:var(--green-90);--sa-modal-container-bg-color:var(--white-100);--sa-card-bg-transparent-color:#fff0;--sa-content-hide-gradient:linear-gradient(to top,var(--white-100),#ffffff80);--sa-spinner-color-1:var(--black-10);--sa-input-border-color:var(--black-10);--sa-disabled-text-color:var(--black-10);--sa-popup-shadow:var(--shadow-elevation-2);--sa-focus-outline-color:#05c;--sa-divider-color:var(--black-20-v2);--sa-aside-background-color:var(--black-100)}[data-color-scheme=dark]{--sa-body-bg-color:var(--black-98);--sa-body-bg-color-2:var(--black-98);--sa-body-bg-color-3:var(--black-98);--sa-body-bg-color-4:var(--black-98);--sa-link-color:var(--blue-70);--sa-card-bg-color:var(--black-95);--sa-card-bg-color-2:var(--black-80);--sa-card-bg-color-3:var(--black-85-v2);--sa-invert-default-color:var(--black-100);--sa-text-color-1:var(--black-10);--sa-text-color-2:var(--black-30);--sa-text-color-3:var(--black-30);--sa-text-color-4:var(--black-30);--sa-text-color-5:var(--black-30);--sa-text-color-6:var(--black-20-v2);--sa-negative-color:var(--red-80);--sa-negative-color-2:var(--red-70-v2);--sa-positive-color:var(--teal-75);--sa-positive-color-2:var(--green-80-v2);--sa-section-separator-color:var(--black-30);--sa-section-separator-thin-color:var(--black-80);--sa-modal-container-bg-color:var(--black-80);--sa-content-hide-gradient:linear-gradient(to top,var(--black-95),#0000);--sa-card-bg-transparent-color:#0000;--sa-spinner-color-1:var(--black-35);--sa-input-border-color:var(--black-30);--sa-disabled-text-color:var(--black-80);--sa-popup-shadow:var(--shadow-elevation-4);--sa-divider-color:var(--black-60-v2);--sa-aside-background-color:var(--black-95)}:root{--sa-border-r-4:4px;--sa-border-r-8:8px;--sa-border-r-10:10px;--sa-border-r-12:12px;--input-size-xs:1.5rem;--input-size-sm:1.875rem;--input-size-md:2.25rem;--input-size-lg:2.75rem;--sa-chart-loading-color:var(--black-100);--sa-chart-axis-label-color:var(--sa-text-color-3);--sa-chart-loading-background-color:var(--black-100-alpha-10);--sa-chart-axis-line-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-10);--sa-chart-tooltip-bg-color:var(--white-100);--sa-chart-tooltip-color:var(--black-70);--sa-chart-series-start-gradient-color:var(--white-100);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-bg-color:#0000;--sa-chart-flag-plot-line-color:var(--black-20);--sa-chart-flag-plot-fill-color:var(--white-100);--sa-chart-axis-tick-color:var(--black-10);--sa-chart-axis-plot-color:var(--black-5);--sa-chart-plot-option-pie-border-color:var(--white-100);--sa-chart-annotation-tooltip-bg-color:var(--black-100)}[data-color-scheme=dark]{--sa-chart-loading-background-color:var(--black-100-alpha-50);--sa-chart-loading-color:var(--black-10);--sa-chart-tooltip-border-color:var(--black-90);--sa-chart-tooltip-bg-color:var(--black-80);--sa-chart-tooltip-color:var(--black-30);--sa-chart-series-start-gradient-color:var(--orange-60-alpha-0);--sa-chart-series-stop-gradient-color:var(--orange-60);--sa-chart-series-color:var(--orange-60);--sa-chart-axis-line-color:var(--black-80);--sa-chart-flag-plot-line-color:var(--black-80);--sa-chart-flag-plot-fill-color:var(--white-96);--sa-chart-axis-tick-color:var(--black-30);--sa-chart-axis-plot-color:var(--black-100);--sa-chart-plot-option-pie-border-color:var(--black-95);--sa-chart-annotation-tooltip-bg-color:var(--black-90)}:root{--badge-gray:var(--black-10);--badge-dark-gray:var(--black-50);--badge-dark-green:var(--green-100);--badge-green:var(--green-90);--badge-light-green:var(--green-80);--sa-buy-color:var(--green-75);--badge-light-lime:var(--green-60);--badge-olive:var(--green-50);--badge-light-orange:var(--yellow-80);--badge-orange:var(--yellow-90);--badge-dark-orange:var(--yellow-100);--badge-light-red:var(--orange-80);--badge-red:var(--orange-100);--badge-amber:var(--orange-90);--badge-dark-red:var(--red-95);--badge-mint:var(--teal-50);--sa-not-covered-color:var(--black-20-v2);--sa-strong-sell-color:var(--red-100-v2);--sa-sell-color:var(--red-70-v2);--sa-hold-color:var(--yellow-80-v2);--sa-buy-color:var(--green-80-v2);--sa-strong-buy-color:var(--green-95-v2);--sa-grade-a-plus:var(--green-100-v2);--sa-grade-a:var(--green-95-v2);--sa-grade-a-minus:var(--green-90-v2);--sa-grade-b-plus:var(--green-85-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-65-v2);--sa-grade-c-plus:var(--yellow-100-v2);--sa-grade-c:var(--sa-hold-color);--sa-grade-c-minus:var(--yellow-70-v2);--sa-grade-d-plus:var(--red-50-v2);--sa-grade-d:var(--red-70-v2);--sa-grade-d-minus:var(--red-80-v2);--sa-grade-f:var(--sa-strong-sell-color)}[data-color-scheme=dark]{--sa-not-covered-color:var(--black-70-v2);--sa-strong-sell-color:var(--red-90-v2);--sa-sell-color:var(--red-40-v2);--sa-hold-color:var(--yellow-60-v2);--sa-buy-color:var(--green-50-v2);--sa-strong-buy-color:var(--green-70-v2);--sa-grade-a-plus:var(--green-75-v2);--sa-grade-a:var(--green-70-v2);--sa-grade-a-minus:var(--green-60-v2);--sa-grade-b-plus:var(--green-55-v2);--sa-grade-b:var(--sa-buy-color);--sa-grade-b-minus:var(--green-45-v2);--sa-grade-c-plus:var(--yellow-90-v2);--sa-grade-c-minus:var(--yellow-50-v2);--sa-grade-d-plus:var(--red-30-v2);--sa-grade-d:var(--red-40-v2);--sa-grade-d-minus:var(--red-60-v2)}*,:after,:before{border:0 solid;box-sizing:border-box}:after,:before{--tw-content:""}html{-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%;-ms-overflow-style:scrollbar;-webkit-tap-highlight-color:var(--black-100-alpha-0);font-family:sans-serif;font-size:16px;height:100%;line-height:1.15}html.ios-wrapper{width:100vw}#page_content_wrapper,.root,body,html{display:flex;flex-direction:column}#page_content_wrapper,.root,body{flex-grow:1;flex-shrink:0}@media print{.root,body{display:block}}.root,body,html{position:relative}body{height:var(--sa-window-inner-height);z-index:0}@media(min-width:1024px){body{overflow-y:scroll}}article,aside,figcaption,figure,footer,header,nav,section{display:block}body{background-color:var(--sa-body-bg-color-4);color:var(--black-100);font-family:-apple-system,BlinkMacSystemFont,Roboto,Arial,Segoe UI,sans-serif,Apple Color Emoji,Segoe UI Emoji,Segoe UI Symbol;font-size:1rem;font-weight:400;line-height:1.5;margin:0;text-align:left}[data-color-scheme=dark] body:not([data-skip-color-scheme]){background-color:var(--black-100);color:var(--black-10)}[tabindex="-1"]:focus{outline:0!important}hr{box-sizing:initial;height:0;overflow:visible}h1,h2,h3,h4,h5,h6{margin-bottom:8px;margin-top:0}p{margin-bottom:18px;margin-top:0}abbr[data-original-title],abbr[title]{border-bottom:0;cursor:help;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}address{font-style:normal;line-height:inherit}address,dl,ol,ul{margin-bottom:18px}dl,ol,ul{margin-top:0}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}dt{font-weight:700}dd{margin-bottom:8px;margin-left:0}blockquote{margin:0 0 18px}dfn{font-style:italic}b,strong{font-weight:bolder}small{font-size:80%}sub,sup{font-size:75%;line-height:1;position:relative;vertical-align:initial}sub{bottom:-.25em}sup{top:-.5em}a{-webkit-text-decoration-skip:objects;background-color:#0000;color:var(--sa-link-color)}a,a:focus,a:hover,a:visited{text-decoration:none}a:hover{text-decoration:underline}a:not([href]):not([tabindex]),a:not([href]):not([tabindex]):focus,a:not([href]):not([tabindex]):hover,a:not([href]):not([tabindex]):visited{color:inherit;text-decoration:none}a:not([href]):not([tabindex]):focus{outline:0}code,kbd,pre,samp{font-family:SFMono-Regular,Menlo,Monaco,Consolas,Liberation Mono,Courier New,monospace;font-size:1em}pre{-ms-overflow-style:scrollbar;margin-bottom:18px;margin-top:0;overflow:auto}figure{margin:0 0 18px}img{background-color:var(--white-96);border-style:none;font-size:.75rem;vertical-align:middle}[data-color-scheme=dark] img:not([data-skip-color-scheme]){background-color:var(--black-90)}svg{overflow:hidden;vertical-align:middle}iframe{border:none}table{border-collapse:collapse}caption{caption-side:bottom;color:var(--black-35);padding-bottom:12px;padding-top:12px;text-align:left}th{text-align:inherit}label{display:inline-block;margin-bottom:8px}button{border-radius:0;cursor:pointer;text-align:center}button,input,optgroup,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=reset],[type=submit],button,html [type=button]{-webkit-appearance:button}button{background:#0000;border:none;color:inherit;font:inherit;margin:0;overflow:hidden;padding:0;width:auto}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}button:focus{outline:1px dotted;outline:5px auto -webkit-focus-ring-color}@media(hover:none)and (pointer:coarse){a:active,a:focus,a:hover,button:active,button:focus,button:hover{outline:0!important;text-decoration:none!important}}input{border:1px solid #0000}input[type=password]{font-family:Arial,Helvetica Neue,Helvetica,sans-serif}input[type=checkbox],input[type=radio]{box-sizing:border-box;padding:0}input[type=date],input[type=datetime-local],input[type=month],input[type=time]{-webkit-appearance:listbox}textarea{overflow:auto;resize:vertical}fieldset{border:0;margin:0;min-width:0;padding:0}legend{color:inherit;display:block;font-size:1.5rem;line-height:inherit;margin-bottom:8px;max-width:100%;padding:0;white-space:normal;width:100%}progress{vertical-align:initial}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:none;outline-offset:-2px}[type=search]::-webkit-search-cancel-button,[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}output{display:inline-block}summary{cursor:pointer;display:list-item}template{display:none}[hidden]{display:none!important}[data-intent-mouse=true] [contentEditable=true]:focus,[data-intent-mouse=true] [tabindex="0"]:focus,[data-intent-mouse=true] a[href]:focus,[data-intent-mouse=true] area[href]:focus,[data-intent-mouse=true] button:not([disabled]):focus,[data-intent-mouse=true] iframe:focus,[data-intent-mouse=true] input:not([disabled]):focus,[data-intent-mouse=true] select:not([disabled]):focus,[data-intent-mouse=true] textarea:not([disabled]):focus{outline:0}[data-intent-mouse=false] [contentEditable=true]:focus,[data-intent-mouse=false] [tabindex="0"]:focus,[data-intent-mouse=false] a[href]:focus,[data-intent-mouse=false] area[href]:focus,[data-intent-mouse=false] button:not([disabled]):focus,[data-intent-mouse=false] iframe:focus,[data-intent-mouse=false] input:not([disabled]):focus,[data-intent-mouse=false] select:not([disabled]):focus,[data-intent-mouse=false] textarea:not([disabled]):focus{outline:2px solid var(--sa-focus-outline-color);outline-offset:-1px}@keyframes kef-shift-rightwards{0%{transform:translateX(-100%)}40%{transform:translateX(0)}60%{transform:translateX(0)}to{transform:translateX(100%)}}@keyframes kef-delay-visibility{0%{opacity:0}to{opacity:1}}.loading{align-items:center;background-color:var(--sa-body-bg-color-4);display:flex;justify-content:center;overflow:hidden;z-index:1}[data-color-scheme=dark] .loading:not([data-skip-color-scheme]){background-color:var(--black-90)}@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){[data-color-scheme=system] .loading{background-color:var(--black-90)}}@supports not (-webkit-touch-callout:none){@media(hover:none)and (pointer:coarse)and (prefers-color-scheme:dark){:not([data-color-scheme=dark]) .loading,:not([data-color-scheme=light]) .loading{background-color:var(--black-90)}}}[data-loading-position=fixed]{height:100vh;left:0;position:fixed;top:0;width:100%}[data-loading-position=absolute]{bottom:0;left:0;position:absolute;right:0;top:0}.loadingDelayed{animation:kef-delay-visibility 3s step-end 1}@media screen and (prefers-reduced-motion:reduce){.loadingDelayed{animation:none}}.appLoading{--env-safe-area-inset-top:env(safe-area-inset-top);animation:kef-shift-rightwards 1s ease-in-out infinite;animation-delay:.8s;background:var(--orange-60);height:2px;opacity:1;position:fixed;right:0;top:var(--env-safe-area-inset-top,0);transform:translateX(100%);width:100%;z-index:1051}.appLoaderInvisible{animation:none;opacity:0}@media screen and (prefers-reduced-motion:reduce){.appLoading{animation:none}}.noScript{padding-top:80px;position:relative;text-align:center;z-index:1030}.noScriptDescription,.noScriptTitle{color:var(--sa-text-color-3);font-size:1.125rem;margin-bottom:18px}.noScriptTitle{font-weight:700}*,:after,:before{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }::backdrop{--tw-border-spacing-x:0;--tw-border-spacing-y:0;--tw-translate-x:0;--tw-translate-y:0;--tw-rotate:0;--tw-skew-x:0;--tw-skew-y:0;--tw-scale-x:1;--tw-scale-y:1;--tw-pan-x: ;--tw-pan-y: ;--tw-pinch-zoom: ;--tw-scroll-snap-strictness:proximity;--tw-gradient-from-position: ;--tw-gradient-via-position: ;--tw-gradient-to-position: ;--tw-ordinal: ;--tw-slashed-zero: ;--tw-numeric-figure: ;--tw-numeric-spacing: ;--tw-numeric-fraction: ;--tw-ring-inset: ;--tw-ring-offset-width:0px;--tw-ring-offset-color:#fff;--tw-ring-color:#3b82f680;--tw-ring-offset-shadow:0 0 #0000;--tw-ring-shadow:0 0 #0000;--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;--tw-blur: ;--tw-brightness: ;--tw-contrast: ;--tw-grayscale: ;--tw-hue-rotate: ;--tw-invert: ;--tw-saturate: ;--tw-sepia: ;--tw-drop-shadow: ;--tw-backdrop-blur: ;--tw-backdrop-brightness: ;--tw-backdrop-contrast: ;--tw-backdrop-grayscale: ;--tw-backdrop-hue-rotate: ;--tw-backdrop-invert: ;--tw-backdrop-opacity: ;--tw-backdrop-saturate: ;--tw-backdrop-sepia: }.\!container{width:100%!important}.container{width:100%}@media (min-width:1264px){.\!container{max-width:1264px!important}.container{max-width:1264px}}@media (min-width:1300px){.\!container{max-width:1300px!important}.container{max-width:1300px}}.aspect-h-1{--tw-aspect-h:1}.aspect-w-1{--tw-aspect-w:1;padding-bottom:calc(var(--tw-aspect-h)/var(--tw-aspect-w)*100%);position:relative}.aspect-w-1>*{bottom:0;height:100%;left:0;position:absolute;right:0;top:0;width:100%}.spinner{display:block;height:1.25rem;width:1.25rem}.spinner,.spinner:before{border-radius:100%;position:absolute}.spinner:before{--tw-content:"";--tw-translate-y:-50%;--tw-translate-x:-50%;--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity));content:var(--tw-content);height:1rem;left:50%;top:50%;transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y));width:1rem}:is([data-color-scheme=dark] .spinner):before{--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity));content:var(--tw-content)}@keyframes spin{to{transform:rotate(1turn)}}.spinner{animation:spin 1s linear infinite;background-image:conic-gradient(var(--black-35),#0000)}@media (prefers-reduced-motion:reduce){.spinner{transition-property:none}}.sr-only{clip:rect(0,0,0,0);border-width:0;height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;white-space:nowrap;width:1px}.pointer-events-none{pointer-events:none}.pointer-events-auto{pointer-events:auto}.\!visible{visibility:visible!important}.visible{visibility:visible}.collapse{visibility:collapse}.static{position:static}.fixed{position:fixed}.absolute{position:absolute}.relative{position:relative}.sticky{position:-webkit-sticky;position:sticky}.inset-0{inset:0}.inset-x-0{left:0;right:0}.-right-2{right:-.125rem}.-top-1{top:-.0625rem}.-top-2{top:-.125rem}.bottom-0{bottom:0}.bottom-10{bottom:.625rem}.bottom-full{bottom:100%}.left-0{left:0}.left-1\/2{left:50%}.left-full{left:100%}.right-0{right:0}.right-12{right:.75rem}.right-16{right:1rem}.right-6{right:.375rem}.right-full{right:100%}.top-0{top:0}.top-1{top:.0625rem}.top-1\/2{top:50%}.top-12{top:.75rem}.top-20{top:1.25rem}.top-full{top:100%}.z-0{z-index:0}.z-1{z-index:1}.z-auto{z-index:auto}.z-modal{z-index:1050}.z-modal-backdrop{z-index:1040}.z-sticky{z-index:1020}.z-tooltip{z-index:1070}.order-first{order:-9999}.m-0{margin:0}.m-4{margin:.25rem}.-mx-12{margin-left:-.75rem;margin-right:-.75rem}.-mx-18{margin-left:-1.125rem;margin-right:-1.125rem}.-my-4{margin-bottom:-.25rem;margin-top:-.25rem}.mx-12{margin-left:.75rem;margin-right:.75rem}.mx-18{margin-left:1.125rem;margin-right:1.125rem}.mx-24{margin-left:1.5rem;margin-right:1.5rem}.mx-auto{margin-left:auto;margin-right:auto}.my-0{margin-bottom:0;margin-top:0}.my-12{margin-bottom:.75rem;margin-top:.75rem}.my-14{margin-bottom:.875rem;margin-top:.875rem}.my-16{margin-bottom:1rem;margin-top:1rem}.my-24{margin-bottom:1.5rem;margin-top:1.5rem}.my-48{margin-bottom:3rem;margin-top:3rem}.-ml-12{margin-left:-.75rem}.-ml-18{margin-left:-1.125rem}.-mt-12{margin-top:-.75rem}.-mt-18{margin-top:-1.125rem}.mb-0{margin-bottom:0}.mb-10{margin-bottom:.625rem}.mb-12{margin-bottom:.75rem}.mb-14{margin-bottom:.875rem}.mb-16{margin-bottom:1rem}.mb-18{margin-bottom:1.125rem}.mb-20{margin-bottom:1.25rem}.mb-24{margin-bottom:1.5rem}.mb-28{margin-bottom:1.75rem}.mb-30{margin-bottom:1.875rem}.mb-32{margin-bottom:2rem}.mb-36{margin-bottom:2.25rem}.mb-4{margin-bottom:.25rem}.mb-40{margin-bottom:2.5rem}.mb-48{margin-bottom:3rem}.mb-6{margin-bottom:.375rem}.mb-8{margin-bottom:.5rem}.mb-auto{margin-bottom:auto}.ml-0{margin-left:0}.ml-12{margin-left:.75rem}.ml-14{margin-left:.875rem}.ml-16{margin-left:1rem}.ml-18{margin-left:1.125rem}.ml-2{margin-left:.125rem}.ml-36{margin-left:2.25rem}.ml-4{margin-left:.25rem}.ml-8{margin-left:.5rem}.ml-auto{margin-left:auto}.mr-10{margin-right:.625rem}.mr-12{margin-right:.75rem}.mr-14{margin-right:.875rem}.mr-16{margin-right:1rem}.mr-18{margin-right:1.125rem}.mr-2{margin-right:.125rem}.mr-24{margin-right:1.5rem}.mr-28{margin-right:1.75rem}.mr-30{margin-right:1.875rem}.mr-36{margin-right:2.25rem}.mr-4{margin-right:.25rem}.mr-6{margin-right:.375rem}.mr-8{margin-right:.5rem}.mr-auto{margin-right:auto}.mt-10{margin-top:.625rem}.mt-12{margin-top:.75rem}.mt-14{margin-top:.875rem}.mt-16{margin-top:1rem}.mt-18{margin-top:1.125rem}.mt-2{margin-top:.125rem}.mt-24{margin-top:1.5rem}.mt-32{margin-top:2rem}.mt-4{margin-top:.25rem}.mt-8{margin-top:.5rem}.mt-auto{margin-top:auto}.box-border{box-sizing:border-box}.block{display:block}.inline-block{display:inline-block}.inline{display:inline}.flex{display:flex}.inline-flex{display:inline-flex}.\!table{display:table!important}.table{display:table}.grid{display:grid}.contents{display:contents}.list-item{display:list-item}.\!hidden{display:none!important}.hidden{display:none}.h-0{height:0}.h-1{height:.0625rem}.h-10{height:.625rem}.h-100{height:6.25rem}.h-12{height:.75rem}.h-120{height:7.5rem}.h-14{height:.875rem}.h-16{height:1rem}.h-170{height:10.625rem}.h-18{height:1.125rem}.h-20{height:1.25rem}.h-24{height:1.5rem}.h-240{height:15rem}.h-26{height:1.625rem}.h-28{height:1.75rem}.h-30{height:1.875rem}.h-32{height:2rem}.h-34{height:2.125rem}.h-36{height:2.25rem}.h-38{height:2.375rem}.h-4{height:.25rem}.h-40{height:2.5rem}.h-44{height:2.75rem}.h-48{height:3rem}.h-50{height:3.125rem}.h-60{height:3.75rem}.h-8{height:.5rem}.h-80{height:5rem}.h-auto{height:auto}.h-full{height:100%}.h-screen{height:100vh}.max-h-24{max-height:1.5rem}.max-h-full{max-height:100%}.min-h-0{min-height:0}.min-h-full{min-height:100%}.min-h-min{min-height:-webkit-min-content;min-height:min-content}.w-0{width:0}.w-1\/2{width:50%}.w-1\/4{width:25%}.w-10{width:.625rem}.w-100{width:6.25rem}.w-12{width:.75rem}.w-120{width:7.5rem}.w-14{width:.875rem}.w-16{width:1rem}.w-170{width:10.625rem}.w-18{width:1.125rem}.w-20{width:1.25rem}.w-24{width:1.5rem}.w-240{width:15rem}.w-26{width:1.625rem}.w-3\/4{width:75%}.w-30{width:1.875rem}.w-32{width:2rem}.w-36{width:2.25rem}.w-40{width:2.5rem}.w-44{width:2.75rem}.w-48{width:3rem}.w-50{width:3.125rem}.w-60{width:3.75rem}.w-8{width:.5rem}.w-80{width:5rem}.w-auto{width:auto}.w-full{width:100%}.w-max{width:-webkit-max-content;width:max-content}.min-w-0{min-width:0}.min-w-full{min-width:100%}.max-w-0{max-width:0}.max-w-5xl{max-width:64rem}.max-w-full{max-width:100%}.flex-1{flex:1 1 0%}.flex-auto{flex:1 1 auto}.flex-none{flex:none}.flex-shrink{flex-shrink:1}.flex-shrink-0,.shrink-0{flex-shrink:0}.flex-grow{flex-grow:1}.flex-grow-0{flex-grow:0}.grow{flex-grow:1}.grow-0{flex-grow:0}.basis-0{flex-basis:0px}.basis-full{flex-basis:100%}.-translate-x-1\/2{--tw-translate-x:-50%}.-translate-x-1\/2,.-translate-y-1\/2{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-translate-y-1\/2{--tw-translate-y:-50%}.translate-x-0{--tw-translate-x:0px}.translate-x-0,.translate-x-12{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.translate-x-12{--tw-translate-x:0.75rem}.translate-y-1{--tw-translate-y:0.0625rem}.-rotate-90,.translate-y-1{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.-rotate-90{--tw-rotate:-90deg}.rotate-0{--tw-rotate:0deg}.rotate-0,.rotate-180{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.rotate-180{--tw-rotate:180deg}.rotate-90{--tw-rotate:90deg}.rotate-90,.transform{transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.cursor-default{cursor:default}.cursor-none{cursor:none}.cursor-pointer{cursor:pointer}.cursor-text{cursor:text}.select-none{-webkit-user-select:none;user-select:none}.resize{resize:both}.list-inside{list-style-position:inside}.list-none{list-style-type:none}.grid-cols-1{grid-template-columns:repeat(1,minmax(0,1fr))}.flex-row{flex-direction:row}.flex-row-reverse{flex-direction:row-reverse}.flex-col{flex-direction:column}.flex-col-reverse{flex-direction:column-reverse}.flex-wrap{flex-wrap:wrap}.flex-nowrap{flex-wrap:nowrap}.items-start{align-items:flex-start}.items-end{align-items:flex-end}.items-center{align-items:center}.items-baseline{align-items:baseline}.items-stretch{align-items:stretch}.justify-start{justify-content:flex-start}.justify-end{justify-content:flex-end}.justify-center{justify-content:center}.justify-between{justify-content:space-between}.justify-items-center{justify-items:center}.gap-16{gap:1rem}.gap-28{gap:1.75rem}.gap-32{gap:2rem}.gap-y-8{row-gap:.5rem}.self-start{align-self:flex-start}.self-stretch{align-self:stretch}.overflow-auto{overflow:auto}.overflow-hidden{overflow:hidden}.overflow-visible{overflow:visible}.overflow-y-auto{overflow-y:auto}.overflow-x-hidden{overflow-x:hidden}.overscroll-contain{overscroll-behavior:contain}.truncate{overflow:hidden;white-space:nowrap}.text-ellipsis,.truncate{text-overflow:ellipsis}.whitespace-nowrap{white-space:nowrap}.whitespace-pre-line{white-space:pre-line}.rounded-0{border-radius:0}.rounded-3{border-radius:.1875rem}.rounded-4{border-radius:.25rem}.rounded-8{border-radius:.5rem}.rounded-full{border-radius:100%}.rounded-b-0{border-bottom-left-radius:0;border-bottom-right-radius:0}.rounded-b-4{border-bottom-left-radius:.25rem;border-bottom-right-radius:.25rem}.rounded-r-8{border-bottom-right-radius:.5rem;border-top-right-radius:.5rem}.rounded-t-4{border-top-left-radius:.25rem;border-top-right-radius:.25rem}.rounded-bl-8{border-bottom-left-radius:.5rem}.rounded-tl-0{border-top-left-radius:0}.border{border-width:.0625rem}.border-0{border-width:0}.border-2{border-width:.125rem}.border-6{border-width:.375rem}.border-y{border-bottom-width:.0625rem;border-top-width:.0625rem}.border-y-0{border-bottom-width:0;border-top-width:0}.border-b{border-bottom-width:.0625rem}.border-b-0{border-bottom-width:0}.border-l-6{border-left-width:.375rem}.border-r-0{border-right-width:0}.border-r-4{border-right-width:.25rem}.border-t{border-top-width:.0625rem}.border-t-0{border-top-width:0}.border-solid{border-style:solid}.border-black{--tw-border-opacity:1;border-color:rgb(0 0 0/var(--tw-border-opacity))}.border-black-10{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.border-black-35{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.border-black-50{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.border-blue-75{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity))}.border-blue-75\/25{border-color:#1a98ff40}.border-blue-75\/50{border-color:#1a98ff80}.border-blue-75\/75{border-color:#1a98ffbf}.border-navy{--tw-border-opacity:1;border-color:rgb(36 40 50/var(--tw-border-opacity))}.border-navy-40{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.border-red{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.border-share-bg-4{border-color:var(--sa-body-bg-color-4)}.border-share-negative{border-color:var(--sa-negative-color)}.border-share-separator-thin{border-color:var(--sa-section-separator-thin-color)}.border-share-text-2{border-color:var(--sa-text-color-2)}.border-transparent{border-color:#0000}.border-y-black-10{border-top-color:rgb(219 219 219/var(--tw-border-opacity))}.border-b-black-10,.border-y-black-10{--tw-border-opacity:1;border-bottom-color:rgb(219 219 219/var(--tw-border-opacity))}.border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.border-l-transparent{border-left-color:#0000}.border-r-transparent{border-right-color:#0000}.border-t-transparent{border-top-color:#0000}.\!bg-green-90{--tw-bg-opacity:1!important;background-color:rgb(93 146 28/var(--tw-bg-opacity))!important}.bg-black{--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}.bg-black-10{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.bg-black-20{--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}.bg-black-30\/40{background-color:#838d8f66}.bg-black-35{--tw-bg-opacity:1;background-color:rgb(117 117 117/var(--tw-bg-opacity))}.bg-black-4{--tw-bg-opacity:1;background-color:rgb(249 249 249/var(--tw-bg-opacity))}.bg-black-5{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.bg-black-50{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.bg-black-v2-20{--tw-bg-opacity:1;background-color:rgb(224 225 228/var(--tw-bg-opacity))}.bg-black-v2-90{--tw-bg-opacity:1;background-color:rgb(16 17 20/var(--tw-bg-opacity))}.bg-black\/60{background-color:#0009}.bg-blue-75{--tw-bg-opacity:1;background-color:rgb(26 152 255/var(--tw-bg-opacity))}.bg-brand-sa{background-color:var(--seeking-alpha-color)}.bg-green{--tw-bg-opacity:1;background-color:rgb(61 95 18/var(--tw-bg-opacity))}.bg-green-v2{--tw-bg-opacity:1;background-color:rgb(24 69 21/var(--tw-bg-opacity))}.bg-green-v2-65{--tw-bg-opacity:1;background-color:rgb(89 163 83/var(--tw-bg-opacity))}.bg-green-v2-80{--tw-bg-opacity:1;background-color:rgb(64 142 58/var(--tw-bg-opacity))}.bg-green-v2-85{--tw-bg-opacity:1;background-color:rgb(44 122 38/var(--tw-bg-opacity))}.bg-green-v2-90{--tw-bg-opacity:1;background-color:rgb(54 99 50/var(--tw-bg-opacity))}.bg-green-v2-95{--tw-bg-opacity:1;background-color:rgb(38 85 35/var(--tw-bg-opacity))}.bg-navy{--tw-bg-opacity:1;background-color:rgb(36 40 50/var(--tw-bg-opacity))}.bg-orange-60{--tw-bg-opacity:1;background-color:rgb(255 114 0/var(--tw-bg-opacity))}.bg-red{--tw-bg-opacity:1;background-color:rgb(201 57 44/var(--tw-bg-opacity))}.bg-red-v2{--tw-bg-opacity:1;background-color:rgb(124 31 31/var(--tw-bg-opacity))}.bg-red-v2-50{--tw-bg-opacity:1;background-color:rgb(222 78 78/var(--tw-bg-opacity))}.bg-red-v2-70{--tw-bg-opacity:1;background-color:rgb(206 52 52/var(--tw-bg-opacity))}.bg-red-v2-80{--tw-bg-opacity:1;background-color:rgb(191 29 29/var(--tw-bg-opacity))}.bg-share-aside-bg{background-color:var(--sa-aside-background-color)}.bg-share-bg-2{background-color:var(--sa-body-bg-color-2)}.bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.bg-share-card-bg{background-color:var(--sa-card-bg-color)}.bg-share-link{background-color:var(--sa-link-color)}.bg-share-modal-container{background-color:var(--sa-modal-container-bg-color)}.bg-share-negative{background-color:var(--sa-negative-color)}.bg-share-positive{background-color:var(--sa-positive-color)}.bg-share-text{background-color:var(--sa-text-color-1)}.bg-share-text-2{background-color:var(--sa-text-color-2)}.bg-share-text-3{background-color:var(--sa-text-color-3)}.bg-teal{--tw-bg-opacity:1;background-color:rgb(10 123 68/var(--tw-bg-opacity))}.bg-transparent{background-color:initial}.bg-white{--tw-bg-opacity:1;background-color:rgb(255 255 255/var(--tw-bg-opacity))}.bg-white-96{--tw-bg-opacity:1;background-color:rgb(243 244 247/var(--tw-bg-opacity))}.bg-yellow-85{--tw-bg-opacity:1;background-color:rgb(254 194 15/var(--tw-bg-opacity))}.bg-yellow-v2{--tw-bg-opacity:1;background-color:rgb(214 193 0/var(--tw-bg-opacity))}.bg-yellow-v2-70{--tw-bg-opacity:1;background-color:rgb(255 235 51/var(--tw-bg-opacity))}.bg-yellow-v2-80{--tw-bg-opacity:1;background-color:rgb(235 213 23/var(--tw-bg-opacity))}.bg-gradient-to-r{background-image:linear-gradient(to right,var(--tw-gradient-stops))}.from-black-10{--tw-gradient-from:#dbdbdb var(--tw-gradient-from-position);--tw-gradient-to:#dbdbdb00 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}.to-white{--tw-gradient-to:#fff var(--tw-gradient-to-position)}.bg-cover{background-size:cover}.bg-clip-padding{background-clip:padding-box}.bg-center{background-position:50%}.bg-no-repeat{background-repeat:no-repeat}.fill-black{fill:#000}.fill-black-10{fill:#dbdbdb}.fill-black-20{fill:#acacac}.fill-black-35{fill:#757575}.fill-black-50{fill:#555}.fill-current{fill:currentColor}.fill-red{fill:#c9392c}.fill-share-negative{fill:var(--sa-negative-color)}.fill-share-positive{fill:var(--sa-positive-color)}.fill-share-text-2{fill:var(--sa-text-color-2)}.fill-share-text-6{fill:var(--sa-text-color-6)}.fill-teal{fill:#0a7b44}.fill-transparent{fill:#0000}.fill-white{fill:#fff}.fill-yellow-90{fill:#efa818}.stroke-black-35{stroke:#757575}.stroke-yellow-90{stroke:#efa818}.object-contain{object-fit:contain}.p-0{padding:0}.p-12{padding:.75rem}.p-16{padding:1rem}.p-18{padding:1.125rem}.p-2{padding:.125rem}.p-4{padding:.25rem}.p-6{padding:.375rem}.p-8{padding:.5rem}.px-0{padding-left:0;padding-right:0}.px-12{padding-left:.75rem;padding-right:.75rem}.px-14{padding-left:.875rem;padding-right:.875rem}.px-18{padding-left:1.125rem;padding-right:1.125rem}.px-20{padding-left:1.25rem;padding-right:1.25rem}.px-24{padding-left:1.5rem;padding-right:1.5rem}.px-32{padding-left:2rem;padding-right:2rem}.px-36{padding-left:2.25rem;padding-right:2.25rem}.px-38{padding-left:2.375rem;padding-right:2.375rem}.px-4{padding-left:.25rem;padding-right:.25rem}.px-6{padding-left:.375rem;padding-right:.375rem}.px-8{padding-left:.5rem;padding-right:.5rem}.py-0{padding-bottom:0;padding-top:0}.py-10{padding-bottom:.625rem;padding-top:.625rem}.py-12{padding-bottom:.75rem;padding-top:.75rem}.py-14{padding-bottom:.875rem;padding-top:.875rem}.py-16{padding-bottom:1rem;padding-top:1rem}.py-18{padding-bottom:1.125rem;padding-top:1.125rem}.py-2{padding-bottom:.125rem;padding-top:.125rem}.py-20{padding-bottom:1.25rem;padding-top:1.25rem}.py-24{padding-bottom:1.5rem;padding-top:1.5rem}.py-26{padding-bottom:1.625rem;padding-top:1.625rem}.py-4{padding-bottom:.25rem;padding-top:.25rem}.py-48{padding-bottom:3rem;padding-top:3rem}.py-6{padding-bottom:.375rem;padding-top:.375rem}.py-8{padding-bottom:.5rem;padding-top:.5rem}.pb-0{padding-bottom:0}.pb-10{padding-bottom:.625rem}.pb-12{padding-bottom:.75rem}.pb-18{padding-bottom:1.125rem}.pb-20{padding-bottom:1.25rem}.pb-24{padding-bottom:1.5rem}.pb-28{padding-bottom:1.75rem}.pb-4{padding-bottom:.25rem}.pb-40{padding-bottom:2.5rem}.pb-48{padding-bottom:3rem}.pb-6{padding-bottom:.375rem}.pb-8{padding-bottom:.5rem}.pl-0{padding-left:0}.pl-12{padding-left:.75rem}.pl-14{padding-left:.875rem}.pl-18{padding-left:1.125rem}.pl-20{padding-left:1.25rem}.pl-24{padding-left:1.5rem}.pl-28{padding-left:1.75rem}.pl-32{padding-left:2rem}.pl-36{padding-left:2.25rem}.pl-40{padding-left:2.5rem}.pr-24{padding-right:1.5rem}.pr-30{padding-right:1.875rem}.pr-38{padding-right:2.375rem}.pr-48{padding-right:3rem}.ps-0{padding-inline-start:0}.pt-0{padding-top:0}.pt-10{padding-top:.625rem}.pt-12{padding-top:.75rem}.pt-14{padding-top:.875rem}.pt-16{padding-top:1rem}.pt-18{padding-top:1.125rem}.pt-2{padding-top:.125rem}.pt-20{padding-top:1.25rem}.pt-24{padding-top:1.5rem}.pt-32{padding-top:2rem}.pt-4{padding-top:.25rem}.pt-42{padding-top:2.625rem}.pt-48{padding-top:3rem}.pt-8{padding-top:.5rem}.text-left{text-align:left}.text-center{text-align:center}.text-right{text-align:right}.align-top{vertical-align:top}.align-middle{vertical-align:middle}.text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.text-2x-large-r{font-size:1.25rem;font-weight:400;line-height:1.5rem}.text-2x-small-b{font-weight:700}.text-2x-small-b,.text-2x-small-r{font-size:.625rem;line-height:.75rem}.text-2x-small-r{font-weight:400}.text-3x-large-2-b{font-size:1.375rem;font-weight:700;line-height:2rem}.text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.text-4x-large-2-b{font-size:1.5rem;font-weight:700;line-height:2.25rem}.text-4x-large-b{font-weight:700}.text-4x-large-b,.text-4x-large-r{font-size:1.5rem;line-height:1.875rem}.text-4x-large-r{font-weight:400}.text-5x-large-b{font-weight:700}.text-5x-large-b,.text-5x-large-r{font-size:1.75rem;line-height:2.125rem}.text-5x-large-r{font-weight:400}.text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.text-7x-large-b{font-weight:700}.text-7x-large-b,.text-7x-large-r{font-size:2.25rem;line-height:2.75rem}.text-7x-large-r{font-weight:400}.text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.text-large-b{font-weight:700}.text-large-b,.text-large-r{font-size:1rem;line-height:1.25rem}.text-large-r{font-weight:400}.text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.text-medium-3-r{font-size:.875rem;font-weight:400;line-height:1.75rem}.text-medium-b{font-weight:700}.text-medium-b,.text-medium-r{font-size:.875rem;line-height:1rem}.text-medium-r{font-weight:400}.text-small-2-r{font-size:.75rem;font-weight:400;line-height:1.25rem}.text-small-b{font-weight:700}.text-small-b,.text-small-r{font-size:.75rem;line-height:.875rem}.text-small-r{font-weight:400}.text-x-large-2-b{font-weight:700}.text-x-large-2-b,.text-x-large-2-r{font-size:1.125rem;line-height:1.625rem}.text-x-large-2-r{font-weight:400}.text-x-large-b{font-weight:700}.text-x-large-b,.text-x-large-r{font-size:1.125rem;line-height:1.375rem}.text-x-large-r{font-weight:400}.text-x-small-r{font-size:.6875rem;font-weight:400;line-height:.8125rem}.font-bold{font-weight:700}.font-medium{font-weight:500}.font-semibold{font-weight:600}.uppercase{text-transform:uppercase}.capitalize{text-transform:capitalize}.italic{font-style:italic}.ordinal{--tw-ordinal:ordinal;font-variant-numeric:var(--tw-ordinal) var(--tw-slashed-zero) var(--tw-numeric-figure) var(--tw-numeric-spacing) var(--tw-numeric-fraction)}.leading-3{line-height:.75rem}.leading-none{line-height:1}.text-black{--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}.text-black-10{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.text-black-20{--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}.text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.text-black-50{--tw-text-opacity:1;color:rgb(85 85 85/var(--tw-text-opacity))}.text-black-60{--tw-text-opacity:1;color:rgb(67 67 72/var(--tw-text-opacity))}.text-black-70{--tw-text-opacity:1;color:rgb(51 51 51/var(--tw-text-opacity))}.text-black-v2-70{--tw-text-opacity:1;color:rgb(63 66 72/var(--tw-text-opacity))}.text-black-v2-90{--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}.text-blue-75{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.text-blue-80{--tw-text-opacity:1;color:rgb(40 103 219/var(--tw-text-opacity))}.text-brand-premium{--tw-text-opacity:1;color:rgb(17 113 143/var(--tw-text-opacity))}.text-brand-pro{--tw-text-opacity:1;color:rgb(204 229 92/var(--tw-text-opacity))}.text-brand-sa{color:var(--seeking-alpha-color)}.text-orange-60{--tw-text-opacity:1;color:rgb(255 114 0/var(--tw-text-opacity))}.text-red{--tw-text-opacity:1;color:rgb(201 57 44/var(--tw-text-opacity))}.text-share-link{color:var(--sa-link-color)}.text-share-negative{color:var(--sa-negative-color)}.text-share-positive{color:var(--sa-positive-color)}.text-share-text{color:var(--sa-text-color-1)}.text-share-text-2{color:var(--sa-text-color-2)}.text-share-text-3{color:var(--sa-text-color-3)}.text-share-text-6{color:var(--sa-text-color-6)}.text-white{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.text-white-96{--tw-text-opacity:1;color:rgb(243 244 247/var(--tw-text-opacity))}.text-yellow-85{--tw-text-opacity:1;color:rgb(254 194 15/var(--tw-text-opacity))}.underline{text-decoration-line:underline}.no-underline{text-decoration-line:none}.opacity-0{opacity:0}.opacity-100{opacity:1}.opacity-30{opacity:.3}.opacity-50{opacity:.5}.opacity-60{opacity:.6}.shadow{--tw-shadow:0 1px 3px 0 #0000001a,0 1px 2px -1px #0000001a;--tw-shadow-colored:0 1px 3px 0 var(--tw-shadow-color),0 1px 2px -1px var(--tw-shadow-color)}.shadow,.shadow-none{box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.shadow-none{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000}.shadow-transparent{--tw-shadow-color:#0000;--tw-shadow:var(--tw-shadow-colored)}.outline-none{outline:2px solid #0000;outline-offset:2px}.outline{outline-style:solid}.blur{--tw-blur:blur(8px)}.blur,.invert{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.invert{--tw-invert:invert(100%)}.\!filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)!important}.filter{filter:var(--tw-blur) var(--tw-brightness) var(--tw-contrast) var(--tw-grayscale) var(--tw-hue-rotate) var(--tw-invert) var(--tw-saturate) var(--tw-sepia) var(--tw-drop-shadow)}.filter-none{filter:none}.transition{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,-webkit-backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke,opacity,box-shadow,transform,filter,backdrop-filter,-webkit-backdrop-filter;transition-timing-function:cubic-bezier(.4,0,.2,1)}.transition-colors{transition-duration:.15s;transition-property:color,background-color,border-color,text-decoration-color,fill,stroke;transition-timing-function:cubic-bezier(.4,0,.2,1)}.pl-safe{padding-left:env(safe-area-inset-left)}.px-safe-offset-10{padding-left:calc(env(safe-area-inset-left) + .625rem);padding-right:calc(env(safe-area-inset-right) + .625rem)}.px-safe-offset-12{padding-left:calc(env(safe-area-inset-left) + .75rem);padding-right:calc(env(safe-area-inset-right) + .75rem)}.px-safe-offset-18{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.px-safe-offset-20{padding-left:calc(env(safe-area-inset-left) + 1.25rem);padding-right:calc(env(safe-area-inset-right) + 1.25rem)}.p-safe-or-20{padding:max(env(safe-area-inset-top),1.25rem) max(env(safe-area-inset-right),1.25rem) max(env(safe-area-inset-bottom),1.25rem) max(env(safe-area-inset-left),1.25rem)}.pt-safe-or-18{padding-top:max(env(safe-area-inset-top),1.125rem)}.pt-safe-or-24{padding-top:max(env(safe-area-inset-top),1.5rem)}.pt-safe-or-6{padding-top:max(env(safe-area-inset-top),.375rem)}.px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.px-safe-or-20{padding-left:max(env(safe-area-inset-left),1.25rem);padding-right:max(env(safe-area-inset-right),1.25rem)}.sa-row-gap-18{margin-bottom:1.125rem;margin-left:-1.125rem;margin-top:-1.125rem}.sa-row-gap-18>*{padding-left:1.125rem;padding-top:1.125rem}.sa-row-gap-20{margin-bottom:1.25rem;margin-left:-1.25rem;margin-top:-1.25rem}.sa-row-gap-20>*{padding-left:1.25rem;padding-top:1.25rem}.sa-row-gap-22{margin-bottom:1.375rem;margin-left:-1.375rem;margin-top:-1.375rem}.sa-row-gap-22>*{padding-left:1.375rem;padding-top:1.375rem}.sa-row-gap-24{margin-bottom:1.5rem;margin-left:-1.5rem;margin-top:-1.5rem}.sa-row-gap-24>*{padding-left:1.5rem;padding-top:1.5rem}.sa-row-gap-32{margin-bottom:2rem;margin-left:-2rem;margin-top:-2rem}.sa-row-gap-32>*{padding-left:2rem;padding-top:2rem}.sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}.sa-row-gap-48{margin-bottom:3rem;margin-left:-3rem;margin-top:-3rem}.sa-row-gap-48>*{padding-left:3rem;padding-top:3rem}.sa-row-collapse-gutter{margin-left:0;margin-top:0}.sa-row-collapse-gutter>*{padding-left:0;padding-top:0}.sa-row-collapse-v-gutter{margin-bottom:0;margin-top:0}.sa-row-collapse-v-gutter>*{padding-top:0}.sa-row-stretch-content>.sa-col>*{flex-grow:1}.vendor-clear-input-button{-moz-appearance:textfield}.vendor-clear-input-button::-webkit-calendar-picker-indicator,.vendor-clear-input-button::-webkit-clear-button,.vendor-clear-input-button::-webkit-inner-spin-button{-webkit-appearance:none;appearance:none;display:none}.vendor-clear-input-button::-webkit-autofill{--shadow-color:#fff;--fill-color:#000;-webkit-text-fill-color:var(--fill-color);box-shadow:0 0 0 1000px var(--shadow-color) inset}[data-color-scheme=dark] .vendor-clear-input-button::-webkit-autofill{--shadow-color:#04080b;--fill-color:#dbdbdb}.vendor-clear-input-button::-ms-clear{display:none}.\[prop\:string\]{prop:string}.marker\:text-blue-75 ::marker{color:#1a98ff}.marker\:text-blue-75::marker{color:#1a98ff}.placeholder\:text-black-35::placeholder{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.placeholder\:text-navy-80::placeholder{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.before\:inline-flex:before{content:var(--tw-content);display:inline-flex}.before\:flex-none:before{content:var(--tw-content);flex:none}.before\:items-center:before{align-items:center;content:var(--tw-content)}.before\:justify-center:before{content:var(--tw-content);justify-content:center}.before\:rounded-full:before{border-radius:100%;content:var(--tw-content)}.before\:border:before{border-width:.0625rem;content:var(--tw-content)}.before\:border-solid:before{border-style:solid;content:var(--tw-content)}.before\:border-blue-75:before{--tw-border-opacity:1;border-color:rgb(26 152 255/var(--tw-border-opacity));content:var(--tw-content)}.before\:text-blue-75:before{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity));content:var(--tw-content)}.before\:content-\[counter\(myCounter\)\]:before{--tw-content:counter(myCounter);content:var(--tw-content)}.after\:absolute:after{content:var(--tw-content);position:absolute}.after\:inset-x-20:after{content:var(--tw-content);left:1.25rem;right:1.25rem}.after\:bottom-0:after{bottom:0;content:var(--tw-content)}.after\:right-18:after{content:var(--tw-content);right:1.125rem}.after\:z-1:after{content:var(--tw-content);z-index:1}.after\:block:after{content:var(--tw-content);display:block}.after\:hidden:after{content:var(--tw-content);display:none}.after\:h-1:after{content:var(--tw-content);height:.0625rem}.after\:h-16:after{content:var(--tw-content);height:1rem}.after\:h-8:after{content:var(--tw-content);height:.5rem}.after\:w-16:after{content:var(--tw-content);width:1rem}.after\:w-8:after{content:var(--tw-content);width:.5rem}.after\:w-full:after{content:var(--tw-content);width:100%}.after\:rotate-180:after{content:var(--tw-content);transform:translate(var(--tw-translate-x),var(--tw-translate-y)) rotate(var(--tw-rotate)) skewX(var(--tw-skew-x)) skewY(var(--tw-skew-y)) scaleX(var(--tw-scale-x)) scaleY(var(--tw-scale-y))}.after\:rotate-180:after{--tw-rotate:180deg}.after\:bg-black-v2-25:after{--tw-bg-opacity:1;background-color:rgb(173 177 186/var(--tw-bg-opacity));content:var(--tw-content)}.after\:content-\[\'\'\]:after{--tw-content:"";content:var(--tw-content)}.first\:pl-0:first-child{padding-left:0}.first\:text-left:first-child{text-align:left}.first\:pt-safe-offset-0:first-child{padding-top:calc(env(safe-area-inset-top))}.first\:px-safe-offset-18:first-child{padding-left:calc(env(safe-area-inset-left) + 1.125rem);padding-right:calc(env(safe-area-inset-right) + 1.125rem)}.last\:mb-0:last-child{margin-bottom:0}.last\:mr-0:last-child{margin-right:0}.last\:border-0:last-child{border-width:0}.last\:border-none:last-child{border-style:none}.last\:pr-0:last-child{padding-right:0}.last\:pr-30:last-child{padding-right:1.875rem}.last\:after\:hidden:last-child:after{content:var(--tw-content);display:none}.only\:mb-18:only-child{margin-bottom:1.125rem}.last-of-type\:mr-0:last-of-type{margin-right:0}.visited\:text-black-60:visited{color:#434348}.visited\:text-black-70:visited{color:#333}.visited\:text-share-text:visited{color:var(--sa-text-color-1)}.visited\:text-share-text-6:visited{color:var(--sa-text-color-6)}.visited\:no-underline:visited{text-decoration-line:none}.invalid\:shadow-none:invalid{--tw-shadow:0 0 #0000;--tw-shadow-colored:0 0 #0000;box-shadow:var(--tw-ring-offset-shadow,0 0 #0000),var(--tw-ring-shadow,0 0 #0000),var(--tw-shadow)}.read-only\:bg-black-5:read-only{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.read-only\:text-black-35:read-only{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.read-only\:text-navy-80:read-only{--tw-text-opacity:1;color:rgb(65 74 95/var(--tw-text-opacity))}.read-only\:opacity-100:read-only{opacity:1}.empty\:hidden:empty{display:none}.focus-within\:border-navy-40:focus-within{--tw-border-opacity:1;border-color:rgb(141 146 159/var(--tw-border-opacity))}.focus-within\:border-share-negative:focus-within{border-color:var(--sa-negative-color)}.hover\:border-black-50:hover{--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}.hover\:bg-black-10:hover{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.hover\:bg-black-5:hover{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.hover\:bg-black-50:hover{--tw-bg-opacity:1;background-color:rgb(85 85 85/var(--tw-bg-opacity))}.hover\:fill-black-50:hover{fill:#555}.hover\:text-black-80:hover{--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}.hover\:text-blue-75:hover{--tw-text-opacity:1;color:rgb(26 152 255/var(--tw-text-opacity))}.hover\:text-share-text:hover{color:var(--sa-text-color-1)}.hover\:text-share-text-6:hover{color:var(--sa-text-color-6)}.hover\:text-white:hover{--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}.hover\:underline:hover{text-decoration-line:underline}.hover\:no-underline:hover{text-decoration-line:none}.focus\:border-black-35:focus{--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}.focus\:border-red:focus{--tw-border-opacity:1;border-color:rgb(201 57 44/var(--tw-border-opacity))}.focus\:fill-black-50:focus{fill:#555}.focus\:text-share-text:focus{color:var(--sa-text-color-1)}.focus\:text-share-text-6:focus{color:var(--sa-text-color-6)}.focus\:underline:focus{text-decoration-line:underline}.focus\:no-underline:focus{text-decoration-line:none}.active\:bg-black-10:active{--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}.disabled\:pointer-events-none:disabled{pointer-events:none}.disabled\:cursor-default:disabled{cursor:default}.disabled\:cursor-none:disabled{cursor:none}.disabled\:border-black-10:disabled{--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}.disabled\:bg-black-5:disabled{--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}.disabled\:text-black-10:disabled{--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}.disabled\:opacity-100:disabled{opacity:1}.disabled\:opacity-40:disabled{opacity:.4}.group:hover .group-hover\:fill-black-35\/50{fill:#75757580}.group:hover .group-hover\:fill-yellow-90\/50{fill:#efa81880}:is([data-color-scheme=dark] .dark\:border-black-10){--tw-border-opacity:1;border-color:rgb(219 219 219/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-30){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-50){--tw-border-opacity:1;border-color:rgb(85 85 85/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-80){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-90){--tw-border-opacity:1;border-color:rgb(35 42 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-black-v2-70){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-blue-70){--tw-border-opacity:1;border-color:rgb(89 148 255/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:border-red-80){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:bg-black){--tw-bg-opacity:1;background-color:rgb(0 0 0/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-10){--tw-bg-opacity:1;background-color:rgb(219 219 219/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30){--tw-bg-opacity:1;background-color:rgb(131 141 143/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-30\/20){background-color:#838d8f33}:is([data-color-scheme=dark] .dark\:bg-black-80){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-90){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-95){--tw-bg-opacity:1;background-color:rgb(17 21 23/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-98){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-70){--tw-bg-opacity:1;background-color:rgb(63 66 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-black-v2-80){--tw-bg-opacity:1;background-color:rgb(33 34 36/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-blue-70){--tw-bg-opacity:1;background-color:rgb(89 148 255/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-45){--tw-bg-opacity:1;background-color:rgb(153 209 148/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-50){--tw-bg-opacity:1;background-color:rgb(135 199 130/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-55){--tw-bg-opacity:1;background-color:rgb(116 189 111/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-60){--tw-bg-opacity:1;background-color:rgb(98 176 93/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-70){--tw-bg-opacity:1;background-color:rgb(85 165 80/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-green-v2-75){--tw-bg-opacity:1;background-color:rgb(72 156 67/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-orange-v2){--tw-bg-opacity:1;background-color:rgb(239 109 10/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-80){--tw-bg-opacity:1;background-color:rgb(217 77 65/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-30){--tw-bg-opacity:1;background-color:rgb(235 136 136/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-40){--tw-bg-opacity:1;background-color:rgb(224 117 117/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-60){--tw-bg-opacity:1;background-color:rgb(214 99 99/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-red-v2-90){--tw-bg-opacity:1;background-color:rgb(185 72 72/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-teal-75){--tw-bg-opacity:1;background-color:rgb(50 166 103/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-50){--tw-bg-opacity:1;background-color:rgb(252 239 126/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:bg-yellow-v2-90){--tw-bg-opacity:1;background-color:rgb(232 218 88/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:from-black-60){--tw-gradient-from:#434348 var(--tw-gradient-from-position);--tw-gradient-to:#43434800 var(--tw-gradient-to-position);--tw-gradient-stops:var(--tw-gradient-from),var(--tw-gradient-to)}:is([data-color-scheme=dark] .dark\:to-black-80){--tw-gradient-to:#2c3032 var(--tw-gradient-to-position)}:is([data-color-scheme=dark] .dark\:fill-black-10){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:fill-black-30){fill:#838d8f}:is([data-color-scheme=dark] .dark\:fill-black-35){fill:#757575}:is([data-color-scheme=dark] .dark\:fill-black-50){fill:#555}:is([data-color-scheme=dark] .dark\:fill-black-80){fill:#2c3032}:is([data-color-scheme=dark] .dark\:fill-black-95){fill:#111517}:is([data-color-scheme=dark] .dark\:text-black){--tw-text-opacity:1;color:rgb(0 0 0/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-10){--tw-text-opacity:1;color:rgb(219 219 219/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-20){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-80){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-95){--tw-text-opacity:1;color:rgb(17 21 23/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-20){--tw-text-opacity:1;color:rgb(224 225 228/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-black-v2-90){--tw-text-opacity:1;color:rgb(16 17 20/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-blue-70){--tw-text-opacity:1;color:rgb(89 148 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:text-white){--tw-text-opacity:1;color:rgb(255 255 255/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:placeholder\:text-black-30)::placeholder{--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:visited\:text-black-10:visited){color:#dbdbdb}:is([data-color-scheme=dark] .dark\:visited\:text-black-20:visited){color:#acacac}:is([data-color-scheme=dark] .dark\:read-only\:text-black-30:read-only){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:focus-within\:border-black-v2-70:focus-within){--tw-border-opacity:1;border-color:rgb(63 66 72/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-20:hover){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-5:hover){--tw-bg-opacity:1;background-color:rgb(242 244 247/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-80:hover){--tw-bg-opacity:1;background-color:rgb(44 48 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:bg-black-90:hover){--tw-bg-opacity:1;background-color:rgb(35 42 50/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:hover\:fill-black-10:hover){fill:#dbdbdb}:is([data-color-scheme=dark] .dark\:hover\:text-black-20:hover){--tw-text-opacity:1;color:rgb(172 172 172/var(--tw-text-opacity))}:is([data-color-scheme=dark] .dark\:hover\:text-share-link:hover){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:focus\:border-black-30:focus){--tw-border-opacity:1;border-color:rgb(131 141 143/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-black-35:focus){--tw-border-opacity:1;border-color:rgb(117 117 117/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:border-red-80:focus){--tw-border-opacity:1;border-color:rgb(217 77 65/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:focus\:text-share-link:focus){color:var(--sa-link-color)}:is([data-color-scheme=dark] .dark\:active\:bg-black-20:active){--tw-bg-opacity:1;background-color:rgb(172 172 172/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:border-black-80:disabled){--tw-border-opacity:1;border-color:rgb(44 48 50/var(--tw-border-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:bg-black-98:disabled){--tw-bg-opacity:1;background-color:rgb(4 8 11/var(--tw-bg-opacity))}:is([data-color-scheme=dark] .dark\:disabled\:text-black-80:disabled){--tw-text-opacity:1;color:rgb(44 48 50/var(--tw-text-opacity))}@media print{.print\:block{display:block}.print\:hidden{display:none}}@media (min-width:375px){.xs\:block{display:block}.xs\:w-0{width:0}.xs\:w-auto{width:auto}.xs\:max-w-full{max-width:100%}.xs\:grow{flex-grow:1}.xs\:basis-1\/12{flex-basis:8.333333%}.xs\:basis-10\/12{flex-basis:83.333333%}.xs\:basis-11\/12{flex-basis:91.666667%}.xs\:basis-2\/12{flex-basis:16.666667%}.xs\:basis-3\/12{flex-basis:25%}.xs\:basis-4\/12{flex-basis:33.333333%}.xs\:basis-5\/12{flex-basis:41.666667%}.xs\:basis-6\/12{flex-basis:50%}.xs\:basis-7\/12{flex-basis:58.333333%}.xs\:basis-8\/12{flex-basis:66.666667%}.xs\:basis-9\/12{flex-basis:75%}.xs\:basis-auto{flex-basis:auto}.xs\:basis-full{flex-basis:100%}}@media (min-width:576px){.sm\:my-0{margin-top:0}.sm\:mb-0,.sm\:my-0{margin-bottom:0}.sm\:mb-10{margin-bottom:.625rem}.sm\:mb-24{margin-bottom:1.5rem}.sm\:mr-0{margin-right:0}.sm\:mt-0{margin-top:0}.sm\:flex{display:flex}.sm\:hidden{display:none}.sm\:h-10{height:.625rem}.sm\:w-0{width:0}.sm\:w-auto{width:auto}.sm\:max-w-full{max-width:100%}.sm\:grow{flex-grow:1}.sm\:basis-1\/12{flex-basis:8.333333%}.sm\:basis-10\/12{flex-basis:83.333333%}.sm\:basis-11\/12{flex-basis:91.666667%}.sm\:basis-2\/12{flex-basis:16.666667%}.sm\:basis-3\/12{flex-basis:25%}.sm\:basis-4\/12{flex-basis:33.333333%}.sm\:basis-5\/12{flex-basis:41.666667%}.sm\:basis-6\/12{flex-basis:50%}.sm\:basis-7\/12{flex-basis:58.333333%}.sm\:basis-8\/12{flex-basis:66.666667%}.sm\:basis-9\/12{flex-basis:75%}.sm\:basis-auto{flex-basis:auto}.sm\:basis-full{flex-basis:100%}.sm\:flex-row{flex-direction:row}.sm\:flex-col{flex-direction:column}.sm\:self-auto{align-self:auto}.sm\:self-start{align-self:flex-start}.sm\:bg-transparent{background-color:initial}.sm\:p-0{padding:0}.sm\:px-12{padding-left:.75rem;padding-right:.75rem}.sm\:px-18{padding-left:1.125rem;padding-right:1.125rem}.sm\:py-10{padding-bottom:.625rem;padding-top:.625rem}.sm\:pb-24{padding-bottom:1.5rem}.sm\:pb-32{padding-bottom:2rem}.sm\:pt-24{padding-top:1.5rem}.sm\:pt-32{padding-top:2rem}.sm\:text-center{text-align:center}.sm\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.sm\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.sm\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.sm\:text-small-2-b{font-size:.75rem;font-weight:700;line-height:1.25rem}.sm\:text-small-b{font-size:.75rem;font-weight:700;line-height:.875rem}.sm\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:sm\:bg-transparent){background-color:initial}:is([data-color-scheme=dark] .sm\:dark\:bg-transparent){background-color:initial}}@media (min-width:768px){.md\:absolute{position:absolute}.md\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.md\:-mx-48{margin-left:-3rem;margin-right:-3rem}.md\:-my-16{margin-bottom:-1rem;margin-top:-1rem}.md\:mx-48{margin-left:3rem;margin-right:3rem}.md\:my-0{margin-bottom:0;margin-top:0}.md\:my-32{margin-bottom:2rem;margin-top:2rem}.md\:-mt-40{margin-top:-2.5rem}.md\:mb-0{margin-bottom:0}.md\:mb-12{margin-bottom:.75rem}.md\:mb-16{margin-bottom:1rem}.md\:mb-18{margin-bottom:1.125rem}.md\:mb-20{margin-bottom:1.25rem}.md\:mb-24{margin-bottom:1.5rem}.md\:mb-30{margin-bottom:1.875rem}.md\:mb-32{margin-bottom:2rem}.md\:mb-40{margin-bottom:2.5rem}.md\:mb-6{margin-bottom:.375rem}.md\:mb-8{margin-bottom:.5rem}.md\:ml-60{margin-left:3.75rem}.md\:ml-8{margin-left:.5rem}.md\:mr-20{margin-right:1.25rem}.md\:mr-48{margin-right:3rem}.md\:mr-6{margin-right:.375rem}.md\:mt-0{margin-top:0}.md\:mt-12{margin-top:.75rem}.md\:mt-16{margin-top:1rem}.md\:mt-18{margin-top:1.125rem}.md\:mt-30{margin-top:1.875rem}.md\:mt-32{margin-top:2rem}.md\:mt-8{margin-top:.5rem}.md\:block{display:block}.md\:flex{display:flex}.md\:inline-flex{display:inline-flex}.md\:hidden{display:none}.md\:h-10{height:.625rem}.md\:h-120{height:7.5rem}.md\:h-14{height:.875rem}.md\:h-170{height:10.625rem}.md\:h-240{height:15rem}.md\:h-30{height:1.875rem}.md\:h-36{height:2.25rem}.md\:h-52{height:3.25rem}.md\:h-auto{height:auto}.md\:max-h-full{max-height:100%}.md\:w-0{width:0}.md\:w-1{width:.0625rem}.md\:w-120{width:7.5rem}.md\:w-14{width:.875rem}.md\:w-170{width:10.625rem}.md\:w-240{width:15rem}.md\:w-36{width:2.25rem}.md\:w-52{width:3.25rem}.md\:w-auto{width:auto}.md\:max-w-full{max-width:100%}.md\:flex-auto{flex:1 1 auto}.md\:flex-none{flex:none}.md\:grow{flex-grow:1}.md\:grow-0{flex-grow:0}.md\:basis-1\/12{flex-basis:8.333333%}.md\:basis-1\/2{flex-basis:50%}.md\:basis-10\/12{flex-basis:83.333333%}.md\:basis-11\/12{flex-basis:91.666667%}.md\:basis-2\/12{flex-basis:16.666667%}.md\:basis-3\/12{flex-basis:25%}.md\:basis-4\/12{flex-basis:33.333333%}.md\:basis-5\/12{flex-basis:41.666667%}.md\:basis-6\/12{flex-basis:50%}.md\:basis-7\/12{flex-basis:58.333333%}.md\:basis-8\/12{flex-basis:66.666667%}.md\:basis-9\/12{flex-basis:75%}.md\:basis-auto{flex-basis:auto}.md\:basis-full{flex-basis:100%}.md\:grid-flow-col{grid-auto-flow:column}.md\:flex-row{flex-direction:row}.md\:flex-row-reverse{flex-direction:row-reverse}.md\:flex-col{flex-direction:column}.md\:flex-wrap{flex-wrap:wrap}.md\:items-center{align-items:center}.md\:justify-start{justify-content:flex-start}.md\:justify-between{justify-content:space-between}.md\:gap-20{gap:1.25rem}.md\:gap-24{gap:1.5rem}.md\:self-auto{align-self:auto}.md\:self-end{align-self:flex-end}.md\:overflow-hidden{overflow:hidden}.md\:overflow-y-auto{overflow-y:auto}.md\:border-l-4{border-left-width:.25rem}.md\:border-solid{border-style:solid}.md\:border-l-blue-75{--tw-border-opacity:1;border-left-color:rgb(26 152 255/var(--tw-border-opacity))}.md\:p-0{padding:0}.md\:p-24{padding:1.5rem}.md\:p-36{padding:2.25rem}.md\:px-0{padding-left:0;padding-right:0}.md\:px-10{padding-left:.625rem;padding-right:.625rem}.md\:px-14{padding-left:.875rem;padding-right:.875rem}.md\:px-18{padding-left:1.125rem;padding-right:1.125rem}.md\:px-2{padding-left:.125rem;padding-right:.125rem}.md\:px-20{padding-left:1.25rem;padding-right:1.25rem}.md\:px-24{padding-left:1.5rem;padding-right:1.5rem}.md\:px-32{padding-left:2rem;padding-right:2rem}.md\:px-36{padding-left:2.25rem;padding-right:2.25rem}.md\:px-4{padding-left:.25rem;padding-right:.25rem}.md\:px-48{padding-left:3rem;padding-right:3rem}.md\:px-52{padding-left:3.25rem;padding-right:3.25rem}.md\:py-10{padding-bottom:.625rem;padding-top:.625rem}.md\:py-16{padding-bottom:1rem;padding-top:1rem}.md\:py-18{padding-bottom:1.125rem;padding-top:1.125rem}.md\:py-2{padding-bottom:.125rem;padding-top:.125rem}.md\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.md\:py-32{padding-bottom:2rem;padding-top:2rem}.md\:py-4{padding-bottom:.25rem;padding-top:.25rem}.md\:py-48{padding-bottom:3rem;padding-top:3rem}.md\:pb-0{padding-bottom:0}.md\:pb-10{padding-bottom:.625rem}.md\:pb-16{padding-bottom:1rem}.md\:pb-2{padding-bottom:.125rem}.md\:pb-20{padding-bottom:1.25rem}.md\:pb-24{padding-bottom:1.5rem}.md\:pb-28{padding-bottom:1.75rem}.md\:pb-32{padding-bottom:2rem}.md\:pb-36{padding-bottom:2.25rem}.md\:pb-40{padding-bottom:2.5rem}.md\:pl-0{padding-left:0}.md\:pl-24{padding-left:1.5rem}.md\:pr-32{padding-right:2rem}.md\:pt-0{padding-top:0}.md\:pt-12{padding-top:.75rem}.md\:pt-16{padding-top:1rem}.md\:pt-20{padding-top:1.25rem}.md\:pt-28{padding-top:1.75rem}.md\:pt-32{padding-top:2rem}.md\:pt-40{padding-top:2.5rem}.md\:pt-48{padding-top:3rem}.md\:pt-8{padding-top:.5rem}.md\:text-left{text-align:left}.md\:text-center{text-align:center}.md\:text-2x-large-2-r{font-size:1.25rem;font-weight:400;line-height:1.875rem}.md\:text-2x-large-b{font-size:1.25rem;font-weight:700;line-height:1.5rem}.md\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.md\:text-3x-large-2-r{font-size:1.375rem;font-weight:400;line-height:2rem}.md\:text-3x-large-b{font-size:1.375rem;font-weight:700;line-height:1.625rem}.md\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.md\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.md\:text-large-2-r{font-size:1rem;font-weight:400;line-height:1.5rem}.md\:text-large-3-r{font-size:1rem;font-weight:400;line-height:1.75rem}.md\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.md\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.md\:text-medium-2-b{font-size:.875rem;font-weight:700;line-height:1.25rem}.md\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.md\:text-small-b{font-weight:700}.md\:text-small-b,.md\:text-small-r{font-size:.75rem;line-height:.875rem}.md\:text-small-r{font-weight:400}.md\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.md\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.md\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.md\:px-safe-offset-24{padding-left:calc(env(safe-area-inset-left) + 1.5rem);padding-right:calc(env(safe-area-inset-right) + 1.5rem)}.md\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.md\:px-safe-or-24{padding-left:max(env(safe-area-inset-left),1.5rem);padding-right:max(env(safe-area-inset-right),1.5rem)}.md\:after\:h-8:after{content:var(--tw-content);height:.5rem}.md\:after\:w-8:after{content:var(--tw-content);width:.5rem}.md\:hover\:underline:hover{text-decoration-line:underline}}@media (min-width:1024px){.lg\:sticky{position:-webkit-sticky;position:sticky}.lg\:top-0{top:0}.lg\:my-12{margin-bottom:.75rem;margin-top:.75rem}.lg\:mb-0{margin-bottom:0}.lg\:mb-12{margin-bottom:.75rem}.lg\:mb-16{margin-bottom:1rem}.lg\:mb-18{margin-bottom:1.125rem}.lg\:mb-2{margin-bottom:.125rem}.lg\:mb-26{margin-bottom:1.625rem}.lg\:mb-32{margin-bottom:2rem}.lg\:mb-48{margin-bottom:3rem}.lg\:mb-64{margin-bottom:4rem}.lg\:mb-8{margin-bottom:.5rem}.lg\:ml-0{margin-left:0}.lg\:mr-12{margin-right:.75rem}.lg\:mr-4{margin-right:.25rem}.lg\:mt-12{margin-top:.75rem}.lg\:mt-16{margin-top:1rem}.lg\:mt-20{margin-top:1.25rem}.lg\:block{display:block}.lg\:flex{display:flex}.lg\:hidden{display:none}.lg\:h-120{height:7.5rem}.lg\:h-16{height:1rem}.lg\:h-28{height:1.75rem}.lg\:h-32{height:2rem}.lg\:h-60{height:3.75rem}.lg\:w-0{width:0}.lg\:w-120{width:7.5rem}.lg\:w-16{width:1rem}.lg\:w-60{width:3.75rem}.lg\:w-auto{width:auto}.lg\:max-w-full{max-width:100%}.lg\:grow{flex-grow:1}.lg\:basis-1\/12{flex-basis:8.333333%}.lg\:basis-10\/12{flex-basis:83.333333%}.lg\:basis-11\/12{flex-basis:91.666667%}.lg\:basis-2\/12{flex-basis:16.666667%}.lg\:basis-3\/12{flex-basis:25%}.lg\:basis-4\/12{flex-basis:33.333333%}.lg\:basis-5\/12{flex-basis:41.666667%}.lg\:basis-6\/12{flex-basis:50%}.lg\:basis-7\/12{flex-basis:58.333333%}.lg\:basis-8\/12{flex-basis:66.666667%}.lg\:basis-9\/12{flex-basis:75%}.lg\:basis-auto{flex-basis:auto}.lg\:basis-full{flex-basis:100%}.lg\:flex-col{flex-direction:column}.lg\:border-0{border-width:0}.lg\:bg-share-bg-4{background-color:var(--sa-body-bg-color-4)}.lg\:fill-share-text-2{fill:var(--sa-text-color-2)}.lg\:p-18{padding:1.125rem}.lg\:py-10{padding-bottom:.625rem;padding-top:.625rem}.lg\:py-20{padding-bottom:1.25rem;padding-top:1.25rem}.lg\:pb-18{padding-bottom:1.125rem}.lg\:pl-30{padding-left:1.875rem}.lg\:pt-0{padding-top:0}.lg\:pt-40{padding-top:2.5rem}.lg\:text-2x-small-b{font-size:.625rem;font-weight:700;line-height:.75rem}.lg\:text-4x-large-b{font-size:1.5rem;font-weight:700;line-height:1.875rem}.lg\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.lg\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.lg\:text-8x-large-b{font-size:2.375rem;font-weight:700;line-height:2.875rem}.lg\:text-medium-2-r{font-size:.875rem;font-weight:400;line-height:1.25rem}.lg\:text-medium-b{font-size:.875rem;font-weight:700;line-height:1rem}.lg\:text-medium-r{font-size:.875rem;font-weight:400;line-height:1rem}.lg\:text-small-r{font-size:.75rem;font-weight:400;line-height:.875rem}.lg\:text-x-large-2-r{font-size:1.125rem;font-weight:400;line-height:1.625rem}.lg\:text-x-large-b{font-size:1.125rem;font-weight:700;line-height:1.375rem}.lg\:text-black-35{--tw-text-opacity:1;color:rgb(117 117 117/var(--tw-text-opacity))}.lg\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}:is([data-color-scheme=dark] .dark\:lg\:text-black-30){--tw-text-opacity:1;color:rgb(131 141 143/var(--tw-text-opacity))}}@media (min-width:1200px){.xl\:mx-0{margin-left:0;margin-right:0}.xl\:mx-auto{margin-left:auto;margin-right:auto}.xl\:my-48{margin-bottom:3rem;margin-top:3rem}.xl\:mb-24{margin-bottom:1.5rem}.xl\:mb-38{margin-bottom:2.375rem}.xl\:ml-38{margin-left:2.375rem}.xl\:ml-8{margin-left:.5rem}.xl\:mr-38{margin-right:2.375rem}.xl\:mr-40{margin-right:2.5rem}.xl\:block{display:block}.xl\:flex{display:flex}.xl\:hidden{display:none}.xl\:h-1{height:.0625rem}.xl\:w-0{width:0}.xl\:w-auto{width:auto}.xl\:w-full{width:100%}.xl\:max-w-full{max-width:100%}.xl\:grow{flex-grow:1}.xl\:basis-1\/12{flex-basis:8.333333%}.xl\:basis-10\/12{flex-basis:83.333333%}.xl\:basis-11\/12{flex-basis:91.666667%}.xl\:basis-2\/12{flex-basis:16.666667%}.xl\:basis-3\/12{flex-basis:25%}.xl\:basis-4\/12{flex-basis:33.333333%}.xl\:basis-5\/12{flex-basis:41.666667%}.xl\:basis-6\/12{flex-basis:50%}.xl\:basis-7\/12{flex-basis:58.333333%}.xl\:basis-8\/12{flex-basis:66.666667%}.xl\:basis-9\/12{flex-basis:75%}.xl\:basis-auto{flex-basis:auto}.xl\:basis-full{flex-basis:100%}.xl\:flex-row{flex-direction:row}.xl\:flex-col{flex-direction:column}.xl\:justify-center{justify-content:center}.xl\:p-24{padding:1.5rem}.xl\:px-0{padding-left:0;padding-right:0}.xl\:px-18{padding-left:1.125rem;padding-right:1.125rem}.xl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xl\:px-48{padding-left:3rem;padding-right:3rem}.xl\:py-0{padding-bottom:0;padding-top:0}.xl\:py-12{padding-bottom:.75rem;padding-top:.75rem}.xl\:py-40{padding-bottom:2.5rem;padding-top:2.5rem}.xl\:py-60{padding-bottom:3.75rem;padding-top:3.75rem}.xl\:pb-40{padding-bottom:2.5rem}.xl\:pt-0{padding-top:0}.xl\:text-4x-large-r{font-size:1.5rem;font-weight:400;line-height:1.875rem}.xl\:text-5x-large-b{font-size:1.75rem;font-weight:700;line-height:2.125rem}.xl\:text-5x-large-r{font-size:1.75rem;font-weight:400;line-height:2.125rem}.xl\:text-6x-large-b{font-size:2rem;font-weight:700;line-height:2.375rem}.xl\:text-9x-large-b{font-size:3.125rem;font-weight:700;line-height:3.125rem}.xl\:text-large-b{font-size:1rem;font-weight:700;line-height:1.25rem}.xl\:text-large-r{font-size:1rem;font-weight:400;line-height:1.25rem}.xl\:text-x-large-r{font-size:1.125rem;font-weight:400;line-height:1.375rem}.xl\:px-safe-or-18{padding-left:max(env(safe-area-inset-left),1.125rem);padding-right:max(env(safe-area-inset-right),1.125rem)}.xl\:sa-row-gap-36{margin-bottom:2.25rem;margin-left:-2.25rem;margin-top:-2.25rem}.xl\:sa-row-gap-36>*{padding-left:2.25rem;padding-top:2.25rem}}@media (min-width:1540px){.xxl\:-mx-24{margin-left:-1.5rem;margin-right:-1.5rem}.xxl\:mx-48{margin-left:3rem;margin-right:3rem}.xxl\:my-0{margin-bottom:0;margin-top:0}.xxl\:mr-80{margin-right:5rem}.xxl\:flex{display:flex}.xxl\:hidden{display:none}.xxl\:h-auto{height:auto}.xxl\:w-0{width:0}.xxl\:w-1{width:.0625rem}.xxl\:w-auto{width:auto}.xxl\:max-w-full{max-width:100%}.xxl\:grow{flex-grow:1}.xxl\:basis-1\/12{flex-basis:8.333333%}.xxl\:basis-10\/12{flex-basis:83.333333%}.xxl\:basis-11\/12{flex-basis:91.666667%}.xxl\:basis-2\/12{flex-basis:16.666667%}.xxl\:basis-3\/12{flex-basis:25%}.xxl\:basis-4\/12{flex-basis:33.333333%}.xxl\:basis-5\/12{flex-basis:41.666667%}.xxl\:basis-6\/12{flex-basis:50%}.xxl\:basis-7\/12{flex-basis:58.333333%}.xxl\:basis-8\/12{flex-basis:66.666667%}.xxl\:basis-9\/12{flex-basis:75%}.xxl\:basis-auto{flex-basis:auto}.xxl\:basis-full{flex-basis:100%}.xxl\:flex-row{flex-direction:row}.xxl\:flex-row-reverse{flex-direction:row-reverse}.xxl\:flex-col{flex-direction:column}.xxl\:px-24{padding-left:1.5rem;padding-right:1.5rem}.xxl\:px-36{padding-left:2.25rem;padding-right:2.25rem}.xxl\:px-64{padding-left:4rem;padding-right:4rem}.xxl\:px-safe-or-36{padding-left:max(env(safe-area-inset-left),2.25rem);padding-right:max(env(safe-area-inset-right),2.25rem)}}</style><meta name="theme-color" content="#333333" ><link rel="manifest" href="/samw/manifest.52d7d67ec34303436765800b76c0582e.json" > <link rel="preload" href="/samw/static/js/app.982fa237.js" as="script"> <link rel="preload" href="/samw/static/js/c.7611.2265ccf6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9048.a372a116.js" as="script"> <link rel="preload" href="/samw/static/js/c.7309.221713ab.js" as="script"> <link rel="preload" href="/samw/static/js/c.7024.e4f9a632.js" as="script"> <link rel="preload" href="/samw/static/js/c.1037.2cb8d213.js" as="script"> <link rel="preload" href="/samw/static/js/c.2971.8a739675.js" as="script"> <link rel="preload" href="/samw/static/js/c.693.b6c2b13b.js" as="script"> <link rel="preload" href="/samw/static/js/c.7723.a12f5d5f.js" as="script"> <link rel="preload" href="/samw/static/js/c.8940.ea3985c6.js" as="script"> <link rel="preload" href="/samw/static/js/c.9323.415f29a9.js" as="script"> <link rel="preload" href="/samw/static/js/c.5169.48e2c582.js" as="script"> <link rel="preload" href="/samw/static/js/c.7683.37daf487.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.3661.f42a537a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9638.453e6eb8.js" as="script"> <link rel="preload" href="/samw/static/js/c.5075.5f3a0046.js" as="script"> <link rel="preload" href="/samw/static/js/c.7103.3b3a4c05.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.8383.0a755660.js" as="script"> <link rel="preload" href="/samw/static/js/c.Article-S.a6f4701e.js" as="script"> <link rel="preload" href="/samw/static/js/c.3918.3b2d278a.js" as="script"> <link rel="preload" href="/samw/static/js/c.BelowContentCards-W.0bca6b0a.js" as="script"> <link rel="preload" href="/samw/static/js/c.9340.0f228286.js" as="script"> <link rel="preload" href="/samw/static/js/c.6144.7d7e839c.js" as="script"> <link rel="preload" href="/samw/static/js/c.7531.716caf1b.js" as="script"><link href="https://seekingalpha.com/javascripts/seeking.xml" rel="search" title="ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript" type="application/opensearchdescription+xml" data-render="ssr"><link href="https://seekingalpha.com/article/4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call" rel="canonical" data-render="ssr"><meta name="description" content="ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ETExecutivesJane Green - IRAndrew Gengos -..." data-render="ssr"><meta name="robots" content="noarchive, max-image-preview:large" data-render="ssr"><meta name="twitter:title" content="ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript" data-render="ssr"><meta name="twitter:description" content="ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ETExecutivesJane Green - IRAndrew Gengos -..." data-render="ssr"><meta name="twitter:card" content="summary_large_image" data-render="ssr"><meta name="twitter:site" content="@SeekingAlpha" data-render="ssr"><meta name="twitter:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><meta property="og:title" content="ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript" data-render="ssr"><meta property="og:description" content="ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ETExecutivesJane Green - IRAndrew Gengos -..." data-render="ssr"><meta property="og:type" content="article" data-render="ssr"><meta property="article:publisher" content="https://www.facebook.com/Seekingalpha" data-render="ssr"><meta name="author" content="SA Transcripts" data-render="ssr"><meta property="article:author" content="https://seekingalpha.com/author/sa-transcripts" data-render="ssr"><meta property="article:published_time" content="2016-11-10T22:11:05-05:00" data-render="ssr"><meta property="article:modified_time" content="2016-11-10T22:11:05-05:00" data-render="ssr"><meta property="og:url" content="https://seekingalpha.com/article/4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call" data-render="ssr"><meta property="og:image" content="https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png" data-render="ssr"><script>window.SA_PRELOAD_DATA = {"statusCode":200,"moneData":{"params":"ssr_poc=yes&financial_statements=show&paywalled_article_content=control&ab_test_distribution_fastly=control&test_mcm_was_ever_pro=control"},"show_cookie_settings_link":false};</script><style>
    :root {
      --headerHeight: 50px;
    }

    @media (min-width: 1024px) {
      :root {
        --headerHeight: 68px;
        --sa-aside-width: 15rem;
      }
    }
  </style><link href="/samw/static/styles/3863.d1c4a9bb.css" rel="stylesheet" ><link href="/samw/static/styles/3661.40ac902e.css" rel="stylesheet" ><link href="/samw/static/styles/Article-S.80fc25df.css" rel="stylesheet" ><link href="/samw/static/styles/BelowContentCards-W.e27d7834.css" rel="stylesheet" ><link href="/samw/static/styles/CommentsContent-W.88e3efad.css" rel="stylesheet" >
        <script>window.SSR_DATA = {"comments":{"entityId":"4022325","entity":"articles","commentsMap":{"response":{"data":[],"included":[],"meta":{"page":{"size":0}},"links":{"next":null,"self":"\u002Farticles\u002F4022325\u002Fcomment_maps?include=user&sort=-top_parent_id"}}},"response":{"data":[],"included":[],"meta":{"page":{"size":0}},"links":{"next":null,"self":"\u002Farticles\u002F4022325\u002Fcomments?include=user&sort=-top_parent_id"}}},"article":{"response":{"data":{"id":"4022325","type":"fullArticle","attributes":{"publishOn":"2016-11-10T22:11:05-05:00","isLockedPro":false,"commentCount":0,"gettyImageUrl":null,"videoPreviewUrl":null,"themes":{"sa-transcripts":{"id":96991,"slug":"sa-transcripts","kind":"common","non_theme":true},"imuc":{"id":14678,"slug":"imuc","kind":"common","non_theme":true},"healthcare":{"id":17896,"slug":"healthcare","kind":"common","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","non_theme":true},"transcripts":{"id":49,"slug":"transcripts","kind":"general","path":"\u002Fearnings\u002Fearnings-call-transcripts","title":"Transcripts"},"us":{"id":326,"slug":"us","kind":"common","non_theme":true},"medical-instruments-supplies":{"id":17909,"slug":"medical-instruments-supplies","kind":"common","non_theme":true},"health-care":{"id":35,"slug":"health-care","kind":"sector","path":"\u002Fstock-ideas\u002Fhealthcare","title":"Healthcare ","sasource":"theme_breadcrumb"}},"title":"ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript","summary":[],"isPaywalled":false,"lastModified":"2016-11-10T22:11:05-05:00","closestTradingDate":"2016-11-11","beforeOpeningHours":false,"proPublishOn":"2016-11-10T22:11:05-05:00","isEarningsSlides":false,"isExclusive":false,"isTranscript":true,"excludedByTag":false,"transcriptPath":null,"likesCount":0,"disabledStatus":"allowed","disabledMessage":null,"status":"published","disclosure":"","articleActionableItem":null,"inEmbargo":false,"isNoindex":false,"isNoarchive":true,"content":"\u003Cp\u003EImmunoCellular Therapeutics, Ltd. (\u003Ca href=\"https:\u002F\u002Fseekingalpha.com\u002Fsymbol\u002FIMUC\" title=\"EOM Pharmaceuticals Holdings, Inc.\"\u003EOTCPK:IMUC\u003C\u002Fa\u003E) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ET\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EExecutives\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EJane Green - IR\u003C\u002Fp\u003E \u003Cp\u003EAndrew Gengos - CEO\u003C\u002Fp\u003E \u003Cp\u003EDavid Fractor - VP, Finance and Principal Accounting Officer\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EAnalysts\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EJason McCarthy - Maxim\u003C\u002Fp\u003E \u003Cp\u003ERon Leger - England Alternatives Investments\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EGood day, ladies and gentlemen and welcome to the ImmunoCellular Therapeutics’ Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] \u003C\u002Fp\u003E \u003Cp\u003EI would now like to introduce your host for today’s conference, Ms. Jane Green of Investor Relations. You may begin.\u003C\u002Fp\u003E \u003Cp\u003E\u003Cstrong\u003EJane Green\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp\u003EGood afternoon and welcome to ImmunoCellular Therapeutics’ conference call to discuss the company’s third quarter 2016 financial results and corporate update. Today’s call is being recorded and is also available via webcast. Participating in today’s call are Chief Executive Officer, Andrew Gengos, and Vice President, Finance and Principal Accounting Officer, David Fractor.\u003C\u002Fp\u003E \u003Cp\u003EFollowing this introduction, Mr. Gengos will discuss the company’s performance and future outlook. Mr. Fractor will review the company’s financial results and then the company will take questions. If you have not yet received a copy of today’s press release, you can obtain one by visiting the company’s website, www.imuc.com.\u003C\u002Fp\u003E \u003Cp\u003EImmunoCellular would like to remind everyone that during the conference call, members of the management team will make certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Examples of these statements may include statements about our plans, objectives, expectations and intentions with respect to the potential and timing for success of our scientific approaches to cancer immunotherapy, our product candidates and research programs, clinical development efforts, operations, financial condition and other statements that are not historical in nature. \u003C\u002Fp\u003E \u003Cp\u003EOur actual results may differ materially from those projected in these forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed\u003Cspan class=\"paywall-full-content invisible\"\u003E in such forward-looking statements include those set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. Please review these and the company’s other filings. We undertake no obligation to update any forward-looking statements after this call.\u003C\u002Fspan\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ENow, I would like to turn the call over to ImmunoCellular CEO, Andrew Gengos.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EAndrew Gengos\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThanks, Jane and thanks to all of you for joining our call today. We welcome the opportunity to provide an update on our company and to review upcoming events. Since our second quarter update, we’ve continued to make progress in implementing our ICT-107 registration trial in patients with newly diagnosed glioblastoma and in conducting our phase 1 trial of ICT-121 in patients with recurrent glioblastoma. I’ll provide brief updates on these programs and also address some of the challenges we are facing this year. I’ll also discuss our ongoing strategies for operating the company. Then, I’ll review our lineup of expected milestones for the remainder of the year, followed by Q&amp;A.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn the ICT-107 trial, in patients with newly diagnosed glioblastoma, we're one of a small number of companies in the cancer immunotherapy arena that we believe to be in the late stage of clinical development. We continue to think that what differentiates our Phase 3 program from any other newly diagnosed glioblastoma is that it's the only trial designed on the basis of data and insights from a placebo-controlled phase 2 trial, which induced overall survival as a primary endpoint.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAs of the beginning of this month, 225 patients have been screened and 11 patients have been randomized. Clinical site activation is continuing with a total of 75 site initiation visits and 66 sites activated to date. All the credit for this progress goes to our extraordinary team that is working tirelessly to move this program forward. While we're pleased with our progress in the third quarter, we became aware that the pace of randomization into our Phase 3 trial was being affected by several factors.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EOne of these factors is increased competition for patients in other newly diagnosed glioblastoma clinical programs. While we welcome the fact that patients with highly lethal cancers have clinical options, we realize that competing for patients presents potential financial and logistical challenges. Another factor pertains to how patients qualify for our trial. We've determined that we may be unnecessarily excluding from the trial a number of eligible patients when they exit standard of care chemo radiation. In other words, we determine that the number of patients who complete screening and then ultimately move on to randomization after chemo radiation is lower than we expected. Thus, the rate of randomization is slower than we would like, despite meeting our patient screening goals. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ETo address these challenges, we're implementing a protocol amendment that's designed to accelerate the pace and efficiency of our patient randomization efforts. The protocol amendment addresses the time required between initial screening and randomization. Remember that patients who are randomized in the trial currently are treated approximately 60 days following initial inclusion in the trial to allow for completion of standard of care chemo radiation and requalification screening for progression. We know that newly diagnosed patients would prefer not to wait a significant period of time before they know they will be included in a clinical trial. The protocol amendment will move randomization earlier, giving patients more certainty of participating. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EWe plan to convert the requalification screening, currently performed in patients exit chemo radiation to just another opportunity to collect clinical information. Patients with clear progression will still be discontinued from the trial at this screening point, but we expect a very large proportion of patients to continue the treatment under the trial protocol. As a consequence of these changes, we now will require at least 500 patients to be randomized instead of the 414 patients we had originally planned. We anticipate that the current slower progress in randomization and the implementation of the amendment will result in an extension of the expected timeline to the completion of the trial by about 12 to 18 months from our original estimates.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EWe plan to submit the protocol member to FDA and other relevant regulators for review and expect to complete the protocol amendment process and formally implement changes at all sites in the first quarter of 2017. Importantly, during this process, we’ll continue to screen and randomize patients and expect the addition of new sites and the streamlining of aphaeresis and manufacturing processes to accelerate the rate of randomization overall. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn our discussion last quarter, we noted that the competitive landscape in newly diagnosed glioblastoma looked favorable for ImmunoCellular, given the suspension and terminations of other programs. We continue to believe that ICT-107 is at the forefront of immunotherapy development in this indication. We continue to have confidence in the value and quality of our Phase 3 program and the therapeutic and commercial potential of ICT-107.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAt the upcoming SNO conference during the week of November 20, there will be two presentations from prior clinical trials of ICT-107. There will be no data from the ongoing Phase 3 trial. Dr. Phuphanich of Cedar Sinai who conducted the phase 1 trial plans to present updated long term survival data from patients in that trial. Our Senior Vice President of Research, Steve Swanson will present data from the Phase 2 ICT-107 trial on the association between overall survival and progression free survival with immunologic response. These data provide support for the link between the ability of ICT-107 to induce antigen specific T. cell responses in HLA-A2 positive patients and the increased overall survival of these patients versus placebo non-responders.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ERelative to ICT-121, the phase 1 open label trial in patients with recurrent glioblastoma has completed enrolment, reaching the target of 20 patients. The trial is being conducted at six sites in the US and preliminary results are expected in the second quarter of 2017. Our current plan is to submit an abstract at ASCO with the goal of being able to present the preliminary results at the conference. As we noted last quarter, because the Phase 1 trial is open label, we can look at the raw data as they are generated. These data have not been scrubbed and validated by the CRO. That only occurs at the end of the trial. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EHowever, the un-validated results we’ve seen so far continue to be encouraging. While there is no perfectly matched historical control group we can use for this trial, there is a 2011 published meta-analysis of standard of care Avastin that shows a median overall survival of 9.3 months for recurrent patients. In the recent Celldex rindopepimut trial, the rindo treated median overall survival was 11.6 months and the Avastin control was also 9.3 months. We currently have eight deaths out of twenty patients enrolled, so our median survival can still move around a bit. But also remember that this is a small trial. Given those caveats, our current median survival is 13.8 months as of October 31, which compares favorably to the published results. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAlso we already have seven patients or 35% alive beyond 18 months whereas in the rindopepimut trial there was a thirty 30% and 15% overall survival at 15% for treatment of placebo patients respectively. We also have four patients or 20% alive at the two year mark. We'll continue to watch these results mature and are hopeful they continue to look encouraging for these patients with such a high unmet need. We're also encouraged that our dendritic cell based cancer immunotherapy platform appears to be performing positively in the second clinical program. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EFinally, a word about our financial status and our strategies to improve our financial standing. As we reported last quarter, we completed an underwritten public offering in August and raised net proceeds of about 6.6 million after deducting the underwriting discount and operating expenses. That amount of capital equates to about a three month runway extension to our cash position. That's obviously not enough to enable us to complete the ICT-107 phase 3 trial or to operate for the long term. In order for us to continue to advance our product candidates in clinical development, we need access to additional capital. However, the options for financing are limited for a company like ours. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAs we've noted in our previous public disclosures without such financing, our ability to continue to advance our product candidates would be limited. The steps we are taking now including the proposed reverse split that is on the ballot for the special meeting of shareholders taking place on November 14 are designed to enhance our ability to keep our company operational and enable us to continue to advance our development programs and expand our cancer immunotherapy platform. At the special meeting of shareholders on November 14, shareholders of record will be asked to vote on a proposal to effect a reverse stock split and a reduction in authorized shares of common stock. In the proxy material sent to all shareholders, the rationale for this proposal was clearly laid out. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn short, the reverse stock split in a ratio of 1 for 40 would reduce the number of issued and outstanding shares to about 3.4 million. In addition, we’ll reduce the number of authorized shares of our common stock from 249 million to 25 million. We expect this proposal, if approved, will provide us the additional common shares we require to continue to raise capital as the need and opportunity arises.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn addition, as we reported in August, we received a notice from the NYSEMKT that the company no longer meets the exchange’s continued listing standards related to our low selling price. The NYSEMKT deemed it appropriate for us to effect a reverse stock split, which we believe will result in an increase to our common stock price. The board believes that a reverse stock split is a potentially effective means for us to maintain compliance with the rules of the NYSEMKT and to avoid or at least mitigate the likely adverse consequences of our common stock being delisted by potentially increasing the price of our common stock. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EOur board and management realize that financing has often involved dilution for existing shareholders. We also realize that our reverse split represents some risks and potential disadvantages as well, which are detailed in the proxy statement. Obviously, we're hopeful that our market value will improve and better reflect the value we see in our company. We sincerely urge shareholders to follow the recommendations of the board and vote in favor of the reverse split. We remain very appreciative to all of our shareholders for your continued support.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn terms of the upcoming milestones, in the ICT-107 program, in the near term, we anticipate continuing to bring clinical sites online. We hope to complete another 20 site initiation visits this year. Longer term, in light of the protocol amendment currently underway, we now anticipate randomization of all patients by the first half of 2019 and an additional 2 to 3 years from then to achieve the number of required events to complete the trial. We plan to conduct a futility interim analysis upon reaching 30% of the events, which should be about the same time as full randomization and an efficacy interim analysis upon reaching 67% of the events, which should be about six months later. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EWe and our collaborators will be presenting updated immune monitoring data from the ICT-107 phase 2 trial and updated long term survival data from the Phase 1 trial at the Society for Neuro-Oncology Annual Scientific Meeting in November. Our two abstracts were recently accepted and we have received oral presentation invitations to deliver both. You can find more details on these presentations in the press release we issued today. In the ICT-121 program, we look forward to continuing to monitor patients with data expected by mid-year 2017. We'll continue to review the raw data and are encouraged with what we see so far. Our research programs are well underway and making progress. We anticipate having one or more T. cell receptors identified for a stem to T. cell clinical candidate or candidates by the end of 2016. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EWe should make an initial attempt to package the T. cell receptor DNA sequence in the antivirus gene therapy construct by the end of this year as well and we're continuing to make progress in our collaboration on the University of Maryland projects that have application to our existing Dendritic cell immunotherapy and stem to T. cell technology platforms. As always, we plan to continue to evaluate opportunities to license or acquire new technology that can further complement and expand our immunotherapy platform and we remain interested in working with pharma companies to explore combination approaches with checkpoint inhibitors and potentially other immunotherapeutic approaches. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EWe're grateful for the continued support of the medical and scientific cancer community and the confidence placed in our company by our collaborators. Now I'd like to ask David Fractor to review our financial results for the third quarter of 2016 and then we’ll up the call for questions. David?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EDavid Fractor\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThank you, Andrew. For the quarter ended September 30, 2016, the company incurred a net loss of $4.8 million or $0.04 per basic and diluted share compared to a net loss of $3.4 million or $0.04 per basic and diluted share for the quarter ended September 30, 2015. During the third quarter 2016, we incurred $4.6 million of research and development expenses compared to $2.7 million in the prior quarter, while general and administrative expenses decreased to 908,000 compared to 1.1 million in the prior year. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThe $1.9 million increase in R&amp;D expenses primarily reflects the additional expenses associated with the phase 3 trial of ICT-107. The decrease in general and administrative expenses reflects lower professional fees in the current quarter. The loss for the current quarter was partially offset by a $1.1 million credit to other income to a reflection in the -- to reflect a reduction in the valuation of our warrant derivative liabilities. In the same quarter of the prior year, the company recorded a corresponding credit of $339,000.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EFor the nine months ended September 30, 2016, the company incurred a net loss of $15.8 million or $0.15 per basic and diluted share compared to a net loss of $8 million or $0.09 per basic and diluted share. During the nine months ended September 30, 2016, we incurred a $13.7 million in research and development expenses compared to $7 million in the prior year. The company also reported that cash used in operations during the nine months ended September 30, 2016 was $16.1 million compared to $13.2 million in the prior year. The increase primarily reflects the additional research and development expenditures in the current year. As of September 30, 2016, we had $15.3 million in cash.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn August, 2016, the company entered into an underwriting agreement with Maxim Group pursuant to which we received net proceeds of approximately $6.6 million after deducting the underwriting discount and offering expenses. From the initial sale of 34.6 million shares of the company's common stock, base warrants to purchase 35.2 million shares a common stock at an exercise price of $0.19 per share and pre-funded warrants to purchase 12,450,000 shares of common stock at an exercise price of $0.01 per share. The underwriters partially exercised their option to purchase additional shares in base warrants and purchased an additional 1.5 million shares of the company’s common stock at a price of $0.15 per share and base warrants to purchase 4.5 million shares. The pre-funded warrants were substantially paid for at the time of the offering and have an exercise price of $0.01 per share. As of September 30, 2016, the company had 138 -- excuse me 137.8 million shares of common stock issued and outstanding. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAdditionally, the terms of the California Institute of Regenerative Medicine award were modified such that the company received an additional $1.5 million during the third quarter as part of the initial award received from CIRM. The total amount of the award and other award conditions remain unchanged. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EAndrew Gengos\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThank you, David. Operator, would you please now open the call for questions?\u003C\u002Fp\u003E \u003Cp id=\"question-answer-session\" class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EQuestion-and-Answer Session\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E[Operator Instructions] And our first question comes from the line of Jason McCarthy with Maxim. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJason McCarthy\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EHi, Andrew. Couple of questions. I guess I’ll start with funding. What is the projected cash runway right now, are you going to receive any more funding from CIRM, I know you got the additional $1.5 million. Outside of a capital raise, reverse split or otherwise, are there other sources from CIRM or other non-dilutive sources of capital that the company could potentially get?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EHi, Jason. Thanks for the question. So you can see that our burn is roughly in the range of $2 million now a month. We think it might go higher as we're in the most expensive part of the trial, because we are manufacturing doses for all patients. So the enrollment randomization period of the trial is the most expensive time in the trial. And because we ended with roughly $15 million, so ended September with $15 million, I mean, you can do the math about how far our runway is. The complication here to get to your CIRM question is that - we're still finalizing the protocol amendment that I discussed in my prepared remarks and because of some of the changes in that in the protocol specifically moving randomization early - to an earlier point in time without going into great detail, it has some consequences on the number of patients who need to enroll in the trial in total.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAnd so I mentioned our previous plan had been 414 patients and now we think it's at least 500. We're still finalizing that number, so I don't - I don't have a precise number but we think it's at least 500. Because the CIRM award, the remaining amount of CIRM award which is about $14.5 million. The lion's share of that almost all of it minus maybe a $1 million is paid out while we enroll according to milestones. Those milestones are set on proportions of enrollment. So if I don't know how many patients yet I need to enroll I can't really predict exactly when those milestones will be achieved. So there's more money coming from CIRM, a lot more but the precise date that it comes is not clear to me yet and whether we would need to finance in front of that or after that, my guess, I’m speculating is before but I don't know.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJason McCarthy\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAnd in terms of the adjustments in the trial number, the proposed enrollment number of at least 500 that's almost as 20% increase and I know you've cut the time down between chemo radiation and ICT-107 treatment. But is the increase in number, how does that alter your powering and is to maybe guard against the risk in that you're now potentially bringing in some early progressors that may not benefit as well.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo let me be clear that the order of how a patient gets treated And the timing for that does not change, so let me just for clarity let me review that. They get surgery, they recover we do initial screening then if they qualify, we manufacture. Then they have to go into chemo radiation and then after chemo radiation that's when the active part of our trial starts. So in the current design we randomize after chemo radiation. In the new proposed protocol, we're going to randomize roughly at the time of manufacturing. So yes we're going to randomize earlier but it doesn't change the timing of the way a patient gets treated with standard of care and put on the trial. What it does is it gives them more certainty that they're actually going to be in the trial. As a consequence. What’s going to happen is we're going to loosen the screening for progression right before randomization.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo that's after chemo radiation right before anonymization. We’re going to loosen that criteria because our experience to-date has shown us that it's too stringent. And so we still will screen out obviously progressing patients at that point in time but I think you're right there's a theoretical risk that we will indeed randomized patients that ultimately were progressing coming out of chemo radiation. And so in order to protect the powering of the trial, said differently keep roughly the same hazard ratio built into the trial, we need to add more patients. And we're working on that with the statistician to be included in our protocol amendment or shortly thereafter to resize the trial and our preliminary kind of analysis says it will be at least 500 but we don't know. And so our intent is to end up with a trial that has very similar powering and their core confidence that it's designed appropriately for the signal that we expect to see in the treated patients that aren't progressing. But it's tolerant of bringing in some set of patients that might in fact the early progresses that are undetectable, did I answer your question?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJason McCarthy\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EI think so, it just reads like - I understand that you've cut the time down. You're going back to randomization or when they qualify you'll start manufacturing, you’ve reduced some of the time between the chemo radiation and when you’ll dose that patient. Is that end piece of the screening process, but I'm looking at it as that is where the increase into 500 might be coming from because there are potential progressors in there, am I just still reading that not the right way?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThere's no difference in the timing of the trial, we haven't decreased the length of the trial or the order of the treatment. But, yes I think you're reading it right because we're randomizing earlier, anybody randomized becomes part of the intent to treat group. The intent-to-treat group is the group of patients that the primary endpoint is calculated on that’s the population because you’re randomizing earlier, you might in fact be randomized - well, we might be in fact randomizing some patients that potentially are progressing through chemo radiation and that we won't detect anymore and screen out right. So, because we expect that our intent-to-treat group will have some patients in there that have already started progressing both in the treated and the placebo arms. We need to put more patients in total into the trial. So that you know said in English the water down signal is beefed back up, you know what I mean.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003EJason McCarthy\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EGot you. That’s exactly the answer, that’s what I was looking for because that’s how I was reading it, now you answer it perfectly. I understand.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E[Operator Instructions] And our next question comes from the line of Ron Leger with England Alternatives Investments. Your line is now open.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAndrew, I’m wondering if you could talk a little bit more about the increased competition that you were mentioning in your comment. And is it such that some of these patients are being screened for multiple trials and they make a choice, send for a certain trial over another. How does that work?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo, as far as we're aware in late stage trials there's three that immediately come to mind, our trial, Northwest Bio has a Phase 3, it's hard to tell from their public information it looks like they've suspended enrollment and they have for a long time, but I don't know that for a fact. So that's out there and then we became aware and you can find this in the public literature that Bristol Myers has started two late stage trials in newly diagnosed glioblastoma totaling about, I think it's close to 900 patients, 850 patients something like that. And so, on the positive side, our ability to screen patients meaning patients they get referred by physicians to be screened for our trial is actually where we had hoped it would be, it's actually on our planned target. But converting those patients to patients that actually enter into the trial, the noun is randomized right, into the trial, randomized patients or adjective I guess.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThat productivity is lower than we need and we think we've understood why we have patients fall off, there are number of reasons. One of which might be due to competition. So let me - that's the nature of your question. So after the patient has surgery and they’re being screened for our trial and they qualify initially on something like HLA status and another inclusion criteria. That's when we manufacture but then they have to wait 60 days under the initial design. That 60 days is when they're getting chemo radiation but they start to wait though that amount of time before they know they'll actually be included in the trial. And that's where we've been losing some portion of patients. They've been withdrawing consent at that point. We don't know exactly why it could be because the trial requires them to have an aphaeresis which a kind of intensive blood draw which might be something they didn't understand or it could be because they have alternatives like the Bristol Meyer's trials where they don't have to have an aphaeresis or they don't have to wait 60 days to know if they'll be randomized.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAnd so that's potentially where and we're speculating because we only have anecdotal data on that. But that's potentially where competition can come in. And if a patient withdraws consent in our trial, yeah, to answer your second question, they can go get screened for another trial. And as long as they haven't been treated in our trial, they’ll be considered for a different trial. So I don't want to say that the entire issue in our trial is losing patients to competition, far be it - far from that I think, but it is certainly a component and we are addressing that by the protocol amendment.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo when you say that your criteria was too strict, can you provide a little more color on what you're doing to loosen that or would you rather not be specific on that?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ENo, I can give you a sense. So one of the problems, if you've been listening to our calls for a while or following the company you know there's an important characteristic in patients relating to what's called their MGMT gene. And roughly a third of the patients have the gene switched off and two thirds have it switched on. You have it switched on that's bad for your prognosis, you’ll typically be expected to have a median survival of maybe 12 to 16 months something like that. If you have it switched off, it's double that. So having the genes switched on is bad and what the - it means to have the gene switched on practically is that you don't get any benefit from chemotherapy.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIn fact the chemotherapy doesn't work for you, it doesn't help you. That's what you would predict. And so those patients still get chemotherapy, chemotherapy still standard of care. And they can actually start progressing while they're getting chemotherapy and remember our trial, the active part of our trial starts after chemotherapy. And so when we were designing the phase 2 with the keep opinion leaders in the field we were strongly advised to do something to rescreen patients coming out of chemotherapy for progression. And if they had progressed to not include them in the trial, progressive disease is no longer newly diagnosed disease. That’s a different disease. And so when we designed the trial we built in a screen for patients to requalify them after chemo radiation, make sure they weren’t progressive.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EIt turns out that that's practically difficult to do because the tumor bed in the brain that's been radiated and has had chemotherapy oftentimes it's difficult to read that area on an MRI and make an assessment as to whether there's scar tissue or progressing disease for example. And so, our criteria for requalifying those patients was too stringent, we know that now. And we’ve loosened that criteria a bit. And so what we expect is we'll be accepting more patients, a greater proportion of patients coming out of chemo radiation then we have to-date in the trial so far under the new protocol. Did I answer your question?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EYes, you did and you expect that this will be accepted by the FDA as well?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EYeah that's our anticipation. We haven't submitted it to them yet. So I'm being a little forward looking here but this is not a major change and we would expect just the standard discussion with FDA and the European regulators and Canadian regulators as well.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo one last question if I could. So considering how hard you’ve worked and you've done a great job of lining this trial up, getting a special protocol assessment, so you’re making sure you're designing it correctly that you’re going to get this looked at by the FDA as a trial that could b something that would lead to [indiscernible]. Is there a fair amount of interest out there in partnering with on it or is it and I know maybe you can’t provide a ton of color on or is there a belief out in pharma that they want to just try to develop their own immune therapy drug because there is a lot of interest in this field.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EI can give you, I can give you my thoughts on that but I'm kind of reading tea leaves, right because I'm not on the other side of the table in Big Pharma. We do have an active dialog with various pharma and large biotech companies regarding this program. It's not every day but it's periodic, their time frames are slow as you might imagine. And there is general interest in our program. However my interpretation of it is they either want to see compelling data meaning registration or they want to wait later until we get further into the trial. There's a theoretical argument that they should be interested, I'll give you that. Big Pharma is working on a generalized immunotherapy for cancer, you might have heard of them called checkpoint inhibitors. These are antibodies that can be used in any patients, so unlike our treatments which are made specifically for our patient from their own cells. These are recombinant protein antibodies that can be used in any patient and Pharma is testing them in a wide range of cancers. \u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThat's a kind of drug pharma likes, right because it can be used in lots of indications and they make it by the kilogram not by the patient. But the problem with that drug is it just is a general immune stimulator in the sense, right. All it really does is allows the population of killer T cells in the patient's body to be more effective against the tumor. So it's a generalized response, what would be interesting in combination with that is to increase the population of antigen specific killer T cells that in theory makes for an interesting combination. And that's what we're working on. ICT-107 and dendritic cell immunotherapy in general seeks to increase the population of antigen specific killer T cells.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo there is a - in my mind a pretty compelling logic for combination of these approaches. Why Pharma is not interest right now in collaborating with us that's hard to say. It could be that they want more data as I said or they want more certainty that maybe after registration not before or they don't believe in the technology at all, right. It's a range of things and I can't know but the discussions that I've had with Pharma recently are, hey, we’re interested, we're watching when you have more data let us know. And that's not very helpful. That doesn't really help you with your question, doesn’t really help me with my process of trying to partner with Pharma but that's what I get told.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ESo what’s the Bristol Myers trial, what drug is that?\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThat’s a PD1 antibody. So it's a checkpoint inhibitor. They have tested that, the trade name is Opdivo, approved drug. It's been approved in some other cancer indications, they've tested it and YERVOY another one of their checkpoint inhibitors in recurrent glioblastoma but they've never tested it before in newly diagnosed glioblastoma and they launched two large trials in newly diagnosed glioblastoma with Opdivo, without any data.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"question\"\u003ERon Leger\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAnd at some point I would think that their trial will again roll the number of patients that they want, so the competition would go down in that.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003E\u003Cspan class=\"answer\"\u003EAndrew Gengos\u003C\u002Fspan\u003E\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EYeah that's correct. I mean, Celldex is another example. Celldex ran a 750 patient phase 3 trial in newly diagnosed glioblastoma. That trial ended within the last year, it actually failed at an interim but it enrolled and it's doable, I think it took a few years to enroll that trial and if you look at Bristol's public statements it seems like they’re expecting it'll be a few years to enroll their trial just like it's a few years to enroll our trial. Remember, there is only 10,000 patients each year in the United States diagnosed with glioblastoma - newly diagnosed glioblastoma. So, it's an orphan indication and it just takes time to enroll a trial like this.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EAnd I'm showing no further questions at this time, I would now like to turn the call back over to Mr. Andrew Gengos, CEO for closing remarks.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EAndrew Gengos\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003EThank you, Vicki. I want to just thank everybody again for participating in today’s call and webcast. We look forward to continuing to communicate with investors in the coming weeks and months and to providing you with additional updates on our progress. Thanks very much, good bye.\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003E\u003Cstrong\u003EOperator\u003C\u002Fstrong\u003E\u003C\u002Fp\u003E \u003Cp class=\"paywall-full-content invisible no-summary-bullets\"\u003ELadies and gentlemen, thank you for participating in today conference. This does conclude the program, you may all disconnect. Everyone have a great day.\u003C\u002Fp\u003E","twitContent":"$IMUC - ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript. https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call?source=tweet ","innerMarketing":null,"marketingBullet":null,"isReit":false,"videoData":null,"marketingBulletVariant":null,"marketingBio":null},"relationships":{"author":{"data":{"id":"44211","type":"author"}},"sentiments":{"data":[]},"primaryTickers":{"data":[{"id":"14678","type":"tag"}]},"secondaryTickers":{"data":[]},"otherTags":{"data":[{"id":"96991","type":"tag"},{"id":"17896","type":"tag"},{"id":"49","type":"tag"},{"id":"326","type":"tag"},{"id":"17909","type":"tag"}]},"coAuthors":{"data":[]},"presentations":{"data":[]},"updates":{"data":[]},"corrections":{"data":[]}},"links":{"self":"\u002Farticle\u002F4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call","canonical":"https:\u002F\u002Fseekingalpha.com\u002Farticle\u002F4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call","uriImage":"https:\u002F\u002Fstatic.seekingalpha.com\u002Fassets\u002Fog_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","schemaImage":null}},"included":[{"id":"44211","type":"author","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":null,"linkedinUrl":null,"twitterUrl":null}},{"id":"14678","type":"tag","attributes":{"slug":"imuc","name":"IMUC","company":"EOM Pharmaceuticals Holdings, Inc.","tagKind":"Tags::Ticker","equityType":"currency","exchange":"OTCMKTS","fundTypeId":0,"isDefunct":false,"currency":"USD","isBdc":false,"isReit":false,"isEtf":false},"relationships":{"sector":{},"subIndustry":{}},"links":{"self":"\u002Fsymbol\u002FIMUC"}},{"id":"96991","type":"tag","attributes":{"slug":"sa-transcripts","name":"SA Transcripts","company":null,"tagKind":"Tags::AuthorTag"},"links":{"self":"\u002Fauthor\u002Fsa-transcripts"}},{"id":"17896","type":"tag","attributes":{"slug":"healthcare","name":"Healthcare","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fhealthcare"}},{"id":"49","type":"tag","attributes":{"slug":"transcripts","name":"Transcripts","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Ftranscripts"}},{"id":"326","type":"tag","attributes":{"slug":"us","name":"United States","company":null,"tagKind":"Tags::Country"},"links":{"self":"\u002Farticles?filters=us"}},{"id":"17909","type":"tag","attributes":{"slug":"medical-instruments-supplies","name":"Medical Instruments & Supplies","company":null,"tagKind":"Tag"},"links":{"self":"\u002Ftag\u002Fmedical-instruments-supplies"}}],"meta":{"proStatus":0,"page":{"title":"ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript","description":"ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ETExecutivesJane Green - IRAndrew Gengos -..."},"path":"\u002Fapi\u002Fv3\u002Farticles\u002F4022325"}},"type":"article","authorData":{"response":{"data":{"id":"44211","type":"fullAuthor","attributes":{"company":null,"slug":"sa-transcripts","userId":101639,"tagId":96991,"image":{"small":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fsmall_pic.png","medium":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fmedium_pic.png","big":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fbig_pic.png","extra_large":"https:\u002F\u002Fstatic3.seekingalpha.com\u002Fimages\u002Fusers_profile\u002F000\u002F101\u002F639\u002Fextra_large_pic.png"},"nick":"SA Transcripts","bio":"Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team","deactivated":null,"memberSince":2007,"contributorSince":2013,"followersCount":140691,"count":{"followers":140691,"articles":334318,"instablogs":0,"marketing_instablogs":0,"following":4,"comments":1,"likes":0,"comment_likes":1,"news":0,"mp_articles":0},"createdAt":"2013-02-20T14:49:48-05:00","showHeadlines":null,"podcasts":{}},"relationships":{"user":{"data":{"id":"101639","type":"user"}},"userBioTags":{"data":[{"id":"958652","type":"userBioTag"}]},"authorResearch":{"data":null}},"links":{"self":"\u002Fauthor\u002Fsa-transcripts","profileUrl":"\u002Fauthor\u002Fsa-transcripts","site":{"url":"https:\u002F\u002Fseekingalpha.com\u002Fearnings\u002Fearnings-call-transcripts","name":"Recent earnings call transcripts","clicks":38681},"linkedinUrl":"","twitterUrl":""}},"included":[{"id":"958652","type":"userBioTag","attributes":{"priority":0,"name":"We cover over 4K calls\u002Fquarter"}}]},"type":"fullAuthor"}}};</script></head><body><script>
        (() => {
          try {
            if (
              window.matchMedia &&
              window.matchMedia('(min-width: 1024px)').matches &&
              window.localStorage.getItem('isAsideOpened') === 'false'
            ) {
              window.document.documentElement.style.setProperty('--sa-aside-width', '3rem')
              window.document.body.classList.add('hydratingAsideCollapsed');
            }
          } catch (err) {
            console.error(err);
          }
        })()
      </script><div class="appLoading appLoaderInvisible" id="app-loader"></div><span id="sprite-source"><svg style="position:absolute;width:0;height:0;visibility:hidden" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><symbol viewBox="0 0 16 16" id="alpha" xmlns="http://www.w3.org/2000/svg"><path d="M3.763 8.396c0 2.468 1.209 4.508 2.82 4.458 2.257-.065 2.918-2.007 2.918-4.474 0-2.468-1.306-4.492-2.917-4.475-1.983.016-2.82 2.023-2.82 4.491Zm-1.756 0C2.345 3.116 6.407 3 6.407 3c2.949.016 3.787 3.225 3.787 3.225.048.18 1.756-2.995 1.756-2.995h.967c-1.982 4.36-1.901 6.137-1.901 6.137-.161 2.352 1.128 3.158 1.128 3.158 1.209.79 1.29-1.513 1.29-1.513.273-.099.434-.197.434-.197.645 3.191-1.289 2.977-1.289 2.977-1.499.165-2.144-2.336-2.144-2.336-2.127 2.863-4.577 2.238-4.577 2.238-4.19-.527-3.851-5.298-3.851-5.298Z"></path></symbol><symbol fill="none" viewBox="0 0 24 23" id="alpha-picks" xmlns="http://www.w3.org/2000/svg"><path fill="#1A98FF" d="M22.562 16.845s-.159 4.545-2.544 2.987c0 0-2.545-1.591-2.227-6.234 0 0-.068-1.54 1.022-5.081-.412.54-.805 1.066-1.172 1.606a35.72 35.72 0 0 0-1.361 2.2l-.008.014-.01.014c-.378.624-.74 1.28-1.076 1.95l-.01.019-.01.019c-.305.565-.569 1.16-.849 1.788l-.003.007-.002.005c-.024.053-.05.104-.078.155-.743 2.465-2.305 4.103-5.189 4.187-3.18.097-5.565-3.928-5.565-8.798s1.653-8.83 5.565-8.863c2.006-.02 3.77 1.56 4.8 3.952.193-.218.382-.419.565-.61.098-.104.197-.207.295-.313l.018-.02.019-.018.363-.366.17-.17c-1.018-1.842-3.017-4.22-6.58-4.24 0 0-8.014.227-8.682 10.648 0 0-.668 9.415 7.601 10.454 0 0 4.834 1.233 9.032-4.415 0 0 1.273 4.934 4.23 4.61 0 0 3.817.421 2.545-5.877 0 0-.318.195-.859.39Z" opacity=".75"></path><path fill="#1A98FF" d="M5.668 7.958c-.213.118-.284.377-.047.637a62.52 62.52 0 0 1 1.605 1.91c.78.92 1.394 1.957 1.937 3.042.33.66.614 1.344.944 2.005.296.612.787.897 1.455.897l.08-.001c.567 0 1.134-.378 1.37-.896.283-.637.566-1.274.897-1.887.354-.707.732-1.391 1.133-2.052.45-.778.921-1.556 1.417-2.287a45.491 45.491 0 0 1 1.582-2.146c.45-.566.898-1.132 1.394-1.675a88.988 88.988 0 0 1 2.078-2.146c.566-.566 1.18-1.108 1.77-1.65.19-.19.378-.354.567-.52.166-.14.19-.306.095-.495A.304.304 0 0 0 23.644.5a.546.546 0 0 0-.077.006.83.83 0 0 0-.33.141c-.284.212-.59.401-.874.613-.662.472-1.346.967-2.007 1.462-.59.449-1.134.92-1.7 1.392-.496.4-.969.825-1.418 1.25-.519.471-.991.967-1.487 1.462-.307.33-.614.637-.921.99-.496.59-.992 1.156-1.464 1.746a56.8 56.8 0 0 0-1.44 1.886c-.237.307-.45.637-.685.967a6.364 6.364 0 0 0-.709-.684c-.496-.495-.968-.99-1.487-1.462-.425-.4-.898-.755-1.346-1.108-.496-.401-1.04-.779-1.559-1.156a.416.416 0 0 0-.267-.105.412.412 0 0 0-.205.058Z"></path></symbol><symbol viewBox="0 0 16 16" id="analysis-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.275 3.108 10.125 2l-3.18 3.064 3.18 3.065 1.15-1.107-1.219-1.175H14V4.282h-3.944l1.219-1.174Zm-5.212 2.74H2V4.281h4.063v1.565Zm-1.338 7.049 1.15 1.107 3.18-3.063-3.18-3.066-1.15 1.108 1.219 1.174H2v1.566h3.944l-1.219 1.174Zm5.212-2.74H14v1.565H9.937v-1.565Z"></path></symbol><symbol viewBox="0 0 16 16" id="arrow-icon" xmlns="http://www.w3.org/2000/svg"><path d="m7.9 4.6-.8.8 2.2 2.1H5.5v1h3.8l-2.2 2.1.8.8L11.2 8 7.9 4.6Z"></path></symbol><symbol viewBox="0 0 16 16" id="authors-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10 5a2 2 0 1 1-4 0 2 2 0 0 1 4 0Zm.935 2.718a4 4 0 1 0-5.87 0C3.235 8.68 2 10.518 2 12.625V15h12v-2.375c0-2.107-1.236-3.944-3.065-4.907ZM8 9c-2.333 0-4 1.743-4 3.625V13h8v-.375C12 10.743 10.333 9 8 9Z"></path></symbol><symbol viewBox="0 0 20 24" id="bell" xmlns="http://www.w3.org/2000/svg"><path d="M16.88 10.49c0-3.54-2.02-5.98-3.54-6.4-1.52-.43-1.46-2.05-1.46-2.05C11.88.91 11.04 0 10 0S8.12.91 8.12 2.04c0 0 .06 1.62-1.46 2.05-1.52.42-3.54 2.86-3.54 6.4C3.12 18 0 17.56 0 20.16h20c0-2.6-3.12-2.15-3.12-9.67zM6.46 21.12A3.72 3.72 0 0 0 10 24a3.7 3.7 0 0 0 3.54-2.88H6.46z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="beta" xmlns="http://www.w3.org/2000/svg"><path fill="#555" d="M0 0h16v16H0z"></path><path d="M5.322 14.11h1.02v-3.053h.094c.316.65.984 1.06 1.927 1.06 1.524 0 2.631-1.101 2.631-2.666V9.44c0-1.171-.615-1.95-1.781-2.244v-.093c.744-.323 1.195-.99 1.195-1.776v-.012c0-1.365-.99-2.255-2.49-2.255-1.64 0-2.596 1.066-2.596 2.912v8.138Zm2.989-2.895c-1.172 0-1.97-.844-1.97-2.186V6.076c0-1.394.54-2.115 1.606-2.115.885 0 1.453.562 1.453 1.412v.012c0 .914-.568 1.406-1.564 1.406h-.522v.902h.516c1.377 0 2.121.61 2.121 1.776v.011c0 .997-.726 1.735-1.64 1.735Z" fill="#fff"></path></symbol><symbol viewBox="0 0 31 25" id="chat" xmlns="http://www.w3.org/2000/svg"><path d="M28.92 5.18a14.04 14.04 0 0 0-5.64-3.79A21.22 21.22 0 0 0 15.5 0c-2.1 0-4.1.28-6.02.82a17.31 17.31 0 0 0-4.95 2.22 11.4 11.4 0 0 0-3.3 3.33A7.42 7.42 0 0 0 0 10.41c0 1.63.52 3.16 1.57 4.58a12.47 12.47 0 0 0 4.28 3.58 9.93 9.93 0 0 1-1.48 3.02c-.17.23-.35.44-.54.65l-.6.62a56.87 56.87 0 0 0-.67.7l-.12.14-.1.15c-.06.08-.09.13-.08.15a.3.3 0 0 1-.04.16c-.03.1-.02.16.01.2v.02c.04.18.15.35.3.47a.7.7 0 0 0 .53.14A19.33 19.33 0 0 0 13 20.7c.87.1 1.7.14 2.51.14 2.81 0 5.41-.46 7.78-1.4a13.88 13.88 0 0 0 5.64-3.78A7.84 7.84 0 0 0 31 10.4c0-1.88-.7-3.63-2.08-5.23z"></path></symbol><symbol viewBox="0 0 16 16" id="chevron-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="m8.793 8-2.647 2.646.708.707L10.207 8 6.854 4.646l-.708.708L8.793 8Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="comparison-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m11.767 1-1.132 1.137 1.3 1.307H9.068v1.608h2.87L10.635 6.36l1.132 1.137L15 4.248 11.767 1ZM3.098 3.068h2.335v2.36H3.098v-2.36Zm-1.5-1.5h5.335V6.928H1.598V1.568Zm8.969 9.004h2.335v2.36h-2.335v-2.36Zm-1.5-1.5h5.335V14.432H9.067V9.072Zm-3.702.569L4.233 8.504 1 11.752 4.233 15l1.132-1.137-1.3-1.307h2.868V10.95h-2.87L5.365 9.64Z"></path></symbol><symbol viewBox="0 0 24 24" fill="none" id="contributor-icon" xmlns="http://www.w3.org/2000/svg"><path d="M4.333 2.125c-1.45.002-2.581 1.293-2.583 2.833v13.46c.002 1.539 1.134 2.83 2.583 2.832h13.095c1.449-.002 2.581-1.293 2.583-2.832V13.83c0-.399-.298-.766-.717-.766s-.716.367-.716.766v4.586c-.001.742-.539 1.3-1.15 1.3H4.333c-.612 0-1.15-.558-1.15-1.3V4.957c0-.74.538-1.298 1.15-1.299h4.143c.419 0 .717-.367.717-.766s-.298-.767-.717-.767H4.333Z" fill="currentColor" stroke="currentColor" stroke-width=".5"></path><path d="M21.898 3.964c.46-.46.526-1.143.15-1.526L20.588.96c-.222-.225-.548-.296-.873-.223a1.332 1.332 0 0 0-.644.362l-.62.62 2.827 2.865.62-.619ZM8.74 11.418c-.27.271-2.032 4.873-2.032 4.873s4.587-1.737 4.857-2.007L19.74 6.12l-2.827-2.865-8.173 8.163Z" fill="currentColor"></path></symbol><symbol fill="none" viewBox="0 0 16 16" id="crown" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" fill-rule="evenodd" d="M10.438 7.927 8 4.558l-2.438 3.37-2.555-1.093.898 4.665h8.19l.898-4.665-2.555 1.092ZM15 4.346 13.334 13H2.666L1 4.346l4.05 1.73L8 2l2.95 4.077L15 4.346Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 20 20" id="drag" xmlns="http://www.w3.org/2000/svg"><path d="M7 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4m6-8a2 2 0 1 0 0-4 2 2 0 0 0 0 4m0 2a2 2 0 1 0 0 4 2 2 0 0 0 0-4m0 6a2 2 0 1 0 0 4 2 2 0 0 0 0-4"></path></symbol><symbol viewBox="0 0 5 21" id="info" xmlns="http://www.w3.org/2000/svg"><circle cx="2.5" cy="2.5" r="2.5"></circle><circle cx="2.5" cy="10.5" r="2.5"></circle><circle cx="2.5" cy="18.5" r="2.5"></circle></symbol><symbol viewBox="0 0 9 10" id="lock" xmlns="http://www.w3.org/2000/svg"><path d="M7.77 4.36h-.36V3.08A3 3 0 0 0 4.5 0a3 3 0 0 0-2.9 3.08v1.28h-.37c-.4 0-.73.34-.73.77v4.1c0 .43.33.77.73.77h6.54c.4 0 .73-.34.73-.77v-4.1a.75.75 0 0 0-.73-.77zm-5.12 0V3.08A1.9 1.9 0 0 1 4.5 1.12a1.9 1.9 0 0 1 1.85 1.96v1.28h-3.7z"></path></symbol><symbol viewBox="0 0 131 26" id="logo" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M.4 18a9.26 9.26 0 0 1-.4 1.82C.7 20.58 2.34 21 3.34 21c2.8 0 5.07-1.74 5.07-4.68 0-4.37-6.46-2.85-6.46-6.63 0-1.45 1.17-2.4 2.58-2.4 1.21 0 2.12.68 2.55 1.79h.2c.17-.58.31-1.15.56-1.68a4.6 4.6 0 0 0-2.94-.99c-2.46 0-4.55 1.3-4.55 3.94 0 4.64 6.42 2.95 6.42 6.77 0 1.62-1.19 3-2.85 3-1.6 0-2.52-.82-3.32-2.14H.4zm11.33-3.28c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.59 3.6a4.55 4.55 0 0 1-3.04 1.42c-2.48 0-3.73-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.89-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.52-1.2l.03-1.08zm3.92-3.6c.12-1.73.96-3.57 2.9-3.57 2.02 0 2.52 1.78 2.56 3.57h-5.46zm6.58 3.6a4.54 4.54 0 0 1-3.03 1.42c-2.48 0-3.74-1.97-3.55-4.27h2.9c1.37 0 2.76.02 4.16.07.2-3.43-1.9-5.03-4.17-5.03-3.05 0-4.7 2.2-4.7 5.05 0 3.18 2.02 5.04 4.85 5.04 1.25 0 2.52-.49 3.53-1.2l.01-1.08zm3.77-13.07c-.31.03-.56.07-.83.07-.28 0-.55-.04-.82-.07v15.41c.27-.02.54-.06.82-.06.27 0 .52.04.83.06v-4.18c0-.89.28-.95.73-.43 1.32 1.5 2.94 3.32 3.92 4.61.33-.02.66-.06 1.03-.06.33 0 .61.04 1 .06v-.1c-1.62-1.85-3.34-3.9-4.82-5.6 1.9-1.79 3.7-3.22 4.52-3.96v-.14c-.31.01-.56.06-.8.06-.3 0-.56-.05-.82-.06l-1.6 1.76-1.28 1.3c-.26.26-1.35 1.43-1.78 1.2-.19-.1-.1-.4-.1-.67v-9.2zm10.37 2.22c0-.58-.5-1.05-1.04-1.05a1.05 1.05 0 0 0 0 2.1c.55 0 1.04-.48 1.04-1.05zm-.22 3.5c-.31.03-.56.07-.82.07-.3 0-.56-.04-.83-.06v9.8c.27-.02.54-.06.83-.06.26 0 .5.04.82.06v-9.8zm1.63 9.47c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-4.76c0-2.53.54-4.1 2.7-4.1 1.92 0 2.27 1.5 2.27 3.4v5.46c.26-.02.53-.06.82-.06.26 0 .51.04.82.06V14.5c0-2.7-.92-4-3.3-4-1.46 0-2.59.74-3.3 1.99v-1.87c-.31.02-.56.06-.83.06-.28 0-.55-.04-.82-.06v9.8zm11.21-6.68c0-1.56.84-2.7 2.32-2.7 1.62 0 2.2 1.22 2.2 2.8 0 1.4-.79 2.69-2.28 2.69-1.5 0-2.3-1.34-2.24-2.8zm6.9-3.18c-.48.08-.97.1-1.47.04l-2.85-.1c-2.99-.1-4.14 1.27-4.14 3.26 0 1.51.76 2.36 1.99 2.93-.8.35-1.41.78-1.41 1.77 0 1.25.65 1.55 1.25 1.66v.16c-1.28.23-2.14 1-2.14 2.48 0 2.16 2.03 3.02 3.72 3.02 3.13 0 5.2-1.64 5.2-4.04 0-1.75-1.12-2.73-3.54-2.73h-1.32c-1.23 0-1.97-.12-1.97-.99 0-1.19 1.24-.98 1.48-.98 2.38 0 4.37-.95 4.37-3.18 0-1.15-.57-2.05-1.41-2.7l2.25.18v-.78zm-4.34 9.7c1.54 0 3.02.14 3.02 2.28 0 1.93-1.77 2.62-3.24 2.62-1.7 0-2.95-.82-2.95-2.48 0-1.66 1.04-2.44 3.17-2.42zm19.16-5.92h-4.5l2.23-5.25 2.28 5.25zm-1.53-7.94h-.47l-6.4 14.34c.22-.02.45-.06.71-.06.25 0 .47.04.76.06.58-1.93 1.32-3.73 2.03-5.54h5.21a77.59 77.59 0 0 1 2.16 5.54c.35-.02.7-.06 1.09-.06.34 0 .67.04 1.06.06L75.77 6.42zm7.73 14.24c.26-.02.52-.06.81-.06.27 0 .51.04.82.06V5.26c-.3.02-.55.06-.82.06-.29 0-.55-.04-.82-.07v15.41zm5.13-2.03h.04c.68 1.28 1.69 1.97 3.16 1.97 2.63 0 4.43-2.03 4.43-5.4 0-2.45-1.47-4.7-4.12-4.7-2.48 0-3.12 1.5-3.47 2.2h-.04v-2.07c-.3.02-.55.06-.82.06-.28 0-.55-.04-.82-.06V25.7c.27-.02.54-.06.82-.06.27 0 .52.04.82.06v-7.06zm0-2.83c0-1.9.62-4.6 3-4.6 2.21 0 2.83 2.08 2.83 4.09 0 2.38-.74 4.45-2.81 4.45-2.1 0-3.02-1.74-3.02-3.94zm9.46 4.86c.26-.02.53-.06.82-.06.26 0 .51.04.82.06v-5.58c0-2.13.84-3.28 2.68-3.28 1.75 0 2.28 1.13 2.28 3.4v5.46c.27-.02.53-.06.82-.06.27 0 .52.04.82.06v-5.93c0-2.58-.92-4-3.3-4-1.45 0-2.58.74-3.3 2V5.24c-.31.03-.56.07-.82.07-.29 0-.56-.04-.82-.07v15.41zm15.23-2.34c0 .15-.41.5-.56.64-.39.4-1.08.78-1.64.78-1.25 0-2-.63-2-1.93 0-1.86 2.08-2.07 3.48-2.34l.72-.14v3zm1.64-4.36c0-2.32-1.17-3.45-3.33-3.45-1.2 0-2.31.45-3.3 1.13v1.15h.23c.14-.45.94-1.42 2.44-1.42 1.54 0 2.4.88 2.4 2.4 0 .99-.56 1.1-2.18 1.38-1.93.3-3.8.61-3.8 2.95 0 1.52 1.28 2.5 2.74 2.5 1.23 0 2.17-.43 3.03-1.29l.19-.18c.16 1.2 1.05 1.37 2.11 1.19.23-.04.47-.15.62-.2v-.46c-1.21.27-1.15-.14-1.15-.94v-4.76z"></path><path color="currentColor" d="M116.78 6.12c.38-5.99 5.1-6.12 5.1-6.12 3.4.02 4.37 3.65 4.37 3.65.04.2 2.02-3.4 2.02-3.4h1.12c-2.28 4.95-2.19 6.98-2.19 6.98-.19 2.66 1.31 3.57 1.31 3.57 1.4.9 1.49-1.71 1.49-1.71.3-.12.5-.22.5-.22.74 3.62-1.49 3.37-1.49 3.37-1.74.18-2.48-2.64-2.48-2.64-2.46 3.24-5.3 2.54-5.3 2.54-4.85-.62-4.45-6.02-4.45-6.02m2.03 0c0 2.8 1.4 5.1 3.26 5.05 2.62-.08 3.38-2.27 3.38-5.08 0-2.8-1.51-5.1-3.38-5.07-2.3.03-3.26 2.3-3.26 5.1"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="marketplace-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M4.196 3.257a2.667 2.667 0 0 0-2.152 4.471C.945 8.308.168 9.357.023 10.584A3.558 3.558 0 0 0 0 11v1.583h2v-.896c0-.378.039-.747.113-1.104H2.06c.03-.105.073-.21.126-.31A5.662 5.662 0 0 1 4.15 7.325a4.317 4.317 0 0 1-.484-1.992c0-.752.191-1.46.529-2.076ZM13.814 10.273a5.661 5.661 0 0 0-1.964-2.948 4.317 4.317 0 0 0 .484-1.992c0-.752-.192-1.46-.53-2.076a2.667 2.667 0 0 1 2.152 4.471c1.098.579 1.875 1.628 2.02 2.855.016.137.024.276.024.417v1.583h-2v-.896c0-.378-.039-.747-.113-1.104h.052a1.66 1.66 0 0 0-.125-.31Z" fill="currentColor"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M9.333 5.333a1.333 1.333 0 1 1-2.666 0 1.333 1.333 0 0 1 2.666 0Zm1.113 2.265a3.333 3.333 0 1 0-4.892 0C4.036 8.398 3.008 9.92 3 11.667v2h10v-2c-.008-1.748-1.036-3.269-2.554-4.069ZM5 11.667C5.012 10.309 6.23 9 8 9s2.988 1.31 3 2.667H5Z" fill="currentColor"></path></symbol><symbol viewBox="0 0 16 16" id="news-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M11.75 2v3H14v9H9.875v-1.5H12.5v-6H4.625a2.25 2.25 0 0 1-2.24-2.467A2.293 2.293 0 0 1 4.69 2h7.059ZM4.659 5h5.591V3.5H4.625a.75.75 0 0 0-.75.825A.772.772 0 0 0 4.66 5Z"></path><path d="M10.625 10.25a.75.75 0 1 0 0-1.5.75.75 0 0 0 0 1.5ZM6.875 13.25V14h1.5v-.938a5.626 5.626 0 0 0-5.438-5.437H2v1.5h.75a4.125 4.125 0 0 1 4.125 4.125Z"></path><path d="M3.875 14v-.75a1.124 1.124 0 0 0-1.125-1.125H2v-1.5h.938v.01a2.625 2.625 0 0 1 2.428 2.427h.01V14H3.874Z"></path></symbol><symbol viewBox="0 0 16 16" id="performance-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M5.429 6.385H2V14h12V8.923h-3.429V3H5.43v3.385Zm1.714-1.693v3.384h.001v4.23H5.43v-4.23H3.714v4.232h8.572v-1.693H10.57v1.692H8.855v-4.23h.002V4.691H7.143Z"></path></symbol><symbol viewBox="0 0 16 16" id="plus-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M8.5 8.5V11h-1V8.5H5v-1h2.5V5h1v2.5H11v1H8.5Z" clip-rule="evenodd"></path></symbol><symbol viewBox="0 0 16 16" id="portfolios-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m15 3.581-1.126 3.384h-1.929l-1.99 3.988-1.931-.966L6.018 13l-2.224-2.228-2.214.739L1 9.768 4.29 8.67l1.443 1.446 1.663-2.498 1.738.87 1.678-3.36h1.74L13.26 3l1.74.581Z"></path></symbol><symbol fill="none" viewBox="0 0 14 12" id="premium" xmlns="http://www.w3.org/2000/svg"><path stroke="#00D885" d="M9 2h4v4"></path><path stroke="#00D885" d="M13 2 7.24 7.65 5.32 5.76 1 10"></path></symbol><symbol viewBox="0 0 22 26" id="presentation" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M9 0h4v2H9V0zm4 9a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm0 3a1 1 0 0 1 1-1h3a1 1 0 1 1 0 2h-3a1 1 0 0 1-1-1zm-4 5v2h.14l-4.79 4.8c-.3.29-.3.77 0 1.07.29.3.77.3 1.06 0L11 19.28l5.59 5.6a.76.76 0 0 0 1.06-1.09L12.85 19H13v-2h7a1 1 0 0 0 1-1V5h1V3H0v2h1v11a1 1 0 0 0 1 1h7zM19 6H3v9h16V6zm-9.5 6.67A3 3 0 0 0 10 11H7V8a3 3 0 1 0 2.5 4.67z"></path><path opacity=".5" d="M11 10a3 3 0 0 0-3-3v3h3z"></path></symbol><symbol viewBox="0 0 23 16" id="pressRelease" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" d="M16.52 3.16a.5.5 0 0 0 .03.7l.15.14c.2.2.52.18.7-.02l2.61-2.8a.5.5 0 0 0-.03-.7l-.14-.14a.5.5 0 0 0-.71.03l-2.6 2.79zM1.21 8.1l9.96-6.64c.15-.16.31-.28.5-.34 1.27-.38 3.1 1.88 4.07 5.06.97 3.18.73 6.08-.55 6.46-.19.06-.39.06-.6 0l-3.25.02a3.01 3.01 0 1 1-6.02.04l-2.7.01c-.64.2-1.47-.68-1.86-1.95C.37 9.49.57 8.3 1.21 8.1zm5.32 4.59a1.8 1.8 0 0 0 2.33 1.9 1.8 1.8 0 0 0 1.27-1.92l-3.6.02zm8.05-6.16c.78 2.55.9 4.77.26 4.96-.64.2-1.78-1.7-2.56-4.25s-.9-4.77-.26-4.96c.64-.2 1.79 1.7 2.56 4.25zm3.94-1.2a.5.5 0 0 0-.33.63l.06.2a.5.5 0 0 0 .62.32l3.65-1.11a.5.5 0 0 0 .33-.63l-.06-.2a.5.5 0 0 0-.62-.33l-3.65 1.12zm-.44 3.1a.5.5 0 0 1 .6-.37l3.72.86a.5.5 0 0 1 .37.6l-.04.2a.5.5 0 0 1-.6.38l-3.72-.86a.5.5 0 0 1-.38-.6l.05-.2z"></path></symbol><symbol viewBox="0 0 35 12" id="pro" xmlns="http://www.w3.org/2000/svg"><path fill="#fff" d="M4.17.09H0V11.9h.85V8.06h3.32c2.93 0 4.7-1.5 4.7-3.98C8.86 1.57 7.1.1 4.16.1zm0 7.18H.85V.87h3.32C6.67.86 8 2.02 8 4.06c0 2.03-1.33 3.2-3.83 3.2zm16.6 4.64-2.91-4.14a3.62 3.62 0 0 0 2.72-3.7c0-2.5-1.76-3.99-4.68-3.99h-4.18v11.83h.85V8.04h3.33c.4 0 .76-.03 1.13-.08l2.77 3.95h.97zm-8.2-4.63V.86h3.33c2.49 0 3.82 1.17 3.82 3.21 0 2.03-1.33 3.22-3.82 3.22h-3.33zM28.63 12c3.46 0 6.05-2.55 6.05-6s-2.6-6-6.05-6c-3.48 0-6.06 2.57-6.06 6s2.58 6 6.06 6zm0-.8a5.07 5.07 0 0 1-5.2-5.2c0-3 2.22-5.2 5.2-5.2A5.07 5.07 0 0 1 33.8 6c0 3-2.22 5.2-5.18 5.2z"></path></symbol><symbol viewBox="0 0 16 16" id="rated-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="m4.1 3.5 1.4 3.7c-.5.3-.9.6-1.2 1L2 2h4.8l1.7 4.5H8c-.189 0-.355.022-.531.046A4.719 4.719 0 0 1 6.8 6.6L5.7 3.5H4.1Zm6.1 0h1.6l-1.4 3.7c.5.3.9.6 1.2 1L14 2H9.2l-.4 1.1.8 2.2.6-1.8ZM8 8c-1.9 0-3.5 1.6-3.5 3.5S6.1 15 8 15s3.5-1.6 3.5-3.5S9.9 8 8 8Zm1.3 5.5L8 12.7l-1.3.8.4-1.5-1.2-1 1.5-.1.6-1.4.6 1.4 1.5.1-1.2 1 .4 1.5Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="save" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm-2.625 1.702c-.016.07-.032.144-.042.221a1.65 1.65 0 0 0-.014.231v11.696L6.53 11.479a.476.476 0 0 0-.439 0l-4.534 2.375V2.33c0-.503.408-.912.911-.912h8.754a1.835 1.835 0 0 0-.1.287Zm3.323 3.847H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 16 16" fill="none" id="saved" xmlns="http://www.w3.org/2000/svg"><path fill="currentColor" d="M13.746.004A.364.364 0 0 0 13.685 0H2.333c-.032.001-.063.007-.095.009L2.237.01A2.333 2.333 0 0 0 .008 2.263l-.007.007L0 2.268V15.53a.47.47 0 0 0 .69.416l5.62-2.942 5.62 2.942a.472.472 0 0 0 .69-.416V6.971h2.91c.26 0 .47-.21.47-.468V1.95C16 .813 14.896.046 13.746.004Zm.698 5.549H12.62V2.33a.912.912 0 0 1 1.824 0v3.222Z"></path></symbol><symbol viewBox="0 0 32 32" id="search" xmlns="http://www.w3.org/2000/svg"><path d="m27.64 25.91-7.16-7.16a9.13 9.13 0 0 0-.8-12.06A9.12 9.12 0 0 0 13.18 4c-2.45 0-4.75.96-6.49 2.7A9.12 9.12 0 0 0 4 13.18c0 2.45.96 4.76 2.7 6.5a9.12 9.12 0 0 0 12.05.8l7.16 7.15a1.22 1.22 0 0 0 1.73 0c.48-.48.48-1.25 0-1.73zM8.42 17.95a6.7 6.7 0 0 1 0-9.53 6.7 6.7 0 0 1 9.52 0 6.7 6.7 0 0 1 1.98 4.77 6.7 6.7 0 0 1-11.5 4.76z"></path></symbol><symbol viewBox="0 0 16 16" id="star" xmlns="http://www.w3.org/2000/svg"><path d="m8 11.706 3.608 1.829-.687-3.867 2.873-2.699-3.974-.557L8 2.86 6.18 6.412l-3.974.557L5.08 9.668l-.688 3.867L8 11.706Zm-4.945 3.627L4 10.026 0 6.269l5.528-.775L8 .666l2.473 4.828L16 6.269l-4 3.757.944 5.307L8 12.827l-4.945 2.506Z"></path></symbol><symbol viewBox="0 0 28 24" id="temple" xmlns="http://www.w3.org/2000/svg"><path d="m14.16.39 11.35 4.08a.98.98 0 0 1 .6 1.27 1 1 0 0 1-1.28.59l-11.14-4-11.42 4.1A1 1 0 0 1 1 5.83a.98.98 0 0 1 .59-1.26L13.3.35a1 1 0 0 1 .85.04zM24 8a1 1 0 0 1-1 1H4a1 1 0 1 1 0-2h19a1 1 0 0 1 1 1zM8 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm14 10a1 1 0 1 0 0-2H5a1 1 0 0 0 0 2h17zm2 3a1 1 0 0 0 0-2H3a1 1 0 0 0 0 2h21zM13 11a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1zm4 1a1 1 0 0 0 0-2h-2a1 1 0 0 0 0 2v5a1 1 0 0 0 2 0v-5zm6-1a1 1 0 0 1-1 1v5a1 1 0 0 1-2 0v-5a1 1 0 0 1 0-2h2a1 1 0 0 1 1 1z"></path></symbol><symbol viewBox="0 0 20 23" id="transcripts" xmlns="http://www.w3.org/2000/svg"><path d="M12.98 7.9a1 1 0 0 0 .14-.12l5.66-5.66A1 1 0 0 0 17.36.71l-5.08 5.08-3.16-3.15a1 1 0 0 0-1.08-.23 1 1 0 0 0-.68.3L1.71 8.36a1 1 0 1 0 1.41 1.42l5.16-5.16 3.28 3.28a1 1 0 0 0 1.41 0zM1 13a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm0 4a1 1 0 1 0 0 2h18a1 1 0 1 0 0-2H1zm-1 5a1 1 0 0 1 1-1h8a1 1 0 1 1 0 2H1a1 1 0 0 1-1-1z"></path></symbol><symbol viewBox="0 0 16 16" id="upgrade-icon" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M16 0H0v16h16V0ZM4 8.662h5.465l-2.401 2.402L8 12l4-4-4-4-.936.937 2.4 2.4H4v1.325Z"></path></symbol><symbol fill="none" viewBox="0 0 36 36" id="warning" xmlns="http://www.w3.org/2000/svg"><path d="M18 36a18 18 0 1 0 0-36 18 18 0 0 0 0 36z" fill="#C9392C"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M19.7 9.7a2 2 0 0 0-3.4 0L8.2 22.97A2 2 0 0 0 9.92 26h16.16a2 2 0 0 0 1.7-3.04L19.72 9.7zm-.46 7.51v-3.94h-2.11v3.94c0 .43.02.85.08 1.27.05.41.12.83.2 1.26h1.54c.09-.43.16-.85.2-1.26.06-.42.09-.84.09-1.27zm-2.27 4.56a1.18 1.18 0 0 0 0 .93c.07.15.16.27.27.38a1.4 1.4 0 0 0 .92.34 1.39 1.39 0 0 0 .91-.34c.12-.11.2-.23.27-.38a1.1 1.1 0 0 0 0-.93 1.1 1.1 0 0 0-.27-.37 1.3 1.3 0 0 0-.91-.34c-.18 0-.35.03-.5.1a1.1 1.1 0 0 0-.69.61z" fill="#fff"></path></symbol></svg></span><div class="root" id="root"><div class="flex h-full flex-col"><div class="j_w r_4 aB_iS"><aside class="shrink-0 print:hidden x_eQ x_eR lg:ml-0 lg:pt-0" data-test-id="aside-nav-panel"><div class="flex max-w-full flex-col bg-share-aside-bg pl-safe fixed bottom-0 z-modal border-t border-solid border-navy lg:border-0 lg:pt-0 x_h x_eS lg:top-0"><div class="x_eT flex grow flex-col"><div class="aa_g6"><div class="flex items-center justify-between bg-share-aside-bg px-12 pt-18 mb-8 only:mb-18" data-test-id="aside-menu-header"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_gi aj_hL"><use xlink:href="#logo"></use></svg></span></a><button aria-label="Collapse main menu" class="inline-flex h-24 w-24 items-center justify-center bg-black-50 p-4 ml-auto translate-x-12" type="button"><svg viewBox="0 0 18 11" xmlns="http://www.w3.org/2000/svg" class="h-14 w-14 shrink-0 fill-white rotate-90" data-test-id="expand-collapse-arrow-button"><path d="M2.1 0 9 6.84 15.9 0 18 2.08 9 11 0 2.08z"></path></svg></button></div></div><nav class="h-0 grow" data-test-id="main-sidebar-nav" id="main-sidebar-nav"><div class="P_g relative h-full w-full P_gC P_gD"><div class="P_gB relative h-full overflow-y-auto overflow-x-hidden"><div></div><div class="pb-24 pt-14 lg:pt-0"><a class="z_eU" href="#content">Skip to content</a><div class="hidden lg:hidden mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative lg:hidden mb-18" data-test-id="upgrade-menu-top"><ul class="m-0 list-none pl-0 lg:flex-col flex flex-col-reverse"><li data-test-id="alpha-picks-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-top">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-top-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=subscribe_to_premium%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-premium"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-top">Subscribe to Premium</span></span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="general-menu-module"><ul class="m-0 list-none pl-0"><li data-test-id="home-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/?source=home%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Home</span></span></a></li><li data-test-id="analysis-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/latest-articles?source=analysis%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#analysis-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Analysis</span></span></a></li><li data-test-id="news-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/market-news?source=news%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#news-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">News</span></span></a></li><li data-test-id="market-performance-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/etfs-and-funds/etf-tables/key_markets?source=market_performance%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#performance-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Market Data</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="experts-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#marketplace-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Investing Groups</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="all-experts-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/marketplace/directory?source=investing_groups%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Explore Investing Groups</span></span><span class="jQ_Hx s_cH jQ_Hv r_ar"><div class="flex items-center"><div class="ml-12 flex"></div></div></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="portfolios-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#portfolios-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Portfolios</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="create-portfolio-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/account/portfolio?source=portfolio%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Create Portfolio</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative" data-test-id="find-and-compare-menu-module"><div><div class="relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu cV_pb py-8 hover:no-underline text-white hover:text-white eY_G jQ_gY cv_oi r_ap" data-test-id="menu-header"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#comparison-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline cV_nr text-small-2-r uppercase">Find &amp; Compare</span></span></div></div><ul class="m-0 list-none pl-0"><li data-test-id="top-stocks-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/96793299-Top-Rated-Stocks?source=top_stocks%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top Stocks</span></span></a></li><li data-test-id="top-et-fs-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs/922b797269-Top-Rated-ETFs?source=top_etfs%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Top ETFs</span></span></a></li><li data-test-id="stock-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners?source=stock_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Stock Screener</span></span></a></li><li data-test-id="etf-screener-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/screeners/etfs?source=etf_screener%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">ETF Screener</span></span></a></li><li data-test-id="comparisons-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/comparison?source=comparisons%3Aexpanded%3Anavbar_left"><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline">Comparisons</span></span></a></li></ul></div><div class="mx-12 h-1 bg-black-50  my-14 lg:my-12" data-test-id="aside-divider"></div><div class="cV_eI relative hidden lg:block mb-18" data-test-id="upgrade-menu-bottom"><ul class="m-0 list-none pl-0"><li data-test-id="alpha-picks-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/alpha-picks/subscribe?source=explore_alpha_picks%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#alpha-picks"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="alpha-picks-link-menu-button-bottom">Explore Alpha Picks</span></span></span></a></li><li data-test-id="upgrade-bottom-menu-button"><a class="py-8 hover:no-underline text-white hover:text-white eY_G relative flex select-none items-center justify-center px-12 text-large-r lg:text-medium-2-r eY_gY eY_tu jQ_gY cv_oi r_ap" href="/subscriptions?source=subscribe_to_premium%3Aexpanded%3Anavbar_left"><span class="jQ_Hv r_ar jQ_Hw s_dm"><span class="flex h-24 w-24 shrink-0 items-center justify-center lg:h-16 lg:w-16 text-brand-premium"><svg class="h-full w-full shrink-0 fill-current"><use xlink:href="#upgrade-icon"></use></svg></span></span><span class="jQ_mB r_4 r_6 r_ap"><span class="jQ_f r_ap bh_l4 bi_fu eY_f no-underline"><span data-test-id="upgrade-link-menu-button-bottom">Subscribe to Premium</span></span></span></a></li></ul></div><div></div></div><div></div></div></div></nav></div></div></aside><div class="j_a r_4 r_am r_ap"><header class="B_B fixed left-0 top-0 w-full lg:sticky B_eX aQ_jg"><div class="container max-w-full xxl:px-safe-or-36 px-safe-or-18 bg-black-v2-90 pt-safe-or-6 flex w-full items-center pb-6 B_eY lg:bg-share-bg-4 shadow-none lg:py-20" data-test-id="grid-container"><div class="grow aa_g6"><!--$--><div class="relative align-middle B_eZ mr-24 grow" data-test-id="search-block"><div class="flex flex-wrap w-full flex-col"><div class="relative w-full"><input autoComplete="on" placeholder="Symbols, Analysts, Keywords" spellcheck="true" aria-label="Symbols, Analysts, Keywords" class="inline-block text-ellipsis bg-clip-padding h-50 py-12 px-12 text-medium-r border border-navy-40 text-black-v2-90 read-only:text-navy-80 placeholder:text-navy-80 bg-white focus-within:border-navy-40 dark:border-black-v2-70 dark:text-black-v2-20 dark:bg-black-v2-80 dark:placeholder:text-black-v2-30 dark:read-only:text-black-v2-30 dark:focus-within:border-black-v2-70 focus:border-black-35 dark:focus:border-black-30 disabled:text-black-10 disabled:bg-black-5 disabled:border-black-10 disabled:opacity-100 dark:disabled:border-black-80 dark:disabled:text-black-80 dark:disabled:bg-black-98 w-full read-only:opacity-100 invalid:shadow-none vendor-clear-input-button dark:placeholder:text-black-30 dark:read-only:text-black-30 pr-38" data-test-id="search-input" type="search" value=""/><span class="sr-only">Entering text into the input field will update the search result below</span><svg class="right-12 w-20 h-20 absolute top-1/2 shrink-0 -translate-y-1/2 pointer-events-none fill-current text-black-35 dark:text-black-30"><use xlink:href="#search"></use></svg></div></div></div><!--/$--></div><div class="aa_g7"><div class="flex items-center"><button aria-controls="main-sidebar-nav" aria-expanded="false" aria-haspopup="true" aria-label="Main menu" class="I_0 r_5 r_6 r_ab I_fz aS_jo aS_jE aS_jT I_fx B_0 mr-8 shrink-0 text-white" type="button"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><span class="R_gL t_eE"><span class="R_gM t_eD" data-test-id="hamburger-menu-button"></span></span></span><span class="I_gn"></span></button><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj h-24 lg:mr-4 lg:h-32"><svg class="aj_gy aj_gi aj_hL B_e2"><use xlink:href="#logo"></use></svg></span></a></div></div><div class="Q_gE r_4 r_6"><div class="Q_0 s_dm r_4 r_6 r_ab"><a class="I_0 r_5 r_6 r_ab I_gb I_fO aS_jn aS_jC aS_jS L_G hidden md:inline-flex" href="/subscriptions?source=content_type%3Areact%7Csource%3Asubscribe_nav_right"><span class=""><span class="text-medium-2-r">Join now</span></span></a></div><div class="Q_0 s_dm r_4 r_6 r_ab aa_g7"><a aria-label="Search for Symbols, analysts, keywords" title="Search" class="I_0 r_5 r_6 r_ab I_fO aS_jn aS_jC aS_jS I_fx L_G L_gv text-white" href="/basic-search"><span class="I_gk r_4 r_6 r_ab r_ar I_gl"><svg width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path fill-rule="evenodd" clip-rule="evenodd" d="M10.53 4a6.53 6.53 0 1 1 0 13.07 6.53 6.53 0 0 1 0-13.07Zm0 1.54a5 5 0 1 0 0 9.99 5 5 0 0 0 0-10Zm9.43 13.38L18.86 20l-2.55-2.59-.01-2.2 3.66 3.71Z" fill="currentColor"></path></svg></span><span class="I_gn">Search for Symbols, analysts, keywords</span></a></div><div class="Q_0 s_dm r_4 r_6 r_ab"><button aria-label="Login / Register" class="I_0 r_5 r_6 r_ab bz_0 aS_jn aS_jC aS_jS aS_jo aS_jE aS_jT" data-test-id="header-button-sign-in" type="button"><span class=""><svg width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg" class="bz_fd"><path fill-rule="evenodd" clip-rule="evenodd" d="M13.53 7.76a1.89 1.89 0 1 0-3.77.01 1.89 1.89 0 0 0 3.77 0Zm1.88 0a3.77 3.77 0 1 1-7.54 0 3.77 3.77 0 0 1 7.54 0ZM7.88 20 9 15.44c.3-1.1.58-1.09 1.71-1.09h1.9c1.12 0 1.4 0 1.7 1.09l1.1 4.56h1.88l-1.17-5.06c-.52-1.9-1.55-2.47-3.53-2.47H10.7c-1.98 0-3 .56-3.53 2.47L6 20h1.88Z" fill="currentColor"></path></svg><span class="bz_f aS_jo aS_jD aS_jS">Log in</span></span></button></div></div></div><div class="absolute inset-x-0 top-full"></div><div></div></header><main class="j_t j_x r_4 r_am r_ap r_4 r_am j_y" id="content"><div class="j_z aQ_jg"></div><!--$--><div class="bL_mL r_4 r_am r_ap"><article class="container xxl:px-safe-or-36 md:px-safe-or-18" data-test-id="article-page"><script type="application/ld+json">{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@type":"Organization","name":"Seeking Alpha","logo":{"@type":"ImageObject","height":60,"url":"https://seekingalpha.com/samw/static/images/PublisherLogo.1a0fb372.png","width":360}},"datePublished":"2016-11-11T03:11:05.000Z","dateModified":"2016-11-11T03:11:05.000Z","description":"ImmunoCellular Therapeutics, Ltd. (OTCPK:IMUC) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ETExecutivesJane Green - IRAndrew Gengos -...","headline":"ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript","about":[{"@type":"Corporation","name":"EOM Pharmaceuticals Holdings, Inc.","tickerSymbol":"OTCMKTS:IMUC","url":"https://seekingalpha.com/symbol/IMUC"}],"image":{"@type":"ImageObject","url":"https://seekingalpha.com/samw/static/images/DefaultArticleImage.f1f9250c.png","height":1200,"width":1200}}</script><div class="cC_ox"><div class="sa-row-gap-18 xl:sa-row-gap-36 sa-row-collapse-v-gutter flex-wrap flex grow last:mb-0 print:block sa-row-gap-18 xl:sa-row-gap-36" data-test-id="grid-row"><div class="grow w-0 basis-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="" data-test-id="article-section"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-0 p-0 mb-8 md:mb-18 print:block" data-test-id="card-container"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="lI_qh s_aG s_aZ s_bm s_aE"><div class="lI_KU s_ed"><a data-test-id="logo" title="Home" class="aj_e2 r_4 r_am" href="/?source=content_type%3Areact%7Csource%3Asite_navigation"><span class="aj_hP r_4 r_aj"><svg class="aj_gy aj_fP aj_hL"><use xlink:href="#logo"></use></svg></span></a></div><header class="sQ_G3 r_4 r_7 r_af r_am"><div class="wv_g r_4 r_7 r_af s_eb cv_oi" data-test-id="quick-links"><div class="wv_Y4 r_4 r_6 r_ah r_ap s_cM s_b7"><div class="wv_Xo s_aW s_aA s_bf"><div class="zi_io" data-test-id="themes-list"><ul class="zi_mY r_4"><li class="zi_mZ r_4 r_6 s_d1"><a data-test-id="theme-links-item" class="I_0 r_5 r_6 r_ab I_f9 I_fw aS_jn aS_jC aS_jT L_G" href="/earnings/earnings-call-transcripts?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Atranscripts%7Cfirst_level_url%3Aarticle"><span class=""><span class="zi_1y it_w0">Transcripts</span></span></a></li></ul></div></div></div><div class="wv_Y3 r_4 r_6 r_af"></div></div><div class="nW_i6 r_4 r_af"><h1 class="nW_Y s_eb aS_jv aS_jN aS_jT aS_kG aS_kY aS_k3" data-test-id="post-title">ImmunoCellular Therapeutics&#x27; (IMUC) CEO Andrew Gengos on Q3 2016 Results - Earnings Call Transcript</h1></div><div class="nW_a r_4 r_af s_eb aS_jo aS_jD aS_jS sQ_Ut r_4 r_6" data-test-id="post-page-meta"><div><span class="nW_ND nW_gY t_eC" data-test-id="post-date">Nov. 10, 2016 10:11 PM ET</span><span class="nW_gY t_eC" data-test-id="post-primary-tickers"><a class="wq_YW" href="/symbol/IMUC?source=content_type%3Areact%7Csection%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AIMUC">EOM Pharmaceuticals Holdings, Inc. (IMUC)</a></span></div></div></header><div class="uw_QM r_4 r_7 r_af s_eb" data-test-id="author-brief"><div class="uw_4 r_4"><a class="uw_Nq tm_Nq" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_icon"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><img alt="SA Transcripts profile picture" class="dark:text-black-100 flex w-full items-center justify-center overflow-hidden bg-white-96 text-white-96 dark:bg-black-30 rounded-full h-full" data-test-id="user-pic" height="36" loading="lazy" src="https://static3.seekingalpha.com/images/users_profile/000/101/639/small_pic.png" srcSet="https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 2x, https://static3.seekingalpha.com/images/users_profile/000/101/639/big_pic.png 3x" width="36"/></div></a><div class="uw_QN r_4 r_ab r_am s_cL"><a class="uw_Nq tm_Nq uw_Md aS_jp aS_jD aS_jT s_dX tm_Md" data-test-id="author-name" href="/author/sa-transcripts?source=content_type%3Areact%7Curl_first_level%3Aarticle%7Csection%3Aauthor_brief%3Asa-transcripts%7Csection_asset%3Aauthor_brief%7Cauthor_name">SA Transcripts</a><div class="uw_rj r_4 r_ah"><div class="sx_T3 aS_jn aS_jC aS_jS uw_QL t_eC aS_jn aS_jC aS_jS">140.69K<!-- --> <!-- -->Follower<!-- -->s</div></div></div></div><div class="mC_LW" role="none"><button data-state-text="Following" class="I_0 r_5 r_6 r_ab I_fP I_fz aS_jo aS_jE aS_jT ky_IU s_ay s_bC s_aZ s_bm qO_I0 r_ar uw_Bf s_cy aQ_jg" data-test-id="follow-button" type="button"><span class=""><span class="ky_IW r_4 r_ab" data-state-placeholder="Following"><span class="ky_IX">Follow</span></span></span></button></div></div><div><div class="paywall-full-content jB_f r_4" data-test-id="article-content"><div class="jB_mC r_ap"><div class="jB_il" data-test-id="content-container"><p>ImmunoCellular Therapeutics, Ltd. (<a href="https://seekingalpha.com/symbol/IMUC" title="EOM Pharmaceuticals Holdings, Inc.">OTCPK:IMUC</a>) Q3 2016 Earnings Conference Call November 10, 2016 5:00 PM ET</p> <p><strong>Executives</strong></p> <p>Jane Green - IR</p> <p>Andrew Gengos - CEO</p> <p>David Fractor - VP, Finance and Principal Accounting Officer</p> <p><strong>Analysts</strong></p> <p>Jason McCarthy - Maxim</p> <p>Ron Leger - England Alternatives Investments</p> <p><strong>Operator</strong></p> <p>Good day, ladies and gentlemen and welcome to the ImmunoCellular Therapeutics’ Third Quarter 2016 Financial Results Conference Call. [Operator Instructions] </p> <p>I would now like to introduce your host for today’s conference, Ms. Jane Green of Investor Relations. You may begin.</p> <p><strong>Jane Green</strong></p> <p>Good afternoon and welcome to ImmunoCellular Therapeutics’ conference call to discuss the company’s third quarter 2016 financial results and corporate update. Today’s call is being recorded and is also available via webcast. Participating in today’s call are Chief Executive Officer, Andrew Gengos, and Vice President, Finance and Principal Accounting Officer, David Fractor.</p> <p>Following this introduction, Mr. Gengos will discuss the company’s performance and future outlook. Mr. Fractor will review the company’s financial results and then the company will take questions. If you have not yet received a copy of today’s press release, you can obtain one by visiting the company’s website, www.imuc.com.</p> <p>ImmunoCellular would like to remind everyone that during the conference call, members of the management team will make certain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Examples of these statements may include statements about our plans, objectives, expectations and intentions with respect to the potential and timing for success of our scientific approaches to cancer immunotherapy, our product candidates and research programs, clinical development efforts, operations, financial condition and other statements that are not historical in nature. </p> <p>Our actual results may differ materially from those projected in these forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed<span class="paywall-full-content invisible"> in such forward-looking statements include those set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. Please review these and the company’s other filings. We undertake no obligation to update any forward-looking statements after this call.</span></p> <p class="paywall-full-content invisible no-summary-bullets">Now, I would like to turn the call over to ImmunoCellular CEO, Andrew Gengos.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Andrew Gengos</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thanks, Jane and thanks to all of you for joining our call today. We welcome the opportunity to provide an update on our company and to review upcoming events. Since our second quarter update, we’ve continued to make progress in implementing our ICT-107 registration trial in patients with newly diagnosed glioblastoma and in conducting our phase 1 trial of ICT-121 in patients with recurrent glioblastoma. I’ll provide brief updates on these programs and also address some of the challenges we are facing this year. I’ll also discuss our ongoing strategies for operating the company. Then, I’ll review our lineup of expected milestones for the remainder of the year, followed by Q&amp;A.</p> <p class="paywall-full-content invisible no-summary-bullets">In the ICT-107 trial, in patients with newly diagnosed glioblastoma, we're one of a small number of companies in the cancer immunotherapy arena that we believe to be in the late stage of clinical development. We continue to think that what differentiates our Phase 3 program from any other newly diagnosed glioblastoma is that it's the only trial designed on the basis of data and insights from a placebo-controlled phase 2 trial, which induced overall survival as a primary endpoint.</p> <p class="paywall-full-content invisible no-summary-bullets">As of the beginning of this month, 225 patients have been screened and 11 patients have been randomized. Clinical site activation is continuing with a total of 75 site initiation visits and 66 sites activated to date. All the credit for this progress goes to our extraordinary team that is working tirelessly to move this program forward. While we're pleased with our progress in the third quarter, we became aware that the pace of randomization into our Phase 3 trial was being affected by several factors.</p> <p class="paywall-full-content invisible no-summary-bullets">One of these factors is increased competition for patients in other newly diagnosed glioblastoma clinical programs. While we welcome the fact that patients with highly lethal cancers have clinical options, we realize that competing for patients presents potential financial and logistical challenges. Another factor pertains to how patients qualify for our trial. We've determined that we may be unnecessarily excluding from the trial a number of eligible patients when they exit standard of care chemo radiation. In other words, we determine that the number of patients who complete screening and then ultimately move on to randomization after chemo radiation is lower than we expected. Thus, the rate of randomization is slower than we would like, despite meeting our patient screening goals. </p> <p class="paywall-full-content invisible no-summary-bullets">To address these challenges, we're implementing a protocol amendment that's designed to accelerate the pace and efficiency of our patient randomization efforts. The protocol amendment addresses the time required between initial screening and randomization. Remember that patients who are randomized in the trial currently are treated approximately 60 days following initial inclusion in the trial to allow for completion of standard of care chemo radiation and requalification screening for progression. We know that newly diagnosed patients would prefer not to wait a significant period of time before they know they will be included in a clinical trial. The protocol amendment will move randomization earlier, giving patients more certainty of participating. </p> <p class="paywall-full-content invisible no-summary-bullets">We plan to convert the requalification screening, currently performed in patients exit chemo radiation to just another opportunity to collect clinical information. Patients with clear progression will still be discontinued from the trial at this screening point, but we expect a very large proportion of patients to continue the treatment under the trial protocol. As a consequence of these changes, we now will require at least 500 patients to be randomized instead of the 414 patients we had originally planned. We anticipate that the current slower progress in randomization and the implementation of the amendment will result in an extension of the expected timeline to the completion of the trial by about 12 to 18 months from our original estimates.</p> <p class="paywall-full-content invisible no-summary-bullets">We plan to submit the protocol member to FDA and other relevant regulators for review and expect to complete the protocol amendment process and formally implement changes at all sites in the first quarter of 2017. Importantly, during this process, we’ll continue to screen and randomize patients and expect the addition of new sites and the streamlining of aphaeresis and manufacturing processes to accelerate the rate of randomization overall. </p> <p class="paywall-full-content invisible no-summary-bullets">In our discussion last quarter, we noted that the competitive landscape in newly diagnosed glioblastoma looked favorable for ImmunoCellular, given the suspension and terminations of other programs. We continue to believe that ICT-107 is at the forefront of immunotherapy development in this indication. We continue to have confidence in the value and quality of our Phase 3 program and the therapeutic and commercial potential of ICT-107.</p> <p class="paywall-full-content invisible no-summary-bullets">At the upcoming SNO conference during the week of November 20, there will be two presentations from prior clinical trials of ICT-107. There will be no data from the ongoing Phase 3 trial. Dr. Phuphanich of Cedar Sinai who conducted the phase 1 trial plans to present updated long term survival data from patients in that trial. Our Senior Vice President of Research, Steve Swanson will present data from the Phase 2 ICT-107 trial on the association between overall survival and progression free survival with immunologic response. These data provide support for the link between the ability of ICT-107 to induce antigen specific T. cell responses in HLA-A2 positive patients and the increased overall survival of these patients versus placebo non-responders.</p> <p class="paywall-full-content invisible no-summary-bullets">Relative to ICT-121, the phase 1 open label trial in patients with recurrent glioblastoma has completed enrolment, reaching the target of 20 patients. The trial is being conducted at six sites in the US and preliminary results are expected in the second quarter of 2017. Our current plan is to submit an abstract at ASCO with the goal of being able to present the preliminary results at the conference. As we noted last quarter, because the Phase 1 trial is open label, we can look at the raw data as they are generated. These data have not been scrubbed and validated by the CRO. That only occurs at the end of the trial. </p> <p class="paywall-full-content invisible no-summary-bullets">However, the un-validated results we’ve seen so far continue to be encouraging. While there is no perfectly matched historical control group we can use for this trial, there is a 2011 published meta-analysis of standard of care Avastin that shows a median overall survival of 9.3 months for recurrent patients. In the recent Celldex rindopepimut trial, the rindo treated median overall survival was 11.6 months and the Avastin control was also 9.3 months. We currently have eight deaths out of twenty patients enrolled, so our median survival can still move around a bit. But also remember that this is a small trial. Given those caveats, our current median survival is 13.8 months as of October 31, which compares favorably to the published results. </p> <p class="paywall-full-content invisible no-summary-bullets">Also we already have seven patients or 35% alive beyond 18 months whereas in the rindopepimut trial there was a thirty 30% and 15% overall survival at 15% for treatment of placebo patients respectively. We also have four patients or 20% alive at the two year mark. We'll continue to watch these results mature and are hopeful they continue to look encouraging for these patients with such a high unmet need. We're also encouraged that our dendritic cell based cancer immunotherapy platform appears to be performing positively in the second clinical program. </p> <p class="paywall-full-content invisible no-summary-bullets">Finally, a word about our financial status and our strategies to improve our financial standing. As we reported last quarter, we completed an underwritten public offering in August and raised net proceeds of about 6.6 million after deducting the underwriting discount and operating expenses. That amount of capital equates to about a three month runway extension to our cash position. That's obviously not enough to enable us to complete the ICT-107 phase 3 trial or to operate for the long term. In order for us to continue to advance our product candidates in clinical development, we need access to additional capital. However, the options for financing are limited for a company like ours. </p> <p class="paywall-full-content invisible no-summary-bullets">As we've noted in our previous public disclosures without such financing, our ability to continue to advance our product candidates would be limited. The steps we are taking now including the proposed reverse split that is on the ballot for the special meeting of shareholders taking place on November 14 are designed to enhance our ability to keep our company operational and enable us to continue to advance our development programs and expand our cancer immunotherapy platform. At the special meeting of shareholders on November 14, shareholders of record will be asked to vote on a proposal to effect a reverse stock split and a reduction in authorized shares of common stock. In the proxy material sent to all shareholders, the rationale for this proposal was clearly laid out. </p> <p class="paywall-full-content invisible no-summary-bullets">In short, the reverse stock split in a ratio of 1 for 40 would reduce the number of issued and outstanding shares to about 3.4 million. In addition, we’ll reduce the number of authorized shares of our common stock from 249 million to 25 million. We expect this proposal, if approved, will provide us the additional common shares we require to continue to raise capital as the need and opportunity arises.</p> <p class="paywall-full-content invisible no-summary-bullets">In addition, as we reported in August, we received a notice from the NYSEMKT that the company no longer meets the exchange’s continued listing standards related to our low selling price. The NYSEMKT deemed it appropriate for us to effect a reverse stock split, which we believe will result in an increase to our common stock price. The board believes that a reverse stock split is a potentially effective means for us to maintain compliance with the rules of the NYSEMKT and to avoid or at least mitigate the likely adverse consequences of our common stock being delisted by potentially increasing the price of our common stock. </p> <p class="paywall-full-content invisible no-summary-bullets">Our board and management realize that financing has often involved dilution for existing shareholders. We also realize that our reverse split represents some risks and potential disadvantages as well, which are detailed in the proxy statement. Obviously, we're hopeful that our market value will improve and better reflect the value we see in our company. We sincerely urge shareholders to follow the recommendations of the board and vote in favor of the reverse split. We remain very appreciative to all of our shareholders for your continued support.</p> <p class="paywall-full-content invisible no-summary-bullets">In terms of the upcoming milestones, in the ICT-107 program, in the near term, we anticipate continuing to bring clinical sites online. We hope to complete another 20 site initiation visits this year. Longer term, in light of the protocol amendment currently underway, we now anticipate randomization of all patients by the first half of 2019 and an additional 2 to 3 years from then to achieve the number of required events to complete the trial. We plan to conduct a futility interim analysis upon reaching 30% of the events, which should be about the same time as full randomization and an efficacy interim analysis upon reaching 67% of the events, which should be about six months later. </p> <p class="paywall-full-content invisible no-summary-bullets">We and our collaborators will be presenting updated immune monitoring data from the ICT-107 phase 2 trial and updated long term survival data from the Phase 1 trial at the Society for Neuro-Oncology Annual Scientific Meeting in November. Our two abstracts were recently accepted and we have received oral presentation invitations to deliver both. You can find more details on these presentations in the press release we issued today. In the ICT-121 program, we look forward to continuing to monitor patients with data expected by mid-year 2017. We'll continue to review the raw data and are encouraged with what we see so far. Our research programs are well underway and making progress. We anticipate having one or more T. cell receptors identified for a stem to T. cell clinical candidate or candidates by the end of 2016. </p> <p class="paywall-full-content invisible no-summary-bullets">We should make an initial attempt to package the T. cell receptor DNA sequence in the antivirus gene therapy construct by the end of this year as well and we're continuing to make progress in our collaboration on the University of Maryland projects that have application to our existing Dendritic cell immunotherapy and stem to T. cell technology platforms. As always, we plan to continue to evaluate opportunities to license or acquire new technology that can further complement and expand our immunotherapy platform and we remain interested in working with pharma companies to explore combination approaches with checkpoint inhibitors and potentially other immunotherapeutic approaches. </p> <p class="paywall-full-content invisible no-summary-bullets">We're grateful for the continued support of the medical and scientific cancer community and the confidence placed in our company by our collaborators. Now I'd like to ask David Fractor to review our financial results for the third quarter of 2016 and then we’ll up the call for questions. David?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>David Fractor</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Andrew. For the quarter ended September 30, 2016, the company incurred a net loss of $4.8 million or $0.04 per basic and diluted share compared to a net loss of $3.4 million or $0.04 per basic and diluted share for the quarter ended September 30, 2015. During the third quarter 2016, we incurred $4.6 million of research and development expenses compared to $2.7 million in the prior quarter, while general and administrative expenses decreased to 908,000 compared to 1.1 million in the prior year. </p> <p class="paywall-full-content invisible no-summary-bullets">The $1.9 million increase in R&amp;D expenses primarily reflects the additional expenses associated with the phase 3 trial of ICT-107. The decrease in general and administrative expenses reflects lower professional fees in the current quarter. The loss for the current quarter was partially offset by a $1.1 million credit to other income to a reflection in the -- to reflect a reduction in the valuation of our warrant derivative liabilities. In the same quarter of the prior year, the company recorded a corresponding credit of $339,000.</p> <p class="paywall-full-content invisible no-summary-bullets">For the nine months ended September 30, 2016, the company incurred a net loss of $15.8 million or $0.15 per basic and diluted share compared to a net loss of $8 million or $0.09 per basic and diluted share. During the nine months ended September 30, 2016, we incurred a $13.7 million in research and development expenses compared to $7 million in the prior year. The company also reported that cash used in operations during the nine months ended September 30, 2016 was $16.1 million compared to $13.2 million in the prior year. The increase primarily reflects the additional research and development expenditures in the current year. As of September 30, 2016, we had $15.3 million in cash.</p> <p class="paywall-full-content invisible no-summary-bullets">In August, 2016, the company entered into an underwriting agreement with Maxim Group pursuant to which we received net proceeds of approximately $6.6 million after deducting the underwriting discount and offering expenses. From the initial sale of 34.6 million shares of the company's common stock, base warrants to purchase 35.2 million shares a common stock at an exercise price of $0.19 per share and pre-funded warrants to purchase 12,450,000 shares of common stock at an exercise price of $0.01 per share. The underwriters partially exercised their option to purchase additional shares in base warrants and purchased an additional 1.5 million shares of the company’s common stock at a price of $0.15 per share and base warrants to purchase 4.5 million shares. The pre-funded warrants were substantially paid for at the time of the offering and have an exercise price of $0.01 per share. As of September 30, 2016, the company had 138 -- excuse me 137.8 million shares of common stock issued and outstanding. </p> <p class="paywall-full-content invisible no-summary-bullets">Additionally, the terms of the California Institute of Regenerative Medicine award were modified such that the company received an additional $1.5 million during the third quarter as part of the initial award received from CIRM. The total amount of the award and other award conditions remain unchanged. </p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Andrew Gengos</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, David. Operator, would you please now open the call for questions?</p> <p id="question-answer-session" class="paywall-full-content invisible no-summary-bullets"><strong>Question-and-Answer Session</strong></p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] And our first question comes from the line of Jason McCarthy with Maxim. Your line is now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Jason McCarthy</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi, Andrew. Couple of questions. I guess I’ll start with funding. What is the projected cash runway right now, are you going to receive any more funding from CIRM, I know you got the additional $1.5 million. Outside of a capital raise, reverse split or otherwise, are there other sources from CIRM or other non-dilutive sources of capital that the company could potentially get?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Hi, Jason. Thanks for the question. So you can see that our burn is roughly in the range of $2 million now a month. We think it might go higher as we're in the most expensive part of the trial, because we are manufacturing doses for all patients. So the enrollment randomization period of the trial is the most expensive time in the trial. And because we ended with roughly $15 million, so ended September with $15 million, I mean, you can do the math about how far our runway is. The complication here to get to your CIRM question is that - we're still finalizing the protocol amendment that I discussed in my prepared remarks and because of some of the changes in that in the protocol specifically moving randomization early - to an earlier point in time without going into great detail, it has some consequences on the number of patients who need to enroll in the trial in total.</p> <p class="paywall-full-content invisible no-summary-bullets">And so I mentioned our previous plan had been 414 patients and now we think it's at least 500. We're still finalizing that number, so I don't - I don't have a precise number but we think it's at least 500. Because the CIRM award, the remaining amount of CIRM award which is about $14.5 million. The lion's share of that almost all of it minus maybe a $1 million is paid out while we enroll according to milestones. Those milestones are set on proportions of enrollment. So if I don't know how many patients yet I need to enroll I can't really predict exactly when those milestones will be achieved. So there's more money coming from CIRM, a lot more but the precise date that it comes is not clear to me yet and whether we would need to finance in front of that or after that, my guess, I’m speculating is before but I don't know.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Jason McCarthy</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And in terms of the adjustments in the trial number, the proposed enrollment number of at least 500 that's almost as 20% increase and I know you've cut the time down between chemo radiation and ICT-107 treatment. But is the increase in number, how does that alter your powering and is to maybe guard against the risk in that you're now potentially bringing in some early progressors that may not benefit as well.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So let me be clear that the order of how a patient gets treated And the timing for that does not change, so let me just for clarity let me review that. They get surgery, they recover we do initial screening then if they qualify, we manufacture. Then they have to go into chemo radiation and then after chemo radiation that's when the active part of our trial starts. So in the current design we randomize after chemo radiation. In the new proposed protocol, we're going to randomize roughly at the time of manufacturing. So yes we're going to randomize earlier but it doesn't change the timing of the way a patient gets treated with standard of care and put on the trial. What it does is it gives them more certainty that they're actually going to be in the trial. As a consequence. What’s going to happen is we're going to loosen the screening for progression right before randomization.</p> <p class="paywall-full-content invisible no-summary-bullets">So that's after chemo radiation right before anonymization. We’re going to loosen that criteria because our experience to-date has shown us that it's too stringent. And so we still will screen out obviously progressing patients at that point in time but I think you're right there's a theoretical risk that we will indeed randomized patients that ultimately were progressing coming out of chemo radiation. And so in order to protect the powering of the trial, said differently keep roughly the same hazard ratio built into the trial, we need to add more patients. And we're working on that with the statistician to be included in our protocol amendment or shortly thereafter to resize the trial and our preliminary kind of analysis says it will be at least 500 but we don't know. And so our intent is to end up with a trial that has very similar powering and their core confidence that it's designed appropriately for the signal that we expect to see in the treated patients that aren't progressing. But it's tolerant of bringing in some set of patients that might in fact the early progresses that are undetectable, did I answer your question?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Jason McCarthy</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I think so, it just reads like - I understand that you've cut the time down. You're going back to randomization or when they qualify you'll start manufacturing, you’ve reduced some of the time between the chemo radiation and when you’ll dose that patient. Is that end piece of the screening process, but I'm looking at it as that is where the increase into 500 might be coming from because there are potential progressors in there, am I just still reading that not the right way?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">There's no difference in the timing of the trial, we haven't decreased the length of the trial or the order of the treatment. But, yes I think you're reading it right because we're randomizing earlier, anybody randomized becomes part of the intent to treat group. The intent-to-treat group is the group of patients that the primary endpoint is calculated on that’s the population because you’re randomizing earlier, you might in fact be randomized - well, we might be in fact randomizing some patients that potentially are progressing through chemo radiation and that we won't detect anymore and screen out right. So, because we expect that our intent-to-treat group will have some patients in there that have already started progressing both in the treated and the placebo arms. We need to put more patients in total into the trial. So that you know said in English the water down signal is beefed back up, you know what I mean.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Jason McCarthy</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Got you. That’s exactly the answer, that’s what I was looking for because that’s how I was reading it, now you answer it perfectly. I understand.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">[Operator Instructions] And our next question comes from the line of Ron Leger with England Alternatives Investments. Your line is now open.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Andrew, I’m wondering if you could talk a little bit more about the increased competition that you were mentioning in your comment. And is it such that some of these patients are being screened for multiple trials and they make a choice, send for a certain trial over another. How does that work?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So, as far as we're aware in late stage trials there's three that immediately come to mind, our trial, Northwest Bio has a Phase 3, it's hard to tell from their public information it looks like they've suspended enrollment and they have for a long time, but I don't know that for a fact. So that's out there and then we became aware and you can find this in the public literature that Bristol Myers has started two late stage trials in newly diagnosed glioblastoma totaling about, I think it's close to 900 patients, 850 patients something like that. And so, on the positive side, our ability to screen patients meaning patients they get referred by physicians to be screened for our trial is actually where we had hoped it would be, it's actually on our planned target. But converting those patients to patients that actually enter into the trial, the noun is randomized right, into the trial, randomized patients or adjective I guess.</p> <p class="paywall-full-content invisible no-summary-bullets">That productivity is lower than we need and we think we've understood why we have patients fall off, there are number of reasons. One of which might be due to competition. So let me - that's the nature of your question. So after the patient has surgery and they’re being screened for our trial and they qualify initially on something like HLA status and another inclusion criteria. That's when we manufacture but then they have to wait 60 days under the initial design. That 60 days is when they're getting chemo radiation but they start to wait though that amount of time before they know they'll actually be included in the trial. And that's where we've been losing some portion of patients. They've been withdrawing consent at that point. We don't know exactly why it could be because the trial requires them to have an aphaeresis which a kind of intensive blood draw which might be something they didn't understand or it could be because they have alternatives like the Bristol Meyer's trials where they don't have to have an aphaeresis or they don't have to wait 60 days to know if they'll be randomized.</p> <p class="paywall-full-content invisible no-summary-bullets">And so that's potentially where and we're speculating because we only have anecdotal data on that. But that's potentially where competition can come in. And if a patient withdraws consent in our trial, yeah, to answer your second question, they can go get screened for another trial. And as long as they haven't been treated in our trial, they’ll be considered for a different trial. So I don't want to say that the entire issue in our trial is losing patients to competition, far be it - far from that I think, but it is certainly a component and we are addressing that by the protocol amendment.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So when you say that your criteria was too strict, can you provide a little more color on what you're doing to loosen that or would you rather not be specific on that?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">No, I can give you a sense. So one of the problems, if you've been listening to our calls for a while or following the company you know there's an important characteristic in patients relating to what's called their MGMT gene. And roughly a third of the patients have the gene switched off and two thirds have it switched on. You have it switched on that's bad for your prognosis, you’ll typically be expected to have a median survival of maybe 12 to 16 months something like that. If you have it switched off, it's double that. So having the genes switched on is bad and what the - it means to have the gene switched on practically is that you don't get any benefit from chemotherapy.</p> <p class="paywall-full-content invisible no-summary-bullets">In fact the chemotherapy doesn't work for you, it doesn't help you. That's what you would predict. And so those patients still get chemotherapy, chemotherapy still standard of care. And they can actually start progressing while they're getting chemotherapy and remember our trial, the active part of our trial starts after chemotherapy. And so when we were designing the phase 2 with the keep opinion leaders in the field we were strongly advised to do something to rescreen patients coming out of chemotherapy for progression. And if they had progressed to not include them in the trial, progressive disease is no longer newly diagnosed disease. That’s a different disease. And so when we designed the trial we built in a screen for patients to requalify them after chemo radiation, make sure they weren’t progressive.</p> <p class="paywall-full-content invisible no-summary-bullets">It turns out that that's practically difficult to do because the tumor bed in the brain that's been radiated and has had chemotherapy oftentimes it's difficult to read that area on an MRI and make an assessment as to whether there's scar tissue or progressing disease for example. And so, our criteria for requalifying those patients was too stringent, we know that now. And we’ve loosened that criteria a bit. And so what we expect is we'll be accepting more patients, a greater proportion of patients coming out of chemo radiation then we have to-date in the trial so far under the new protocol. Did I answer your question?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yes, you did and you expect that this will be accepted by the FDA as well?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yeah that's our anticipation. We haven't submitted it to them yet. So I'm being a little forward looking here but this is not a major change and we would expect just the standard discussion with FDA and the European regulators and Canadian regulators as well.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So one last question if I could. So considering how hard you’ve worked and you've done a great job of lining this trial up, getting a special protocol assessment, so you’re making sure you're designing it correctly that you’re going to get this looked at by the FDA as a trial that could b something that would lead to [indiscernible]. Is there a fair amount of interest out there in partnering with on it or is it and I know maybe you can’t provide a ton of color on or is there a belief out in pharma that they want to just try to develop their own immune therapy drug because there is a lot of interest in this field.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">I can give you, I can give you my thoughts on that but I'm kind of reading tea leaves, right because I'm not on the other side of the table in Big Pharma. We do have an active dialog with various pharma and large biotech companies regarding this program. It's not every day but it's periodic, their time frames are slow as you might imagine. And there is general interest in our program. However my interpretation of it is they either want to see compelling data meaning registration or they want to wait later until we get further into the trial. There's a theoretical argument that they should be interested, I'll give you that. Big Pharma is working on a generalized immunotherapy for cancer, you might have heard of them called checkpoint inhibitors. These are antibodies that can be used in any patients, so unlike our treatments which are made specifically for our patient from their own cells. These are recombinant protein antibodies that can be used in any patient and Pharma is testing them in a wide range of cancers. </p> <p class="paywall-full-content invisible no-summary-bullets">That's a kind of drug pharma likes, right because it can be used in lots of indications and they make it by the kilogram not by the patient. But the problem with that drug is it just is a general immune stimulator in the sense, right. All it really does is allows the population of killer T cells in the patient's body to be more effective against the tumor. So it's a generalized response, what would be interesting in combination with that is to increase the population of antigen specific killer T cells that in theory makes for an interesting combination. And that's what we're working on. ICT-107 and dendritic cell immunotherapy in general seeks to increase the population of antigen specific killer T cells.</p> <p class="paywall-full-content invisible no-summary-bullets">So there is a - in my mind a pretty compelling logic for combination of these approaches. Why Pharma is not interest right now in collaborating with us that's hard to say. It could be that they want more data as I said or they want more certainty that maybe after registration not before or they don't believe in the technology at all, right. It's a range of things and I can't know but the discussions that I've had with Pharma recently are, hey, we’re interested, we're watching when you have more data let us know. And that's not very helpful. That doesn't really help you with your question, doesn’t really help me with my process of trying to partner with Pharma but that's what I get told.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">So what’s the Bristol Myers trial, what drug is that?</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">That’s a PD1 antibody. So it's a checkpoint inhibitor. They have tested that, the trade name is Opdivo, approved drug. It's been approved in some other cancer indications, they've tested it and YERVOY another one of their checkpoint inhibitors in recurrent glioblastoma but they've never tested it before in newly diagnosed glioblastoma and they launched two large trials in newly diagnosed glioblastoma with Opdivo, without any data.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="question">Ron Leger</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">And at some point I would think that their trial will again roll the number of patients that they want, so the competition would go down in that.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong><span class="answer">Andrew Gengos</span></strong></p> <p class="paywall-full-content invisible no-summary-bullets">Yeah that's correct. I mean, Celldex is another example. Celldex ran a 750 patient phase 3 trial in newly diagnosed glioblastoma. That trial ended within the last year, it actually failed at an interim but it enrolled and it's doable, I think it took a few years to enroll that trial and if you look at Bristol's public statements it seems like they’re expecting it'll be a few years to enroll their trial just like it's a few years to enroll our trial. Remember, there is only 10,000 patients each year in the United States diagnosed with glioblastoma - newly diagnosed glioblastoma. So, it's an orphan indication and it just takes time to enroll a trial like this.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">And I'm showing no further questions at this time, I would now like to turn the call back over to Mr. Andrew Gengos, CEO for closing remarks.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Andrew Gengos</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Thank you, Vicki. I want to just thank everybody again for participating in today’s call and webcast. We look forward to continuing to communicate with investors in the coming weeks and months and to providing you with additional updates on our progress. Thanks very much, good bye.</p> <p class="paywall-full-content invisible no-summary-bullets"><strong>Operator</strong></p> <p class="paywall-full-content invisible no-summary-bullets">Ladies and gentlemen, thank you for participating in today conference. This does conclude the program, you may all disconnect. Everyone have a great day.</p></div><div class="above_now_read-piano-placeholder"></div><div><ul><li class="jB_Gz" data-test-id="analysis-and-news-bullet">Read more current<!-- --> <!-- -->IMUC<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/symbol/IMUC"><span class="">analysis and news</span></a></li><li class="jB_Gz" data-test-id="earnings-call-transcripts-bullet">View all<!-- --> <a class="I_0 r_5 r_6 r_ab L_G L_gv" href="/earnings/earnings-call-transcripts"><span class="">earnings call transcripts</span></a></li></ul></div></div></div></div><div class="piano-paywall-container"></div><div></div><footer class="nO_S r_4 r_af aQ_jg paywall-full-content" data-test-id="post-footer"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><button class="vt_p9 sA_T6 r_4 r_6 vt_hT" data-test-id="like-button" type="button"><svg viewBox="0 0 19 16" xmlns="http://www.w3.org/2000/svg" class="vt_fd"><path d="M17.8 7.18h-2.69V15h2.69zm-4.86 6.4s.1 1.32-1.34 1.32H4.26s-1.86-2.13-3.2-6.7C.64 6.78 2.7 6.57 2.7 6.57h5.17S5.9 4.04 5.7 2.21C5.5.38 7.26.69 8.39 2.71c1.14 2.04 4.55 3.86 4.55 3.86v7z"></path></svg><span class="vt_hV vt_gn">Like</span></button></span><button aria-expanded="false" aria-label="Share options" class="dV_ry dV_rw r_ar r_4 r_6 r_ab dV_fy aS_jp aS_jD aS_jS dV_o4" data-test-id="custom-share-button" type="button"><span class="dV_h bh_l4"><span class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd"><svg viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg" class="nP_fd"><path d="M14.8 17.14a2.7 2.7 0 0 1-2.13-2.7l.01-.3-3.88-1.73-3.97-1.77c-.07-.03-.11 0-.3.17a2.67 2.67 0 1 1 0-3.83l.23.23 3.96-1.77 3.96-1.76-.01-.3c-.04-.7.24-1.44.74-1.97.64-.67 1.7-.96 2.6-.72A2.73 2.73 0 0 1 18 3.13a2.67 2.67 0 0 1-4.56 2.02l-.19-.18L9.3 6.73 5.33 8.5v.83l3.94 1.75 3.95 1.76.24-.22a2.67 2.67 0 1 1 1.35 4.52z"></path></svg><span class="nP_hV s_cL nP_gn">Share</span></span></span></button><a class="nP_G nP_Nx r_4 r_6 s_aG s_bJ s_aQ s_bd nO_Ns" data-test-id="comment-button" href="/article/4022325-immunocellular-therapeutics-imuc-ceo-andrew-gengos-on-q3-2016-results-earnings-call#comments"><svg viewBox="0 0 16 15" xmlns="http://www.w3.org/2000/svg" class="nP_fd nO_Nw"><path d="M7.04 12.28a8.8 8.8 0 0 1-4.6 2.21.79.79 0 0 1-.63-.2.91.91 0 0 1-.28-.45.61.61 0 0 1-.01-.4c0 .03-.01.04 0 .07-.03-.14.01-.21.1-.37l.08-.12.06-.07.05-.07.04-.04.23-.28.27-.32a4.07 4.07 0 0 0 .7-1.37 6.3 6.3 0 0 1-1.76-1.8 4.84 4.84 0 0 1-.17-5c.4-.73.94-1.36 1.62-1.88A7.87 7.87 0 0 1 5.12.95a9.23 9.23 0 0 1 6.6.32 6.87 6.87 0 0 1 2.74 2.12 4.93 4.93 0 0 1 0 6.05c-.68.9-1.6 1.6-2.74 2.12a8.97 8.97 0 0 1-4.68.72z" fill="none"></path></svg><span class="nP_hV s_cL nO_gn">Comment</span></a></footer></div></div></div></section><!--$--><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:hidden" data-test-id="recommended-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="paywall-full-content"><div class="w-full pb-6 pt-24 md:pb-10 md:pt-20"><div class="-mx-12 -my-4 flex flex-grow items-center flex-wrap"><div class="mr-auto flex flex-shrink flex-grow-0 px-12 py-4"><h4 class="m-0 inline-block text-5x-large-r text-black-35 dark:text-black-30 md:text-4x-large-r" data-test-id="recommended-for-you-card-title">Recommended For You</h4></div></div></div><div data-test-id="post-skeleton"><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:1"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.8333333333333334"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.6666666666666667"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.5"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.33333333333333337"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div><div class="gY_a fF_gY r_4 lz_KI s_aE s_bH lz_KI s_aE s_bH lz_KM lz_KM" data-test-id="post-skeleton-row" style="opacity:0.16666666666666674"><span class="fY_uZ t_eD fY_vV gY_e9 s_ds" data-test-id="loader"></span><div class="gY_hV r_4 r_ab r_am"><span class="fY_uZ t_eD fY_vV gY_Y gY_qw s_d1" data-test-id="loader"></span><span class="fY_uZ t_eD fY_vV gY_D" data-test-id="loader"></span></div></div></div></div></div></div></section><div class="sz_T5" id="comments-card"><section class="mx-auto flex w-full flex-col justify-between bg-white dark:bg-black-95 pt-24 md:pt-12 pb-24 px-safe-offset-18 md:pb-20 md:px-safe-or-24 mb-8 md:mb-18 print:block" data-test-id="comments-section"><div class="flex flex-col flex-wrap print:block"><div class="w-full max-w-full"><div class="sz_qh"><div class="paywall-full-content"><div class="pn_Pd r_4 r_6 s_eg" data-scroll-id="comments" data-test-id="comments-header" id="comments"><h4 class="pn_Y r_4 r_6 aS_jt aS_jJ aS_jS s_dd s_dT" data-test-id="comments-counter">Comments</h4><div><button aria-expanded="false" aria-label="Sort By" class="dV_ry dV_rw r_ar r_4 r_6 r_ab dV_fy aS_jp aS_jD aS_jS dV_o4" data-test-id="sort-comments-button" type="button"><span class="dV_h bh_l4"><span class="su_TW r_4 r_6"><span class="su_TX s_dm aR_jh aS_jo aS_jE aS_jS">Newest</span><div class="tQ_Vv su_fd r_4 r_6"><span class="su_TY"><svg viewBox="0 0 15 16" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h6.15v3.7H0V0zm0 6.15h11.08v3.7H0v-3.7zm0 6.16h14.77V16H0v-3.7z"></path></svg></span></div></span></span></button></div><button aria-expanded="false" aria-label="Comment options" class="dV_ry dV_rw r_ar r_4 r_6 r_ab dV_fy aS_jp aS_jD aS_jS dV_o4 sv_T0 s_cH" data-test-id="dropdown" type="button"><span class="dV_h bh_l4"><span class="sv_oR r_4 r_6 r_ab"><svg class="sv_TZ"><use xlink:href="#info"></use></svg></span></span></button></div><!--$--><div class="vx_g rl_g s_ed aQ_jg" data-test-id="add-comment-form"><div class="vx_Sc rl_Sc r_4"><div class="vx_Gj s_ds"><div class="flex shrink-0 items-center justify-center relative w-36 h-36 rounded-full" data-test-id="user-pic-wrapper"><div class="" data-test-id="user-pic"></div></div></div><div class="vx_Sd rl_Sd"><div aria-label="Comment content" class="border border-black-10 bg-white text-black placeholder:text-black-35 read-only:text-black-35 read-only:bg-black-5 dark:border-black-80 dark:bg-black-98 dark:text-black-10 placeholder:text-black-35 read-only:text-black-35 dark:placeholder:text-black-30 dark:read-only:text-black-30 focus:border-black-35 dark:focus:border-black-30 rounded-tl-0 rounded-bl-8 rounded-r-8 vx_Se rl_Se s_eb s_aA s_aW s_bj s_bE vd_XZ" contenteditable="true" data-test-id="add-comment-input" placeholder="Be the first to comment" role="textbox" tabindex="0"></div><div class="vx_wv rl_wv r_4 r_6 r_ac"><button disabled="" class="I_0 r_5 r_6 r_ab I_fP I_fz aS_jo aS_jE aS_jT vx_Sg rl_Sg s_cR" data-test-id="publish-comment-button" type="button"><span class="">Publish</span></button></div></div></div></div><div></div><div class="xN_hV s_ca aS_jo aS_jD aS_jS"><span>To report an error in this transcript<!-- -->, <button class="I_0 r_5 r_6 r_ab zq_1P" data-test-id="report-problem-with-article" type="button"><span class="">click here</span></button>.</span>Contact us to<!-- --> <a data-test-id="transcript-add-your-company" href="/page/contact?question=Transcript%20Inquiries">add your company</a> <!-- -->to our coverage or<!-- --> <a data-test-id="transcript-in-your-business" href="/page/contact?question=Transcript%20Inquiries">use transcripts in your business</a>. Learn more about Seeking Alpha transcripts<!-- --> <a data-test-id="learn-more-about-transcripts" href="/page/sa_transcripts">here</a>.<!-- --> <!-- -->Your feedback matters to us!</div><!--/$--></div></div></div></div></section></div><!--/$--></div></div><div class="lg:basis-auto lg:w-auto lg:flex lg:flex-col grow-0 sm:basis-full sm:flex sm:flex-col grow-0 empty:hidden relative min-h-1 min-w-0 w-full max-w-full grow sa-col" data-test-id="grid-col"><div class="ja_qj aQ_jg r_4 r_am s_bH" data-test-id="right-rail"><!--$--><div></div><!--/$--></div></div></div></div></article></div><!--/$--></main><div class="l_L"><div></div><div></div></div><!--$--><!--/$--><div data-test-id="after-layout-content-slot"></div></div></div><div class="e_a s_eA s_cy s_dd s_dS r_4 r_ac s_aU s_bh" id="google-one-tap-popup-container"></div><div class="g_p t_eB" id="px-captcha-wrapper"><div class="g_g s_eA s_cy s_dd s_dS s_aE s_bH"><div class="g_f"><div id="px-captcha"></div><div><div class="g_q s_d9">To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.</div><div class="g_q s_d9">Is this happening to you frequently? Please<!-- --> <a href="https://seekingalpha.userecho.com/?source=captcha">report it on our feedback forum.</a></div><div class="g_q s_d9">If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.</div></div><div class="px-reference-id"></div></div></div></div></div></div><noscript><iframe height="0" src="https://www.googletagmanager.com/ns.html?id=GTM-MSK9R8B" style="display:none;visibility:hidden" title="google-tag-manager" width="0"></iframe></noscript><script async="" src="/samw/static/js/app.982fa237.js"></script></body></html>